#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Cocaine dependence and thalamic functional connectivity: a multivariate pattern analysis
#Text=Cocaine dependence is associated with deficits in cognitive control.
1-1	0-7	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]
1-2	8-18	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]
1-3	19-22	and	_
1-4	23-31	thalamic	_
1-5	32-42	functional	_
1-6	43-55	connectivity	_
1-7	55-56	:	_
1-8	57-58	a	_
1-9	59-71	multivariate	_
1-10	72-79	pattern	_
1-11	80-88	analysis	_
1-12	89-96	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
1-13	97-107	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
1-14	108-110	is	_
1-15	111-121	associated	_
1-16	122-126	with	_
1-17	127-135	deficits	_
1-18	136-138	in	_
1-19	139-148	cognitive	_
1-20	149-156	control	_
1-21	156-157	.	_

#Text=Previous studies demonstrated that chronic cocaine use affects the activity and functional connectivity of the thalamus, a subcortical structure critical for cognitive functioning.
2-1	158-166	Previous	_
2-2	167-174	studies	_
2-3	175-187	demonstrated	_
2-4	188-192	that	_
2-5	193-200	chronic	_
2-6	201-208	cocaine	_
2-7	209-212	use	_
2-8	213-220	affects	_
2-9	221-224	the	_
2-10	225-233	activity	_
2-11	234-237	and	_
2-12	238-248	functional	_
2-13	249-261	connectivity	_
2-14	262-264	of	_
2-15	265-268	the	_
2-16	269-277	thalamus	_
2-17	277-278	,	_
2-18	279-280	a	_
2-19	281-292	subcortical	_
2-20	293-302	structure	_
2-21	303-311	critical	_
2-22	312-315	for	_
2-23	316-325	cognitive	_
2-24	326-337	functioning	_
2-25	337-338	.	_

#Text=However, the thalamus contains nuclei heterogeneous in functions, and it is not known how thalamic subregions contribute to cognitive dysfunctions in cocaine dependence.
3-1	339-346	However	_
3-2	346-347	,	_
3-3	348-351	the	_
3-4	352-360	thalamus	_
3-5	361-369	contains	_
3-6	370-376	nuclei	_
3-7	377-390	heterogeneous	_
3-8	391-393	in	_
3-9	394-403	functions	_
3-10	403-404	,	_
3-11	405-408	and	_
3-12	409-411	it	_
3-13	412-414	is	_
3-14	415-418	not	_
3-15	419-424	known	_
3-16	425-428	how	_
3-17	429-437	thalamic	_
3-18	438-448	subregions	_
3-19	449-459	contribute	_
3-20	460-462	to	_
3-21	463-472	cognitive	_
3-22	473-485	dysfunctions	_
3-23	486-488	in	_
3-24	489-496	cocaine	_
3-25	497-507	dependence	_
3-26	507-508	.	_

#Text=To address this issue, we used multivariate pattern analysis (MVPA) to examine how functional connectivity of the thalamus distinguishes 100 cocaine-dependent participants (CD) from 100 demographically matched healthy control individuals (HC).
4-1	509-511	To	_
4-2	512-519	address	_
4-3	520-524	this	_
4-4	525-530	issue	_
4-5	530-531	,	_
4-6	532-534	we	_
4-7	535-539	used	_
4-8	540-552	multivariate	_
4-9	553-560	pattern	_
4-10	561-569	analysis	_
4-11	570-571	(	_
4-12	571-575	MVPA	_
4-13	575-576	)	_
4-14	577-579	to	_
4-15	580-587	examine	_
4-16	588-591	how	_
4-17	592-602	functional	_
4-18	603-615	connectivity	_
4-19	616-618	of	_
4-20	619-622	the	_
4-21	623-631	thalamus	_
4-22	632-645	distinguishes	_
4-23	646-649	100	_
4-24	650-667	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]
4-25	668-680	participants	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]
4-26	681-682	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]
4-27	682-684	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]
4-28	684-685	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]
4-29	686-690	from	_
4-30	691-694	100	_
4-31	695-710	demographically	_
4-32	711-718	matched	_
4-33	719-726	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-34	727-734	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-35	735-746	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-36	747-748	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-37	748-750	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-38	750-751	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
4-39	751-752	.	_

#Text=We characterized six task-related networks with independent component analysis of fMRI data of a stop signal task and employed MVPA to distinguish CD from HC on the basis of voxel-wise thalamic connectivity to the six independent components.
5-1	753-755	We	_
5-2	756-769	characterized	_
5-3	770-773	six	_
5-4	774-786	task-related	_
5-5	787-795	networks	_
5-6	796-800	with	_
5-7	801-812	independent	_
5-8	813-822	component	_
5-9	823-831	analysis	_
5-10	832-834	of	_
5-11	835-839	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-12	840-844	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-13	845-847	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-14	848-849	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-15	850-854	stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-16	855-861	signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-17	862-866	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]
5-18	867-870	and	_
5-19	871-879	employed	_
5-20	880-884	MVPA	_
5-21	885-887	to	_
5-22	888-899	distinguish	_
5-23	900-902	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-24	903-907	from	_
5-25	908-910	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-26	911-913	on	_
5-27	914-917	the	_
5-28	918-923	basis	_
5-29	924-926	of	_
5-30	927-937	voxel-wise	_
5-31	938-946	thalamic	_
5-32	947-959	connectivity	_
5-33	960-962	to	_
5-34	963-966	the	_
5-35	967-970	six	_
5-36	971-982	independent	_
5-37	983-993	components	_
5-38	993-994	.	_

#Text=In an unbiased model of distinct training and testing data, the analysis correctly classified 72% of subjects with leave-one-out cross-validation (p < 0.001), superior to comparison brain regions with similar voxel counts (p < 0.004, two-sample t test).
6-1	995-997	In	_
6-2	998-1000	an	_
6-3	1001-1009	unbiased	_
6-4	1010-1015	model	_
6-5	1016-1018	of	_
6-6	1019-1027	distinct	_
6-7	1028-1036	training	_
6-8	1037-1040	and	_
6-9	1041-1048	testing	_
6-10	1049-1053	data	_
6-11	1053-1054	,	_
6-12	1055-1058	the	_
6-13	1059-1067	analysis	_
6-14	1068-1077	correctly	_
6-15	1078-1088	classified	_
6-16	1089-1092	72%	_
6-17	1093-1095	of	_
6-18	1096-1104	subjects	_
6-19	1105-1109	with	_
6-20	1110-1123	leave-one-out	_
6-21	1124-1140	cross-validation	_
6-22	1141-1142	(	_
6-23	1142-1143	p	_
6-24	1143-1144	 	_
6-25	1144-1145	<	_
6-26	1145-1146	 	_
6-27	1146-1151	0.001	_
6-28	1151-1152	)	_
6-29	1152-1153	,	_
6-30	1154-1162	superior	_
6-31	1163-1165	to	_
6-32	1166-1176	comparison	_
6-33	1177-1182	brain	_
6-34	1183-1190	regions	_
6-35	1191-1195	with	_
6-36	1196-1203	similar	_
6-37	1204-1209	voxel	_
6-38	1210-1216	counts	_
6-39	1217-1218	(	_
6-40	1218-1219	p	_
6-41	1219-1220	 	_
6-42	1220-1221	<	_
6-43	1221-1222	 	_
6-44	1222-1227	0.004	_
6-45	1227-1228	,	_
6-46	1229-1239	two-sample	_
6-47	1240-1241	t	_
6-48	1242-1246	test	_
6-49	1246-1247	)	_
6-50	1247-1248	.	_

#Text=Thalamic voxels that form the basis of classification aggregate in distinct subclusters, suggesting that connectivities of thalamic subnuclei distinguish CD from HC.
7-1	1249-1257	Thalamic	_
7-2	1258-1264	voxels	_
7-3	1265-1269	that	_
7-4	1270-1274	form	_
7-5	1275-1278	the	_
7-6	1279-1284	basis	_
7-7	1285-1287	of	_
7-8	1288-1302	classification	_
7-9	1303-1312	aggregate	_
7-10	1313-1315	in	_
7-11	1316-1324	distinct	_
7-12	1325-1336	subclusters	_
7-13	1336-1337	,	_
7-14	1338-1348	suggesting	_
7-15	1349-1353	that	_
7-16	1354-1368	connectivities	_
7-17	1369-1371	of	_
7-18	1372-1380	thalamic	_
7-19	1381-1390	subnuclei	_
7-20	1391-1402	distinguish	_
7-21	1403-1405	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
7-22	1406-1410	from	_
7-23	1411-1413	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-24	1413-1414	.	_

#Text=Further, linear regressions provided suggestive evidence for a correlation of the thalamic connectivities with clinical variables and performance measures on the stop signal task.
8-1	1415-1422	Further	_
8-2	1422-1423	,	_
8-3	1424-1430	linear	_
8-4	1431-1442	regressions	_
8-5	1443-1451	provided	_
8-6	1452-1462	suggestive	_
8-7	1463-1471	evidence	_
8-8	1472-1475	for	_
8-9	1476-1477	a	_
8-10	1478-1489	correlation	_
8-11	1490-1492	of	_
8-12	1493-1496	the	_
8-13	1497-1505	thalamic	_
8-14	1506-1520	connectivities	_
8-15	1521-1525	with	_
8-16	1526-1534	clinical	_
8-17	1535-1544	variables	_
8-18	1545-1548	and	_
8-19	1549-1560	performance	_
8-20	1561-1569	measures	_
8-21	1570-1572	on	_
8-22	1573-1576	the	_
8-23	1577-1581	stop	_
8-24	1582-1588	signal	_
8-25	1589-1593	task	_
8-26	1593-1594	.	_

#Text=Together, these findings support thalamic circuit dysfunction in cognitive control as an important neural marker of cocaine dependence.
9-1	1595-1603	Together	_
9-2	1603-1604	,	_
9-3	1605-1610	these	_
9-4	1611-1619	findings	_
9-5	1620-1627	support	_
9-6	1628-1636	thalamic	_
9-7	1637-1644	circuit	_
9-8	1645-1656	dysfunction	_
9-9	1657-1659	in	_
9-10	1660-1669	cognitive	_
9-11	1670-1677	control	_
9-12	1678-1680	as	_
9-13	1681-1683	an	_
9-14	1684-1693	important	_
9-15	1694-1700	neural	_
9-16	1701-1707	marker	_
9-17	1708-1710	of	_
9-18	1711-1718	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]
9-19	1719-1729	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]
9-20	1729-1730	.	_

#Text=Highlights
#Text=Cocaine dependence is associated with thalamic dysfunction and cognitive deficits.
10-1	1731-1741	Highlights	_
10-2	1742-1749	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]
10-3	1750-1760	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]
10-4	1761-1763	is	_
10-5	1764-1774	associated	_
10-6	1775-1779	with	_
10-7	1780-1788	thalamic	_
10-8	1789-1800	dysfunction	_
10-9	1801-1804	and	_
10-10	1805-1814	cognitive	_
10-11	1815-1823	deficits	_
10-12	1823-1824	.	_

#Text=The thalamus comprises subnuclei that differ in cognitive functions.
11-1	1825-1828	The	_
11-2	1829-1837	thalamus	_
11-3	1838-1847	comprises	_
11-4	1848-1857	subnuclei	_
11-5	1858-1862	that	_
11-6	1863-1869	differ	_
11-7	1870-1872	in	_
11-8	1873-1882	cognitive	_
11-9	1883-1892	functions	_
11-10	1892-1893	.	_

#Text=MVPA of thalamic connectivity distinguishes addicted from healthy individuals.
12-1	1894-1898	MVPA	_
12-2	1899-1901	of	_
12-3	1902-1910	thalamic	_
12-4	1911-1923	connectivity	_
12-5	1924-1937	distinguishes	_
12-6	1938-1946	addicted	_
12-7	1947-1951	from	_
12-8	1952-1959	healthy	_
12-9	1960-1971	individuals	_
12-10	1971-1972	.	_

#Text=Thalamic voxels that identify addicts aggregate in clusters, resembling subnuclei.
13-1	1973-1981	Thalamic	_
13-2	1982-1988	voxels	_
13-3	1989-1993	that	_
13-4	1994-2002	identify	_
13-5	2003-2010	addicts	_
13-6	2011-2020	aggregate	_
13-7	2021-2023	in	_
13-8	2024-2032	clusters	_
13-9	2032-2033	,	_
13-10	2034-2044	resembling	_
13-11	2045-2054	subnuclei	_
13-12	2054-2055	.	_

#Text=Connectivity of thalamic clusters reflects specific changes in SST performance.
14-1	2056-2068	Connectivity	_
14-2	2069-2071	of	_
14-3	2072-2080	thalamic	_
14-4	2081-2089	clusters	_
14-5	2090-2098	reflects	_
14-6	2099-2107	specific	_
14-7	2108-2115	changes	_
14-8	2116-2118	in	_
14-9	2119-2122	SST	_
14-10	2123-2134	performance	_
14-11	2134-2135	.	_

#Text=Introduction
#Text=Cocaine dependence is a chronic, relapsing disorder.
15-1	2136-2148	Introduction	_
15-2	2149-2156	Cocaine	_
15-3	2157-2167	dependence	_
15-4	2168-2170	is	_
15-5	2171-2172	a	_
15-6	2173-2180	chronic	_
15-7	2180-2181	,	_
15-8	2182-2191	relapsing	_
15-9	2192-2200	disorder	_
15-10	2200-2201	.	_

#Text=Previous studies have implicated deficits in cognitive control as a critical psychological factor contributing to continued drug use in dependent individuals.
16-1	2202-2210	Previous	_
16-2	2211-2218	studies	_
16-3	2219-2223	have	_
16-4	2224-2234	implicated	_
16-5	2235-2243	deficits	_
16-6	2244-2246	in	_
16-7	2247-2256	cognitive	_
16-8	2257-2264	control	_
16-9	2265-2267	as	_
16-10	2268-2269	a	_
16-11	2270-2278	critical	_
16-12	2279-2292	psychological	_
16-13	2293-2299	factor	_
16-14	2300-2312	contributing	_
16-15	2313-2315	to	_
16-16	2316-2325	continued	_
16-17	2326-2330	drug	_
16-18	2331-2334	use	_
16-19	2335-2337	in	_
16-20	2338-2347	dependent	_
16-21	2348-2359	individuals	_
16-22	2359-2360	.	_

#Text=Numerous imaging studies described cortical and subcortical dysfunctions in individuals addicted to cocaine or other stimulants.
17-1	2361-2369	Numerous	_
17-2	2370-2377	imaging	_
17-3	2378-2385	studies	_
17-4	2386-2395	described	_
17-5	2396-2404	cortical	_
17-6	2405-2408	and	_
17-7	2409-2420	subcortical	_
17-8	2421-2433	dysfunctions	_
17-9	2434-2436	in	_
17-10	2437-2448	individuals	_
17-11	2449-2457	addicted	_
17-12	2458-2460	to	_
17-13	2461-2468	cocaine	_
17-14	2469-2471	or	_
17-15	2472-2477	other	_
17-16	2478-2488	stimulants	_
17-17	2488-2489	.	_

#Text=For instance, chronic cocaine users showed hypo-activation of the thalamus during a visual spatial attention task.
18-1	2490-2493	For	_
18-2	2494-2502	instance	_
18-3	2502-2503	,	_
18-4	2504-2511	chronic	_
18-5	2512-2519	cocaine	_
18-6	2520-2525	users	_
18-7	2526-2532	showed	_
18-8	2533-2548	hypo-activation	_
18-9	2549-2551	of	_
18-10	2552-2555	the	_
18-11	2556-2564	thalamus	_
18-12	2565-2571	during	_
18-13	2572-2573	a	_
18-14	2574-2580	visual	_
18-15	2581-2588	spatial	_
18-16	2589-2598	attention	_
18-17	2599-2603	task	_
18-18	2603-2604	.	_

#Text=More recently, in a longitudinal study, we showed that decreased error-related activation of the thalamus predicts relapse and time to relapse to drug use in cocaine dependent individuals.
19-1	2605-2609	More	_
19-2	2610-2618	recently	_
19-3	2618-2619	,	_
19-4	2620-2622	in	_
19-5	2623-2624	a	_
19-6	2625-2637	longitudinal	_
19-7	2638-2643	study	_
19-8	2643-2644	,	_
19-9	2645-2647	we	_
19-10	2648-2654	showed	_
19-11	2655-2659	that	_
19-12	2660-2669	decreased	_
19-13	2670-2683	error-related	_
19-14	2684-2694	activation	_
19-15	2695-2697	of	_
19-16	2698-2701	the	_
19-17	2702-2710	thalamus	_
19-18	2711-2719	predicts	_
19-19	2720-2727	relapse	_
19-20	2728-2731	and	_
19-21	2732-2736	time	_
19-22	2737-2739	to	_
19-23	2740-2747	relapse	_
19-24	2748-2750	to	_
19-25	2751-2755	drug	_
19-26	2756-2759	use	_
19-27	2760-2762	in	_
19-28	2763-2770	cocaine	_
19-29	2771-2780	dependent	_
19-30	2781-2792	individuals	_
19-31	2792-2793	.	_

#Text=On the other hand, increased thalamic activations were observed in individuals with cocaine dependence and other addictive disorders when they were exposed to drug cues or situational factors related to drug use.
20-1	2794-2796	On	_
20-2	2797-2800	the	_
20-3	2801-2806	other	_
20-4	2807-2811	hand	_
20-5	2811-2812	,	_
20-6	2813-2822	increased	_
20-7	2823-2831	thalamic	_
20-8	2832-2843	activations	_
20-9	2844-2848	were	_
20-10	2849-2857	observed	_
20-11	2858-2860	in	_
20-12	2861-2872	individuals	_
20-13	2873-2877	with	_
20-14	2878-2885	cocaine	_
20-15	2886-2896	dependence	_
20-16	2897-2900	and	_
20-17	2901-2906	other	_
20-18	2907-2916	addictive	_
20-19	2917-2926	disorders	_
20-20	2927-2931	when	_
20-21	2932-2936	they	_
20-22	2937-2941	were	_
20-23	2942-2949	exposed	_
20-24	2950-2952	to	_
20-25	2953-2957	drug	_
20-26	2958-2962	cues	_
20-27	2963-2965	or	_
20-28	2966-2977	situational	_
20-29	2978-2985	factors	_
20-30	2986-2993	related	_
20-31	2994-2996	to	_
20-32	2997-3001	drug	_
20-33	3002-3005	use	_
20-34	3005-3006	.	_

#Text=This seeming inconsistency may relate to functional heterogeneity of the thalamus, with some subregions mediating craving and others subserving control of craving.
21-1	3007-3011	This	_
21-2	3012-3019	seeming	_
21-3	3020-3033	inconsistency	_
21-4	3034-3037	may	_
21-5	3038-3044	relate	_
21-6	3045-3047	to	_
21-7	3048-3058	functional	_
21-8	3059-3072	heterogeneity	_
21-9	3073-3075	of	_
21-10	3076-3079	the	_
21-11	3080-3088	thalamus	_
21-12	3088-3089	,	_
21-13	3090-3094	with	_
21-14	3095-3099	some	_
21-15	3100-3110	subregions	_
21-16	3111-3120	mediating	_
21-17	3121-3128	craving	_
21-18	3129-3132	and	_
21-19	3133-3139	others	_
21-20	3140-3150	subserving	_
21-21	3151-3158	control	_
21-22	3159-3161	of	_
21-23	3162-3169	craving	_
21-24	3169-3170	.	_

#Text=Understanding how thalamic cortical circuits respond to different psychological constructs and behavioral contexts will help elucidate the multifaceted etiologies of cocaine addiction.
22-1	3171-3184	Understanding	_
22-2	3185-3188	how	_
22-3	3189-3197	thalamic	_
22-4	3198-3206	cortical	_
22-5	3207-3215	circuits	_
22-6	3216-3223	respond	_
22-7	3224-3226	to	_
22-8	3227-3236	different	_
22-9	3237-3250	psychological	_
22-10	3251-3261	constructs	_
22-11	3262-3265	and	_
22-12	3266-3276	behavioral	_
22-13	3277-3285	contexts	_
22-14	3286-3290	will	_
22-15	3291-3295	help	_
22-16	3296-3305	elucidate	_
22-17	3306-3309	the	_
22-18	3310-3322	multifaceted	_
22-19	3323-3333	etiologies	_
22-20	3334-3336	of	_
22-21	3337-3344	cocaine	_
22-22	3345-3354	addiction	_
22-23	3354-3355	.	_

#Text=Many studies have demonstrated altered cerebral functional connectivities in cocaine dependence.
23-1	3356-3360	Many	_
23-2	3361-3368	studies	_
23-3	3369-3373	have	_
23-4	3374-3386	demonstrated	_
23-5	3387-3394	altered	_
23-6	3395-3403	cerebral	_
23-7	3404-3414	functional	_
23-8	3415-3429	connectivities	_
23-9	3430-3432	in	_
23-10	3433-3440	cocaine	_
23-11	3441-3451	dependence	_
23-12	3451-3452	.	_

#Text=Reduced connectivities were observed in cocaine users between the thalamus and midbrain, putamen and ventral tegmental area, and anterior cingulate cortex.
24-1	3453-3460	Reduced	_
24-2	3461-3475	connectivities	_
24-3	3476-3480	were	_
24-4	3481-3489	observed	_
24-5	3490-3492	in	_
24-6	3493-3500	cocaine	_
24-7	3501-3506	users	_
24-8	3507-3514	between	_
24-9	3515-3518	the	_
24-10	3519-3527	thalamus	_
24-11	3528-3531	and	_
24-12	3532-3540	midbrain	_
24-13	3540-3541	,	_
24-14	3542-3549	putamen	_
24-15	3550-3553	and	_
24-16	3554-3561	ventral	_
24-17	3562-3571	tegmental	_
24-18	3572-3576	area	_
24-19	3576-3577	,	_
24-20	3578-3581	and	_
24-21	3582-3590	anterior	_
24-22	3591-3600	cingulate	_
24-23	3601-3607	cortex	_
24-24	3607-3608	.	_

#Text=The connectivity between the thalamus and midbrain and ventral tegmental area correlated negatively with the number of years of cocaine use.
25-1	3609-3612	The	_
25-2	3613-3625	connectivity	_
25-3	3626-3633	between	_
25-4	3634-3637	the	_
25-5	3638-3646	thalamus	_
25-6	3647-3650	and	_
25-7	3651-3659	midbrain	_
25-8	3660-3663	and	_
25-9	3664-3671	ventral	_
25-10	3672-3681	tegmental	_
25-11	3682-3686	area	_
25-12	3687-3697	correlated	_
25-13	3698-3708	negatively	_
25-14	3709-3713	with	_
25-15	3714-3717	the	_
25-16	3718-3724	number	_
25-17	3725-3727	of	_
25-18	3728-3733	years	_
25-19	3734-3736	of	_
25-20	3737-3744	cocaine	_
25-21	3745-3748	use	_
25-22	3748-3749	.	_

#Text=These studies suggest that cocaine use affects not only the activity but also connectivity of the thalamus.
26-1	3750-3755	These	_
26-2	3756-3763	studies	_
26-3	3764-3771	suggest	_
26-4	3772-3776	that	_
26-5	3777-3784	cocaine	_
26-6	3785-3788	use	_
26-7	3789-3796	affects	_
26-8	3797-3800	not	_
26-9	3801-3805	only	_
26-10	3806-3809	the	_
26-11	3810-3818	activity	_
26-12	3819-3822	but	_
26-13	3823-3827	also	_
26-14	3828-3840	connectivity	_
26-15	3841-3843	of	_
26-16	3844-3847	the	_
26-17	3848-3856	thalamus	_
26-18	3856-3857	.	_

#Text=Investigating the functional connectivities of the thalamus may further uncover circuit-level disturbances in cocaine dependence.
27-1	3858-3871	Investigating	_
27-2	3872-3875	the	_
27-3	3876-3886	functional	_
27-4	3887-3901	connectivities	_
27-5	3902-3904	of	_
27-6	3905-3908	the	_
27-7	3909-3917	thalamus	_
27-8	3918-3921	may	_
27-9	3922-3929	further	_
27-10	3930-3937	uncover	_
27-11	3938-3951	circuit-level	_
27-12	3952-3964	disturbances	_
27-13	3965-3967	in	_
27-14	3968-3975	cocaine	_
27-15	3976-3986	dependence	_
27-16	3986-3987	.	_

#Text=Connectivity analysis has delineated functional subclusters of the thalamus in accordance with anatomy.
28-1	3988-4000	Connectivity	_
28-2	4001-4009	analysis	_
28-3	4010-4013	has	_
28-4	4014-4024	delineated	_
28-5	4025-4035	functional	_
28-6	4036-4047	subclusters	_
28-7	4048-4050	of	_
28-8	4051-4054	the	_
28-9	4055-4063	thalamus	_
28-10	4064-4066	in	_
28-11	4067-4077	accordance	_
28-12	4078-4082	with	_
28-13	4083-4090	anatomy	_
28-14	4090-4091	.	_

#Text=Multivariate pattern analysis (MVPA), a data-driven technique, can provide new insights into cerebral functional organization.
29-1	4092-4104	Multivariate	_
29-2	4105-4112	pattern	_
29-3	4113-4121	analysis	_
29-4	4122-4123	(	_
29-5	4123-4127	MVPA	_
29-6	4127-4128	)	_
29-7	4128-4129	,	_
29-8	4130-4131	a	_
29-9	4132-4143	data-driven	_
29-10	4144-4153	technique	_
29-11	4153-4154	,	_
29-12	4155-4158	can	_
29-13	4159-4166	provide	_
29-14	4167-4170	new	_
29-15	4171-4179	insights	_
29-16	4180-4184	into	_
29-17	4185-4193	cerebral	_
29-18	4194-4204	functional	_
29-19	4205-4217	organization	_
29-20	4217-4218	.	_

#Text=Compared to univariate analyses, MVPA fully utilizes activity patterns across multiple variables and increases sensitivity in differential diagnostics.
30-1	4219-4227	Compared	_
30-2	4228-4230	to	_
30-3	4231-4241	univariate	_
30-4	4242-4250	analyses	_
30-5	4250-4251	,	_
30-6	4252-4256	MVPA	_
30-7	4257-4262	fully	_
30-8	4263-4271	utilizes	_
30-9	4272-4280	activity	_
30-10	4281-4289	patterns	_
30-11	4290-4296	across	_
30-12	4297-4305	multiple	_
30-13	4306-4315	variables	_
30-14	4316-4319	and	_
30-15	4320-4329	increases	_
30-16	4330-4341	sensitivity	_
30-17	4342-4344	in	_
30-18	4345-4357	differential	_
30-19	4358-4369	diagnostics	_
30-20	4369-4370	.	_

#Text=MVPA has been used to predict behavioral variables and outcomes, decode cognitive states, and identify patients with depression, functional dyspepsia, autism, binge-eating, mild cognitive impairment/Alzheimer's disease, attention-deficit/hyperactivity disorder, and schizophrenia, in a variety of behavioral contexts.
31-1	4371-4375	MVPA	_
31-2	4376-4379	has	_
31-3	4380-4384	been	_
31-4	4385-4389	used	_
31-5	4390-4392	to	_
31-6	4393-4400	predict	_
31-7	4401-4411	behavioral	_
31-8	4412-4421	variables	_
31-9	4422-4425	and	_
31-10	4426-4434	outcomes	_
31-11	4434-4435	,	_
31-12	4436-4442	decode	_
31-13	4443-4452	cognitive	_
31-14	4453-4459	states	_
31-15	4459-4460	,	_
31-16	4461-4464	and	_
31-17	4465-4473	identify	_
31-18	4474-4482	patients	_
31-19	4483-4487	with	_
31-20	4488-4498	depression	_
31-21	4498-4499	,	_
31-22	4500-4510	functional	_
31-23	4511-4520	dyspepsia	_
31-24	4520-4521	,	_
31-25	4522-4528	autism	_
31-26	4528-4529	,	_
31-27	4530-4542	binge-eating	_
31-28	4542-4543	,	_
31-29	4544-4548	mild	_
31-30	4549-4558	cognitive	_
31-31	4559-4569	impairment	_
31-32	4569-4570	/	_
31-33	4570-4581	Alzheimer's	_
31-34	4582-4589	disease	_
31-35	4589-4590	,	_
31-36	4591-4608	attention-deficit	_
31-37	4608-4609	/	_
31-38	4609-4622	hyperactivity	_
31-39	4623-4631	disorder	_
31-40	4631-4632	,	_
31-41	4633-4636	and	_
31-42	4637-4650	schizophrenia	_
31-43	4650-4651	,	_
31-44	4652-4654	in	_
31-45	4655-4656	a	_
31-46	4657-4664	variety	_
31-47	4665-4667	of	_
31-48	4668-4678	behavioral	_
31-49	4679-4687	contexts	_
31-50	4687-4688	.	_

#Text=However, to our knowledge, no studies have used MVPA to examine brain activity and connectivity in cocaine addiction.
32-1	4689-4696	However	_
32-2	4696-4697	,	_
32-3	4698-4700	to	_
32-4	4701-4704	our	_
32-5	4705-4714	knowledge	_
32-6	4714-4715	,	_
32-7	4716-4718	no	_
32-8	4719-4726	studies	_
32-9	4727-4731	have	_
32-10	4732-4736	used	_
32-11	4737-4741	MVPA	_
32-12	4742-4744	to	_
32-13	4745-4752	examine	_
32-14	4753-4758	brain	_
32-15	4759-4767	activity	_
32-16	4768-4771	and	_
32-17	4772-4784	connectivity	_
32-18	4785-4787	in	_
32-19	4788-4795	cocaine	_
32-20	4796-4805	addiction	_
32-21	4805-4806	.	_

#Text=Here, we applied MVPA to examine altered thalamic functional connectivity in participants with cocaine dependence (CD).
33-1	4807-4811	Here	_
33-2	4811-4812	,	_
33-3	4813-4815	we	_
33-4	4816-4823	applied	_
33-5	4824-4828	MVPA	_
33-6	4829-4831	to	_
33-7	4832-4839	examine	_
33-8	4840-4847	altered	_
33-9	4848-4856	thalamic	_
33-10	4857-4867	functional	_
33-11	4868-4880	connectivity	_
33-12	4881-4883	in	_
33-13	4884-4896	participants	_
33-14	4897-4901	with	_
33-15	4902-4909	cocaine	_
33-16	4910-4920	dependence	_
33-17	4921-4922	(	_
33-18	4922-4924	CD	_
33-19	4924-4925	)	_
33-20	4925-4926	.	_

#Text=Our earlier work of independent component analysis identified six independent networks of cognitive control from the stop signal task.
34-1	4927-4930	Our	_
34-2	4931-4938	earlier	_
34-3	4939-4943	work	_
34-4	4944-4946	of	_
34-5	4947-4958	independent	_
34-6	4959-4968	component	_
34-7	4969-4977	analysis	_
34-8	4978-4988	identified	_
34-9	4989-4992	six	_
34-10	4993-5004	independent	_
34-11	5005-5013	networks	_
34-12	5014-5016	of	_
34-13	5017-5026	cognitive	_
34-14	5027-5034	control	_
34-15	5035-5039	from	_
34-16	5040-5043	the	_
34-17	5044-5048	stop	_
34-18	5049-5055	signal	_
34-19	5056-5060	task	_
34-20	5060-5061	.	_

#Text=We sought to distinguish CD from healthy controls (HC) with MVPA of voxel-wise thalamic connectivity to these six task-related networks (please see Methods).
35-1	5062-5064	We	_
35-2	5065-5071	sought	_
35-3	5072-5074	to	_
35-4	5075-5086	distinguish	_
35-5	5087-5089	CD	_
35-6	5090-5094	from	_
35-7	5095-5102	healthy	_
35-8	5103-5111	controls	_
35-9	5112-5113	(	_
35-10	5113-5115	HC	_
35-11	5115-5116	)	_
35-12	5117-5121	with	_
35-13	5122-5126	MVPA	_
35-14	5127-5129	of	_
35-15	5130-5140	voxel-wise	_
35-16	5141-5149	thalamic	_
35-17	5150-5162	connectivity	_
35-18	5163-5165	to	_
35-19	5166-5171	these	_
35-20	5172-5175	six	_
35-21	5176-5188	task-related	_
35-22	5189-5197	networks	_
35-23	5198-5199	(	_
35-24	5199-5205	please	_
35-25	5206-5209	see	_
35-26	5210-5217	Methods	_
35-27	5217-5218	)	_
35-28	5218-5219	.	_

#Text=We posited that, first, thalamic connectivity to these networks should distinguish CD from HC at an accuracy higher than comparison regions with similar volumes (number of voxels).
36-1	5220-5222	We	_
36-2	5223-5230	posited	_
36-3	5231-5235	that	_
36-4	5235-5236	,	_
36-5	5237-5242	first	_
36-6	5242-5243	,	_
36-7	5244-5252	thalamic	_
36-8	5253-5265	connectivity	_
36-9	5266-5268	to	_
36-10	5269-5274	these	_
36-11	5275-5283	networks	_
36-12	5284-5290	should	_
36-13	5291-5302	distinguish	_
36-14	5303-5305	CD	_
36-15	5306-5310	from	_
36-16	5311-5313	HC	_
36-17	5314-5316	at	_
36-18	5317-5319	an	_
36-19	5320-5328	accuracy	_
36-20	5329-5335	higher	_
36-21	5336-5340	than	_
36-22	5341-5351	comparison	_
36-23	5352-5359	regions	_
36-24	5360-5364	with	_
36-25	5365-5372	similar	_
36-26	5373-5380	volumes	_
36-27	5381-5382	(	_
36-28	5382-5388	number	_
36-29	5389-5391	of	_
36-30	5392-5398	voxels	_
36-31	5398-5399	)	_
36-32	5399-5400	.	_

#Text=Second, the voxels of which the connectivities to a set of independent components determine the “membership” should aggregate in clusters (as subnuclei) rather than distribute randomly.
37-1	5401-5407	Second	_
37-2	5407-5408	,	_
37-3	5409-5412	the	_
37-4	5413-5419	voxels	_
37-5	5420-5422	of	_
37-6	5423-5428	which	_
37-7	5429-5432	the	_
37-8	5433-5447	connectivities	_
37-9	5448-5450	to	_
37-10	5451-5452	a	_
37-11	5453-5456	set	_
37-12	5457-5459	of	_
37-13	5460-5471	independent	_
37-14	5472-5482	components	_
37-15	5483-5492	determine	_
37-16	5493-5496	the	_
37-17	5497-5498	“	_
37-18	5498-5508	membership	_
37-19	5508-5509	”	_
37-20	5510-5516	should	_
37-21	5517-5526	aggregate	_
37-22	5527-5529	in	_
37-23	5530-5538	clusters	_
37-24	5539-5540	(	_
37-25	5540-5542	as	_
37-26	5543-5552	subnuclei	_
37-27	5552-5553	)	_
37-28	5554-5560	rather	_
37-29	5561-5565	than	_
37-30	5566-5576	distribute	_
37-31	5577-5585	randomly	_
37-32	5585-5586	.	_

#Text=Thus, we have these specific aims: to investigate whether we could identify CD using only functional connectivity of the thalamus; to examine how the individual voxels of the thalamus distinguish CD from HC with functional connectivities for cognitive control; and to explore the correlation of these connectivities with clinical and performance variables.
38-1	5587-5591	Thus	_
38-2	5591-5592	,	_
38-3	5593-5595	we	_
38-4	5596-5600	have	_
38-5	5601-5606	these	_
38-6	5607-5615	specific	_
38-7	5616-5620	aims	_
38-8	5620-5621	:	_
38-9	5622-5624	to	_
38-10	5625-5636	investigate	_
38-11	5637-5644	whether	_
38-12	5645-5647	we	_
38-13	5648-5653	could	_
38-14	5654-5662	identify	_
38-15	5663-5665	CD	_
38-16	5666-5671	using	_
38-17	5672-5676	only	_
38-18	5677-5687	functional	_
38-19	5688-5700	connectivity	_
38-20	5701-5703	of	_
38-21	5704-5707	the	_
38-22	5708-5716	thalamus	_
38-23	5716-5717	;	_
38-24	5718-5720	to	_
38-25	5721-5728	examine	_
38-26	5729-5732	how	_
38-27	5733-5736	the	_
38-28	5737-5747	individual	_
38-29	5748-5754	voxels	_
38-30	5755-5757	of	_
38-31	5758-5761	the	_
38-32	5762-5770	thalamus	_
38-33	5771-5782	distinguish	_
38-34	5783-5785	CD	_
38-35	5786-5790	from	_
38-36	5791-5793	HC	_
38-37	5794-5798	with	_
38-38	5799-5809	functional	_
38-39	5810-5824	connectivities	_
38-40	5825-5828	for	_
38-41	5829-5838	cognitive	_
38-42	5839-5846	control	_
38-43	5846-5847	;	_
38-44	5848-5851	and	_
38-45	5852-5854	to	_
38-46	5855-5862	explore	_
38-47	5863-5866	the	_
38-48	5867-5878	correlation	_
38-49	5879-5881	of	_
38-50	5882-5887	these	_
38-51	5888-5902	connectivities	_
38-52	5903-5907	with	_
38-53	5908-5916	clinical	_
38-54	5917-5920	and	_
38-55	5921-5932	performance	_
38-56	5933-5942	variables	_
38-57	5942-5943	.	_

#Text=Materials and methods
#Text=Subjects, informed consent, and assessment
#Text=One hundred recently abstinent participants (62 men) with cocaine dependence (CD) and one hundred age- and gender-matched healthy adult (HC) subjects (55 men) participated in this study (Table 1).
39-1	5944-5953	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
39-2	5954-5957	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
39-3	5958-5965	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
39-4	5966-5974	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-5	5974-5975	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-6	5976-5984	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-7	5985-5992	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-8	5992-5993	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-9	5994-5997	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-10	5998-6008	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-11	6009-6012	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-12	6013-6020	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-13	6021-6029	recently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-14	6030-6039	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-15	6040-6052	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-16	6053-6054	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-17	6054-6056	62	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-18	6057-6060	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-19	6060-6061	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-20	6062-6066	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-21	6067-6074	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]
39-22	6075-6085	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]
39-23	6086-6087	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]
39-24	6087-6089	CD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]
39-25	6089-6090	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]
39-26	6091-6094	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-27	6095-6098	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-28	6099-6106	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-29	6107-6110	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-30	6110-6111	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-31	6112-6115	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-32	6116-6130	gender-matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-33	6131-6138	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-34	6139-6144	adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-35	6145-6146	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-36	6146-6148	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]
39-37	6148-6149	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-38	6150-6158	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-39	6159-6160	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-40	6160-6162	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-41	6163-6166	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-42	6166-6167	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-43	6168-6180	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-44	6181-6183	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-45	6184-6188	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-46	6189-6194	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-47	6195-6196	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-48	6196-6201	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-49	6202-6203	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-50	6203-6204	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
39-51	6204-6205	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=CD met criteria for current cocaine dependence, as diagnosed by the Structured Clinical Interview for DSM-IV.
40-1	6206-6208	CD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[12]
40-2	6209-6212	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-3	6213-6221	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-4	6222-6225	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-5	6226-6233	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-6	6234-6241	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[13]
40-7	6242-6252	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[13]
40-8	6252-6253	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-9	6254-6256	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-10	6257-6266	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-11	6267-6269	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-12	6270-6273	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
40-13	6274-6284	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[14]
40-14	6285-6293	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[14]
40-15	6294-6303	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[14]
40-16	6304-6307	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[14]
40-17	6308-6314	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[14]
40-18	6314-6315	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=Recent cocaine use was confirmed by urine toxicology screens.
41-1	6316-6322	Recent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-2	6323-6330	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-3	6331-6334	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-4	6335-6338	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-5	6339-6348	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-6	6349-6351	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-7	6352-6357	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-8	6358-6368	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-9	6369-6376	screens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
41-10	6376-6377	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=They were drug-free while staying in an inpatient unit prior to the current fMRI study.
42-1	6378-6382	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-2	6383-6387	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-3	6388-6397	drug-free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-4	6398-6403	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-5	6404-6411	staying	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-6	6412-6414	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-7	6415-6417	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-8	6418-6427	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-9	6428-6432	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-10	6433-6438	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-11	6439-6441	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-12	6442-6445	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-13	6446-6453	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-14	6454-6458	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[15]
42-15	6459-6464	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
42-16	6464-6465	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=All subjects were physically healthy with no major medical illnesses or current use of prescription medications.
43-1	6466-6469	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-2	6470-6478	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-3	6479-6483	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-4	6484-6494	physically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-5	6495-6502	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-6	6503-6507	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-7	6508-6510	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-8	6511-6516	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-9	6517-6524	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-10	6525-6534	illnesses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-11	6535-6537	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-12	6538-6545	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-13	6546-6549	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-14	6550-6552	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-15	6553-6565	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-16	6566-6577	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
43-17	6577-6578	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=None reported having a history of head injury or neurological illness.
44-1	6579-6583	None	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-2	6584-6592	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-3	6593-6599	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-4	6600-6601	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-5	6602-6609	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-6	6610-6612	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-7	6613-6617	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-8	6618-6624	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-9	6625-6627	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-10	6628-6640	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-11	6641-6648	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
44-12	6648-6649	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=Other exclusion criteria included dependence on another psychoactive substance (except nicotine) and current or past history of psychotic disorders.
45-1	6650-6655	Other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-2	6656-6665	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-3	6666-6674	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-4	6675-6683	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-5	6684-6694	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-6	6695-6697	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-7	6698-6705	another	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-8	6706-6718	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-9	6719-6728	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-10	6729-6730	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-11	6730-6736	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-12	6737-6745	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-13	6745-6746	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-14	6747-6750	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-15	6751-6758	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-16	6759-6761	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-17	6762-6766	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-18	6767-6774	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-19	6775-6777	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-20	6778-6787	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-21	6788-6797	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
45-22	6797-6798	.	_

#Text=Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms were excluded as well.
46-1	6799-6810	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-2	6811-6815	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-3	6816-6823	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-4	6824-6834	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-5	6835-6837	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-6	6838-6845	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-7	6846-6854	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-8	6855-6864	requiring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-9	6865-6874	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-10	6875-6877	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-11	6878-6887	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-12	6888-6893	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-13	6894-6901	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-14	6902-6905	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-15	6906-6911	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-16	6912-6920	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-17	6921-6925	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-18	6926-6934	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-19	6935-6937	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-20	6938-6942	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
46-21	6942-6943	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=The Human Investigation committee at Yale University School of Medicine approved all study procedures, and all subjects signed an informed consent prior to study participation.
47-1	6944-6947	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-2	6948-6953	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-3	6954-6967	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-4	6968-6977	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-5	6978-6980	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-6	6981-6985	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-7	6986-6996	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-8	6997-7003	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-9	7004-7006	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-10	7007-7015	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-11	7016-7024	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-12	7025-7028	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-13	7029-7034	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-14	7035-7045	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-15	7045-7046	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-16	7047-7050	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-17	7051-7054	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-18	7055-7063	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-19	7064-7070	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-20	7071-7073	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-21	7074-7082	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-22	7083-7090	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-23	7091-7096	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-24	7097-7099	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-25	7100-7105	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-26	7106-7119	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-27	7119-7120	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=CD's were assessed with the Beck Depression Inventory and the State-Trait Anxiety Inventory at admission.
48-1	7121-7125	CD's	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
48-2	7126-7130	were	_
48-3	7131-7139	assessed	_
48-4	7140-7144	with	_
48-5	7145-7148	the	_
48-6	7149-7153	Beck	_
48-7	7154-7164	Depression	_
48-8	7165-7174	Inventory	_
48-9	7175-7178	and	_
48-10	7179-7182	the	_
48-11	7183-7194	State-Trait	_
48-12	7195-7202	Anxiety	_
48-13	7203-7212	Inventory	_
48-14	7213-7215	at	_
48-15	7216-7225	admission	_
48-16	7225-7226	.	_

#Text=The mean (± SD) BDI (12.2 ± 8.9) and STAI state (36.2 ± 10.7) and trait (40.7 ± 11.2) scores were within the range reported previously for individuals with cocaine dependence.
49-1	7227-7230	The	_
49-2	7231-7235	mean	_
49-3	7236-7237	(	_
49-4	7237-7238	±	_
49-5	7238-7239	 	_
49-6	7239-7241	SD	_
49-7	7241-7242	)	_
49-8	7243-7246	BDI	_
49-9	7247-7248	(	_
49-10	7248-7252	12.2	_
49-11	7252-7253	 	_
49-12	7253-7254	±	_
49-13	7254-7255	 	_
49-14	7255-7258	8.9	_
49-15	7258-7259	)	_
49-16	7260-7263	and	_
49-17	7264-7268	STAI	_
49-18	7269-7274	state	_
49-19	7275-7276	(	_
49-20	7276-7280	36.2	_
49-21	7280-7281	 	_
49-22	7281-7282	±	_
49-23	7282-7283	 	_
49-24	7283-7287	10.7	_
49-25	7287-7288	)	_
49-26	7289-7292	and	_
49-27	7293-7298	trait	_
49-28	7299-7300	(	_
49-29	7300-7304	40.7	_
49-30	7304-7305	 	_
49-31	7305-7306	±	_
49-32	7306-7307	 	_
49-33	7307-7311	11.2	_
49-34	7311-7312	)	_
49-35	7313-7319	scores	_
49-36	7320-7324	were	_
49-37	7325-7331	within	_
49-38	7332-7335	the	_
49-39	7336-7341	range	_
49-40	7342-7350	reported	_
49-41	7351-7361	previously	_
49-42	7362-7365	for	_
49-43	7366-7377	individuals	_
49-44	7378-7382	with	_
49-45	7383-7390	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[17]
49-46	7391-7401	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[17]
49-47	7401-7402	.	_

#Text=Cocaine craving was assessed with the cocaine craving questionnaire, brief version (CCQ-Brief), for all participants every two to three days.
50-1	7403-7410	Cocaine	_
50-2	7411-7418	craving	_
50-3	7419-7422	was	_
50-4	7423-7431	assessed	_
50-5	7432-7436	with	_
50-6	7437-7440	the	_
50-7	7441-7448	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-8	7449-7456	craving	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-9	7457-7470	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-10	7470-7471	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-11	7472-7477	brief	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-12	7478-7485	version	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-13	7486-7487	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-14	7487-7496	CCQ-Brief	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-15	7496-7497	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion[18]
50-16	7497-7498	,	_
50-17	7499-7502	for	_
50-18	7503-7506	all	_
50-19	7507-7519	participants	_
50-20	7520-7525	every	_
50-21	7526-7529	two	_
50-22	7530-7532	to	_
50-23	7533-7538	three	_
50-24	7539-7543	days	_
50-25	7543-7544	.	_

#Text=The CCQ-Brief is a 10-item questionnaire, abbreviated from the CCQ-Now.
51-1	7545-7548	The	_
51-2	7549-7558	CCQ-Brief	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire\_BriefVersion
51-3	7559-7561	is	_
51-4	7562-7563	a	_
51-5	7564-7566	10	_
51-6	7566-7567	-	_
51-7	7567-7571	item	_
51-8	7572-7585	questionnaire	_
51-9	7585-7586	,	_
51-10	7587-7598	abbreviated	_
51-11	7599-7603	from	_
51-12	7604-7607	the	_
51-13	7608-7615	CCQ-Now	_
51-14	7615-7616	.	_

#Text=It is highly correlated with the CCQ-Now and other cocaine craving measures.
52-1	7617-7619	It	_
52-2	7620-7622	is	_
52-3	7623-7629	highly	_
52-4	7630-7640	correlated	_
52-5	7641-7645	with	_
52-6	7646-7649	the	_
52-7	7650-7657	CCQ-Now	_
52-8	7658-7661	and	_
52-9	7662-7667	other	_
52-10	7668-7675	cocaine	_
52-11	7676-7683	craving	_
52-12	7684-7692	measures	_
52-13	7692-7693	.	_

#Text=Each item was rated on a scale from 1 to 7, with a higher total score (ranging from 10 to 70) indicating greater craving.
53-1	7694-7698	Each	_
53-2	7699-7703	item	_
53-3	7704-7707	was	_
53-4	7708-7713	rated	_
53-5	7714-7716	on	_
53-6	7717-7718	a	_
53-7	7719-7724	scale	_
53-8	7725-7729	from	_
53-9	7730-7731	1	_
53-10	7732-7734	to	_
53-11	7735-7736	7	_
53-12	7736-7737	,	_
53-13	7738-7742	with	_
53-14	7743-7744	a	_
53-15	7745-7751	higher	_
53-16	7752-7757	total	_
53-17	7758-7763	score	_
53-18	7764-7765	(	_
53-19	7765-7772	ranging	_
53-20	7773-7777	from	_
53-21	7778-7780	10	_
53-22	7781-7783	to	_
53-23	7784-7786	70	_
53-24	7786-7787	)	_
53-25	7788-7798	indicating	_
53-26	7799-7806	greater	_
53-27	7807-7814	craving	_
53-28	7814-7815	.	_

#Text=CDs averaged CCQ scores of 20.0 ± 7.8 across all assessments and 18.0 ± 5.5 on the day or within 2–3 days of the scan.
54-1	7816-7819	CDs	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
54-2	7820-7828	averaged	_
54-3	7829-7832	CCQ	_
54-4	7833-7839	scores	_
54-5	7840-7842	of	_
54-6	7843-7847	20.0	_
54-7	7847-7848	 	_
54-8	7848-7849	±	_
54-9	7849-7850	 	_
54-10	7850-7853	7.8	_
54-11	7854-7860	across	_
54-12	7861-7864	all	_
54-13	7865-7876	assessments	_
54-14	7877-7880	and	_
54-15	7881-7885	18.0	_
54-16	7885-7886	 	_
54-17	7886-7887	±	_
54-18	7887-7888	 	_
54-19	7888-7891	5.5	_
54-20	7892-7894	on	_
54-21	7895-7898	the	_
54-22	7899-7902	day	_
54-23	7903-7905	or	_
54-24	7906-7912	within	_
54-25	7913-7914	2	_
54-26	7914-7915	–	_
54-27	7915-7916	3	_
54-28	7916-7917	 	_
54-29	7917-7921	days	_
54-30	7922-7924	of	_
54-31	7925-7928	the	_
54-32	7929-7933	scan	_
54-33	7933-7934	.	_

#Text=The majority of CDs received all of these assessments, and subjects with missing data were not included in the correlation analyses (see below).
55-1	7935-7938	The	_
55-2	7939-7947	majority	_
55-3	7948-7950	of	_
55-4	7951-7954	CDs	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
55-5	7955-7963	received	_
55-6	7964-7967	all	_
55-7	7968-7970	of	_
55-8	7971-7976	these	_
55-9	7977-7988	assessments	_
55-10	7988-7989	,	_
55-11	7990-7993	and	_
55-12	7994-8002	subjects	_
55-13	8003-8007	with	_
55-14	8008-8015	missing	_
55-15	8016-8020	data	_
55-16	8021-8025	were	_
55-17	8026-8029	not	_
55-18	8030-8038	included	_
55-19	8039-8041	in	_
55-20	8042-8045	the	_
55-21	8046-8057	correlation	_
55-22	8058-8066	analyses	_
55-23	8067-8068	(	_
55-24	8068-8071	see	_
55-25	8072-8077	below	_
55-26	8077-8078	)	_
55-27	8078-8079	.	_

#Text=Behavioral task and scan procedures
#Text=We employed a stop-signal task (SST) as detailed in our previous studies.
56-1	8080-8090	Behavioral	_
56-2	8091-8095	task	_
56-3	8096-8099	and	_
56-4	8100-8104	scan	_
56-5	8105-8115	procedures	_
56-6	8116-8118	We	_
56-7	8119-8127	employed	_
56-8	8128-8129	a	_
56-9	8130-8141	stop-signal	_
56-10	8142-8146	task	_
56-11	8147-8148	(	_
56-12	8148-8151	SST	_
56-13	8151-8152	)	_
56-14	8153-8155	as	_
56-15	8156-8164	detailed	_
56-16	8165-8167	in	_
56-17	8168-8171	our	_
56-18	8172-8180	previous	_
56-19	8181-8188	studies	_
56-20	8188-8189	.	_

#Text=Briefly, there were two trial types: “go” and “stop,” randomly intermixed.
57-1	8190-8197	Briefly	_
57-2	8197-8198	,	_
57-3	8199-8204	there	_
57-4	8205-8209	were	_
57-5	8210-8213	two	_
57-6	8214-8219	trial	_
57-7	8220-8225	types	_
57-8	8225-8226	:	_
57-9	8227-8228	“	_
57-10	8228-8230	go	_
57-11	8230-8231	”	_
57-12	8232-8235	and	_
57-13	8236-8237	“	_
57-14	8237-8241	stop	_
57-15	8241-8242	,	_
57-16	8242-8243	”	_
57-17	8244-8252	randomly	_
57-18	8253-8263	intermixed	_
57-19	8263-8264	.	_

#Text=A small dot appeared on the screen to engage attention at the beginning of a go trial.
58-1	8265-8266	A	_
58-2	8267-8272	small	_
58-3	8273-8276	dot	_
58-4	8277-8285	appeared	_
58-5	8286-8288	on	_
58-6	8289-8292	the	_
58-7	8293-8299	screen	_
58-8	8300-8302	to	_
58-9	8303-8309	engage	_
58-10	8310-8319	attention	_
58-11	8320-8322	at	_
58-12	8323-8326	the	_
58-13	8327-8336	beginning	_
58-14	8337-8339	of	_
58-15	8340-8341	a	_
58-16	8342-8344	go	_
58-17	8345-8350	trial	_
58-18	8350-8351	.	_

#Text=After a randomized time interval (fore-period) between 1s and 5s, the dot turned into a circle, prompting the subjects to quickly press a button.
59-1	8352-8357	After	_
59-2	8358-8359	a	_
59-3	8360-8370	randomized	_
59-4	8371-8375	time	_
59-5	8376-8384	interval	_
59-6	8385-8386	(	_
59-7	8386-8397	fore-period	_
59-8	8397-8398	)	_
59-9	8399-8406	between	_
59-10	8407-8409	1s	_
59-11	8410-8413	and	_
59-12	8414-8416	5s	_
59-13	8416-8417	,	_
59-14	8418-8421	the	_
59-15	8422-8425	dot	_
59-16	8426-8432	turned	_
59-17	8433-8437	into	_
59-18	8438-8439	a	_
59-19	8440-8446	circle	_
59-20	8446-8447	,	_
59-21	8448-8457	prompting	_
59-22	8458-8461	the	_
59-23	8462-8470	subjects	_
59-24	8471-8473	to	_
59-25	8474-8481	quickly	_
59-26	8482-8487	press	_
59-27	8488-8489	a	_
59-28	8490-8496	button	_
59-29	8496-8497	.	_

#Text=The circle vanished at button press or after 1s had elapsed, whichever came first, and the trial terminated.
60-1	8498-8501	The	_
60-2	8502-8508	circle	_
60-3	8509-8517	vanished	_
60-4	8518-8520	at	_
60-5	8521-8527	button	_
60-6	8528-8533	press	_
60-7	8534-8536	or	_
60-8	8537-8542	after	_
60-9	8543-8545	1s	_
60-10	8546-8549	had	_
60-11	8550-8557	elapsed	_
60-12	8557-8558	,	_
60-13	8559-8568	whichever	_
60-14	8569-8573	came	_
60-15	8574-8579	first	_
60-16	8579-8580	,	_
60-17	8581-8584	and	_
60-18	8585-8588	the	_
60-19	8589-8594	trial	_
60-20	8595-8605	terminated	_
60-21	8605-8606	.	_

#Text=A premature button press prior to the appearance of the circle also terminated the trial.
61-1	8607-8608	A	_
61-2	8609-8618	premature	_
61-3	8619-8625	button	_
61-4	8626-8631	press	_
61-5	8632-8637	prior	_
61-6	8638-8640	to	_
61-7	8641-8644	the	_
61-8	8645-8655	appearance	_
61-9	8656-8658	of	_
61-10	8659-8662	the	_
61-11	8663-8669	circle	_
61-12	8670-8674	also	_
61-13	8675-8685	terminated	_
61-14	8686-8689	the	_
61-15	8690-8695	trial	_
61-16	8695-8696	.	_

#Text=Three quarters of all trials were go trials.
62-1	8697-8702	Three	_
62-2	8703-8711	quarters	_
62-3	8712-8714	of	_
62-4	8715-8718	all	_
62-5	8719-8725	trials	_
62-6	8726-8730	were	_
62-7	8731-8733	go	_
62-8	8734-8740	trials	_
62-9	8740-8741	.	_

#Text=In a stop trial, an additional “X,” the “stop” signal, appeared after the go signal.
63-1	8742-8744	In	_
63-2	8745-8746	a	_
63-3	8747-8751	stop	_
63-4	8752-8757	trial	_
63-5	8757-8758	,	_
63-6	8759-8761	an	_
63-7	8762-8772	additional	_
63-8	8773-8774	“	_
63-9	8774-8775	X	_
63-10	8775-8776	,	_
63-11	8776-8777	”	_
63-12	8778-8781	the	_
63-13	8782-8783	“	_
63-14	8783-8787	stop	_
63-15	8787-8788	”	_
63-16	8789-8795	signal	_
63-17	8795-8796	,	_
63-18	8797-8805	appeared	_
63-19	8806-8811	after	_
63-20	8812-8815	the	_
63-21	8816-8818	go	_
63-22	8819-8825	signal	_
63-23	8825-8826	.	_

#Text=The subjects were instructed to withhold button pressing upon seeing the stop signal.
64-1	8827-8830	The	_
64-2	8831-8839	subjects	_
64-3	8840-8844	were	_
64-4	8845-8855	instructed	_
64-5	8856-8858	to	_
64-6	8859-8867	withhold	_
64-7	8868-8874	button	_
64-8	8875-8883	pressing	_
64-9	8884-8888	upon	_
64-10	8889-8895	seeing	_
64-11	8896-8899	the	_
64-12	8900-8904	stop	_
64-13	8905-8911	signal	_
64-14	8911-8912	.	_

#Text=Likewise, a trial terminated at button press or when 1s had elapsed since the appearance of the stop signal.
65-1	8913-8921	Likewise	_
65-2	8921-8922	,	_
65-3	8923-8924	a	_
65-4	8925-8930	trial	_
65-5	8931-8941	terminated	_
65-6	8942-8944	at	_
65-7	8945-8951	button	_
65-8	8952-8957	press	_
65-9	8958-8960	or	_
65-10	8961-8965	when	_
65-11	8966-8968	1s	_
65-12	8969-8972	had	_
65-13	8973-8980	elapsed	_
65-14	8981-8986	since	_
65-15	8987-8990	the	_
65-16	8991-9001	appearance	_
65-17	9002-9004	of	_
65-18	9005-9008	the	_
65-19	9009-9013	stop	_
65-20	9014-9020	signal	_
65-21	9020-9021	.	_

#Text=The stop trials constituted the remaining one quarter of the trials.
66-1	9022-9025	The	_
66-2	9026-9030	stop	_
66-3	9031-9037	trials	_
66-4	9038-9049	constituted	_
66-5	9050-9053	the	_
66-6	9054-9063	remaining	_
66-7	9064-9067	one	_
66-8	9068-9075	quarter	_
66-9	9076-9078	of	_
66-10	9079-9082	the	_
66-11	9083-9089	trials	_
66-12	9089-9090	.	_

#Text=There was an inter-trial-interval of 2 s.
67-1	9091-9096	There	_
67-2	9097-9100	was	_
67-3	9101-9103	an	_
67-4	9104-9124	inter-trial-interval	_
67-5	9125-9127	of	_
67-6	9128-9129	2	_
67-7	9130-9131	s	_
67-8	9131-9132	.	_

#Text=The stop signal delay (SSD) started at 200 ms and varied from one stop trial to the next according to a staircase procedure, increasing and decreasing by 64 ms each after a successful and failed stop trial.
68-1	9133-9136	The	_
68-2	9137-9141	stop	_
68-3	9142-9148	signal	_
68-4	9149-9154	delay	_
68-5	9155-9156	(	_
68-6	9156-9159	SSD	_
68-7	9159-9160	)	_
68-8	9161-9168	started	_
68-9	9169-9171	at	_
68-10	9172-9175	200	_
68-11	9176-9178	ms	_
68-12	9179-9182	and	_
68-13	9183-9189	varied	_
68-14	9190-9194	from	_
68-15	9195-9198	one	_
68-16	9199-9203	stop	_
68-17	9204-9209	trial	_
68-18	9210-9212	to	_
68-19	9213-9216	the	_
68-20	9217-9221	next	_
68-21	9222-9231	according	_
68-22	9232-9234	to	_
68-23	9235-9236	a	_
68-24	9237-9246	staircase	_
68-25	9247-9256	procedure	_
68-26	9256-9257	,	_
68-27	9258-9268	increasing	_
68-28	9269-9272	and	_
68-29	9273-9283	decreasing	_
68-30	9284-9286	by	_
68-31	9287-9289	64	_
68-32	9290-9292	ms	_
68-33	9293-9297	each	_
68-34	9298-9303	after	_
68-35	9304-9305	a	_
68-36	9306-9316	successful	_
68-37	9317-9320	and	_
68-38	9321-9327	failed	_
68-39	9328-9332	stop	_
68-40	9333-9338	trial	_
68-41	9338-9339	.	_

#Text=Subjects were instructed to respond to the go signal quickly while keeping in mind that a stop signal could appear occasionally.
69-1	9340-9348	Subjects	_
69-2	9349-9353	were	_
69-3	9354-9364	instructed	_
69-4	9365-9367	to	_
69-5	9368-9375	respond	_
69-6	9376-9378	to	_
69-7	9379-9382	the	_
69-8	9383-9385	go	_
69-9	9386-9392	signal	_
69-10	9393-9400	quickly	_
69-11	9401-9406	while	_
69-12	9407-9414	keeping	_
69-13	9415-9417	in	_
69-14	9418-9422	mind	_
69-15	9423-9427	that	_
69-16	9428-9429	a	_
69-17	9430-9434	stop	_
69-18	9435-9441	signal	_
69-19	9442-9447	could	_
69-20	9448-9454	appear	_
69-21	9455-9467	occasionally	_
69-22	9467-9468	.	_

#Text=Each subject completed four 10 min runs of the task after a practice session outside the scanner.
70-1	9469-9473	Each	_
70-2	9474-9481	subject	_
70-3	9482-9491	completed	_
70-4	9492-9496	four	_
70-5	9497-9499	10	_
70-6	9499-9500	 	_
70-7	9500-9503	min	_
70-8	9504-9508	runs	_
70-9	9509-9511	of	_
70-10	9512-9515	the	_
70-11	9516-9520	task	_
70-12	9521-9526	after	_
70-13	9527-9528	a	_
70-14	9529-9537	practice	_
70-15	9538-9545	session	_
70-16	9546-9553	outside	_
70-17	9554-9557	the	_
70-18	9558-9565	scanner	_
70-19	9565-9566	.	_

#Text=With the staircase procedure, we anticipated that the subjects would succeed in withholding their response in approximately 50% of stop trials.
71-1	9567-9571	With	_
71-2	9572-9575	the	_
71-3	9576-9585	staircase	_
71-4	9586-9595	procedure	_
71-5	9595-9596	,	_
71-6	9597-9599	we	_
71-7	9600-9611	anticipated	_
71-8	9612-9616	that	_
71-9	9617-9620	the	_
71-10	9621-9629	subjects	_
71-11	9630-9635	would	_
71-12	9636-9643	succeed	_
71-13	9644-9646	in	_
71-14	9647-9658	withholding	_
71-15	9659-9664	their	_
71-16	9665-9673	response	_
71-17	9674-9676	in	_
71-18	9677-9690	approximately	_
71-19	9691-9694	50%	_
71-20	9695-9697	of	_
71-21	9698-9702	stop	_
71-22	9703-9709	trials	_
71-23	9709-9710	.	_

#Text=Analyses of behavioral data
#Text=We computed a critical SSD that represents the time delay between go and stop signals that a subject would need to succeed in 50% of the stop trials.
72-1	9711-9719	Analyses	_
72-2	9720-9722	of	_
72-3	9723-9733	behavioral	_
72-4	9734-9738	data	_
72-5	9739-9741	We	_
72-6	9742-9750	computed	_
72-7	9751-9752	a	_
72-8	9753-9761	critical	_
72-9	9762-9765	SSD	_
72-10	9766-9770	that	_
72-11	9771-9781	represents	_
72-12	9782-9785	the	_
72-13	9786-9790	time	_
72-14	9791-9796	delay	_
72-15	9797-9804	between	_
72-16	9805-9807	go	_
72-17	9808-9811	and	_
72-18	9812-9816	stop	_
72-19	9817-9824	signals	_
72-20	9825-9829	that	_
72-21	9830-9831	a	_
72-22	9832-9839	subject	_
72-23	9840-9845	would	_
72-24	9846-9850	need	_
72-25	9851-9853	to	_
72-26	9854-9861	succeed	_
72-27	9862-9864	in	_
72-28	9865-9868	50%	_
72-29	9869-9871	of	_
72-30	9872-9875	the	_
72-31	9876-9880	stop	_
72-32	9881-9887	trials	_
72-33	9887-9888	.	_

#Text=Specifically, SSDs across trials were grouped into runs, with each run defined as a monotonically increasing or decreasing series.
73-1	9889-9901	Specifically	_
73-2	9901-9902	,	_
73-3	9903-9907	SSDs	_
73-4	9908-9914	across	_
73-5	9915-9921	trials	_
73-6	9922-9926	were	_
73-7	9927-9934	grouped	_
73-8	9935-9939	into	_
73-9	9940-9944	runs	_
73-10	9944-9945	,	_
73-11	9946-9950	with	_
73-12	9951-9955	each	_
73-13	9956-9959	run	_
73-14	9960-9967	defined	_
73-15	9968-9970	as	_
73-16	9971-9972	a	_
73-17	9973-9986	monotonically	_
73-18	9987-9997	increasing	_
73-19	9998-10000	or	_
73-20	10001-10011	decreasing	_
73-21	10012-10018	series	_
73-22	10018-10019	.	_

#Text=We derived a mid-run estimate by taking the middle SSD (or average of the two middle SSDs when there was an even number of SSDs) of every second run.
74-1	10020-10022	We	_
74-2	10023-10030	derived	_
74-3	10031-10032	a	_
74-4	10033-10040	mid-run	_
74-5	10041-10049	estimate	_
74-6	10050-10052	by	_
74-7	10053-10059	taking	_
74-8	10060-10063	the	_
74-9	10064-10070	middle	_
74-10	10071-10074	SSD	_
74-11	10075-10076	(	_
74-12	10076-10078	or	_
74-13	10079-10086	average	_
74-14	10087-10089	of	_
74-15	10090-10093	the	_
74-16	10094-10097	two	_
74-17	10098-10104	middle	_
74-18	10105-10109	SSDs	_
74-19	10110-10114	when	_
74-20	10115-10120	there	_
74-21	10121-10124	was	_
74-22	10125-10127	an	_
74-23	10128-10132	even	_
74-24	10133-10139	number	_
74-25	10140-10142	of	_
74-26	10143-10147	SSDs	_
74-27	10147-10148	)	_
74-28	10149-10151	of	_
74-29	10152-10157	every	_
74-30	10158-10164	second	_
74-31	10165-10168	run	_
74-32	10168-10169	.	_

#Text=The critical SSD was computed by taking the mean of all mid-run SSDs.
75-1	10170-10173	The	_
75-2	10174-10182	critical	_
75-3	10183-10186	SSD	_
75-4	10187-10190	was	_
75-5	10191-10199	computed	_
75-6	10200-10202	by	_
75-7	10203-10209	taking	_
75-8	10210-10213	the	_
75-9	10214-10218	mean	_
75-10	10219-10221	of	_
75-11	10222-10225	all	_
75-12	10226-10233	mid-run	_
75-13	10234-10238	SSDs	_
75-14	10238-10239	.	_

#Text=It was reported that, except for experiments with a small number of trials (less than 30), the mid-run estimate was close to the maximum likelihood estimate of X50 (50% positive response; i.e., 50% stop success or SS in the SST,).
76-1	10240-10242	It	_
76-2	10243-10246	was	_
76-3	10247-10255	reported	_
76-4	10256-10260	that	_
76-5	10260-10261	,	_
76-6	10262-10268	except	_
76-7	10269-10272	for	_
76-8	10273-10284	experiments	_
76-9	10285-10289	with	_
76-10	10290-10291	a	_
76-11	10292-10297	small	_
76-12	10298-10304	number	_
76-13	10305-10307	of	_
76-14	10308-10314	trials	_
76-15	10315-10316	(	_
76-16	10316-10320	less	_
76-17	10321-10325	than	_
76-18	10326-10328	30	_
76-19	10328-10329	)	_
76-20	10329-10330	,	_
76-21	10331-10334	the	_
76-22	10335-10342	mid-run	_
76-23	10343-10351	estimate	_
76-24	10352-10355	was	_
76-25	10356-10361	close	_
76-26	10362-10364	to	_
76-27	10365-10368	the	_
76-28	10369-10376	maximum	_
76-29	10377-10387	likelihood	_
76-30	10388-10396	estimate	_
76-31	10397-10399	of	_
76-32	10400-10403	X50	_
76-33	10404-10405	(	_
76-34	10405-10408	50%	_
76-35	10409-10417	positive	_
76-36	10418-10426	response	_
76-37	10426-10427	;	_
76-38	10428-10431	i.e	_
76-39	10431-10432	.	_
76-40	10432-10433	,	_
76-41	10434-10437	50%	_
76-42	10438-10442	stop	_
76-43	10443-10450	success	_
76-44	10451-10453	or	_
76-45	10454-10456	SS	_
76-46	10457-10459	in	_
76-47	10460-10463	the	_
76-48	10464-10467	SST	_
76-49	10467-10468	,	_
76-50	10468-10469	)	_
76-51	10469-10470	.	_

#Text=The stop signal reaction time (SSRT) was computed by subtracting the critical SSD from the median go trial reaction time (RT).
77-1	10471-10474	The	_
77-2	10475-10479	stop	_
77-3	10480-10486	signal	_
77-4	10487-10495	reaction	_
77-5	10496-10500	time	_
77-6	10501-10502	(	_
77-7	10502-10506	SSRT	_
77-8	10506-10507	)	_
77-9	10508-10511	was	_
77-10	10512-10520	computed	_
77-11	10521-10523	by	_
77-12	10524-10535	subtracting	_
77-13	10536-10539	the	_
77-14	10540-10548	critical	_
77-15	10549-10552	SSD	_
77-16	10553-10557	from	_
77-17	10558-10561	the	_
77-18	10562-10568	median	_
77-19	10569-10571	go	_
77-20	10572-10577	trial	_
77-21	10578-10586	reaction	_
77-22	10587-10591	time	_
77-23	10592-10593	(	_
77-24	10593-10595	RT	_
77-25	10595-10596	)	_
77-26	10596-10597	.	_

#Text=We computed the fore-period effect as an index of motor preparedness during the SST.
78-1	10598-10600	We	_
78-2	10601-10609	computed	_
78-3	10610-10613	the	_
78-4	10614-10625	fore-period	_
78-5	10626-10632	effect	_
78-6	10633-10635	as	_
78-7	10636-10638	an	_
78-8	10639-10644	index	_
78-9	10645-10647	of	_
78-10	10648-10653	motor	_
78-11	10654-10666	preparedness	_
78-12	10667-10673	during	_
78-13	10674-10677	the	_
78-14	10678-10681	SST	_
78-15	10681-10682	.	_

#Text=Briefly, longer fore-periods are associated with faster RTs.
79-1	10683-10690	Briefly	_
79-2	10690-10691	,	_
79-3	10692-10698	longer	_
79-4	10699-10711	fore-periods	_
79-5	10712-10715	are	_
79-6	10716-10726	associated	_
79-7	10727-10731	with	_
79-8	10732-10738	faster	_
79-9	10739-10742	RTs	_
79-10	10742-10743	.	_

#Text=RT was compared between go trials with a fore-period between 3 and 5 s and between 1 and 3 s, and the effect size of RT difference was defined as fore-period effect.
80-1	10744-10746	RT	_
80-2	10747-10750	was	_
80-3	10751-10759	compared	_
80-4	10760-10767	between	_
80-5	10768-10770	go	_
80-6	10771-10777	trials	_
80-7	10778-10782	with	_
80-8	10783-10784	a	_
80-9	10785-10796	fore-period	_
80-10	10797-10804	between	_
80-11	10805-10806	3	_
80-12	10807-10810	and	_
80-13	10811-10812	5	_
80-14	10813-10814	s	_
80-15	10815-10818	and	_
80-16	10819-10826	between	_
80-17	10827-10828	1	_
80-18	10829-10832	and	_
80-19	10833-10834	3	_
80-20	10835-10836	s	_
80-21	10836-10837	,	_
80-22	10838-10841	and	_
80-23	10842-10845	the	_
80-24	10846-10852	effect	_
80-25	10853-10857	size	_
80-26	10858-10860	of	_
80-27	10861-10863	RT	_
80-28	10864-10874	difference	_
80-29	10875-10878	was	_
80-30	10879-10886	defined	_
80-31	10887-10889	as	_
80-32	10890-10901	fore-period	_
80-33	10902-10908	effect	_
80-34	10908-10909	.	_

#Text=It is also known that in a RT task, the RT of a correct response is prolonged following an error, compared with other correct responses, and this prolonged RT is thought to reflect error monitoring.
81-1	10910-10912	It	_
81-2	10913-10915	is	_
81-3	10916-10920	also	_
81-4	10921-10926	known	_
81-5	10927-10931	that	_
81-6	10932-10934	in	_
81-7	10935-10936	a	_
81-8	10937-10939	RT	_
81-9	10940-10944	task	_
81-10	10944-10945	,	_
81-11	10946-10949	the	_
81-12	10950-10952	RT	_
81-13	10953-10955	of	_
81-14	10956-10957	a	_
81-15	10958-10965	correct	_
81-16	10966-10974	response	_
81-17	10975-10977	is	_
81-18	10978-10987	prolonged	_
81-19	10988-10997	following	_
81-20	10998-11000	an	_
81-21	11001-11006	error	_
81-22	11006-11007	,	_
81-23	11008-11016	compared	_
81-24	11017-11021	with	_
81-25	11022-11027	other	_
81-26	11028-11035	correct	_
81-27	11036-11045	responses	_
81-28	11045-11046	,	_
81-29	11047-11050	and	_
81-30	11051-11055	this	_
81-31	11056-11065	prolonged	_
81-32	11066-11068	RT	_
81-33	11069-11071	is	_
81-34	11072-11079	thought	_
81-35	11080-11082	to	_
81-36	11083-11090	reflect	_
81-37	11091-11096	error	_
81-38	11097-11107	monitoring	_
81-39	11107-11108	.	_

#Text=We thus computed the RT difference between the go trials that followed a stop error (SE) and those that followed another go trial, and termed the effect size of this RT difference “post-error slowing” (PES).
82-1	11109-11111	We	_
82-2	11112-11116	thus	_
82-3	11117-11125	computed	_
82-4	11126-11129	the	_
82-5	11130-11132	RT	_
82-6	11133-11143	difference	_
82-7	11144-11151	between	_
82-8	11152-11155	the	_
82-9	11156-11158	go	_
82-10	11159-11165	trials	_
82-11	11166-11170	that	_
82-12	11171-11179	followed	_
82-13	11180-11181	a	_
82-14	11182-11186	stop	_
82-15	11187-11192	error	_
82-16	11193-11194	(	_
82-17	11194-11196	SE	_
82-18	11196-11197	)	_
82-19	11198-11201	and	_
82-20	11202-11207	those	_
82-21	11208-11212	that	_
82-22	11213-11221	followed	_
82-23	11222-11229	another	_
82-24	11230-11232	go	_
82-25	11233-11238	trial	_
82-26	11238-11239	,	_
82-27	11240-11243	and	_
82-28	11244-11250	termed	_
82-29	11251-11254	the	_
82-30	11255-11261	effect	_
82-31	11262-11266	size	_
82-32	11267-11269	of	_
82-33	11270-11274	this	_
82-34	11275-11277	RT	_
82-35	11278-11288	difference	_
82-36	11289-11290	“	_
82-37	11290-11300	post-error	_
82-38	11301-11308	slowing	_
82-39	11308-11309	”	_
82-40	11310-11311	(	_
82-41	11311-11314	PES	_
82-42	11314-11315	)	_
82-43	11315-11316	.	_

#Text=Imaging protocol
#Text=Conventional T1-weighted spin echo sagittal anatomical images were acquired for slice localization using a 3T scanner (Siemens Trio).
83-1	11317-11324	Imaging	_
83-2	11325-11333	protocol	_
83-3	11334-11346	Conventional	_
83-4	11347-11349	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]
83-5	11349-11350	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]
83-6	11350-11358	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]
83-7	11359-11363	spin	_
83-8	11364-11368	echo	_
83-9	11369-11377	sagittal	_
83-10	11378-11388	anatomical	_
83-11	11389-11395	images	_
83-12	11396-11400	were	_
83-13	11401-11409	acquired	_
83-14	11410-11413	for	_
83-15	11414-11419	slice	_
83-16	11420-11432	localization	_
83-17	11433-11438	using	_
83-18	11439-11440	a	_
83-19	11441-11443	3T	_
83-20	11444-11451	scanner	_
83-21	11452-11453	(	_
83-22	11453-11460	Siemens	_
83-23	11461-11465	Trio	_
83-24	11465-11466	)	_
83-25	11466-11467	.	_

#Text=Anatomical images of the functional slice locations were next obtained with spin-echo imaging in the axial plane parallel to the AC–PC line with TR = 300 ms, TE = 2.5 ms, bandwidth = 300 Hz/pixel, flip angle = 60°, field of view = 220 mm × 220 mm, matrix = 256 × 256, 32 slices with slice thickness = 4 mm and no gap.
84-1	11468-11478	Anatomical	_
84-2	11479-11485	images	_
84-3	11486-11488	of	_
84-4	11489-11492	the	_
84-5	11493-11503	functional	_
84-6	11504-11509	slice	_
84-7	11510-11519	locations	_
84-8	11520-11524	were	_
84-9	11525-11529	next	_
84-10	11530-11538	obtained	_
84-11	11539-11543	with	_
84-12	11544-11553	spin-echo	_
84-13	11554-11561	imaging	_
84-14	11562-11564	in	_
84-15	11565-11568	the	_
84-16	11569-11574	axial	_
84-17	11575-11580	plane	_
84-18	11581-11589	parallel	_
84-19	11590-11592	to	_
84-20	11593-11596	the	_
84-21	11597-11602	AC–PC	_
84-22	11603-11607	line	_
84-23	11608-11612	with	_
84-24	11613-11615	TR	_
84-25	11615-11616	 	_
84-26	11616-11617	=	_
84-27	11617-11618	 	_
84-28	11618-11621	300	_
84-29	11621-11622	 	_
84-30	11622-11624	ms	_
84-31	11624-11625	,	_
84-32	11626-11628	TE	_
84-33	11628-11629	 	_
84-34	11629-11630	=	_
84-35	11630-11631	 	_
84-36	11631-11634	2.5	_
84-37	11634-11635	 	_
84-38	11635-11637	ms	_
84-39	11637-11638	,	_
84-40	11639-11648	bandwidth	_
84-41	11648-11649	 	_
84-42	11649-11650	=	_
84-43	11650-11651	 	_
84-44	11651-11654	300	_
84-45	11654-11655	 	_
84-46	11655-11657	Hz	_
84-47	11657-11658	/	_
84-48	11658-11663	pixel	_
84-49	11663-11664	,	_
84-50	11665-11669	flip	_
84-51	11670-11675	angle	_
84-52	11675-11676	 	_
84-53	11676-11677	=	_
84-54	11677-11678	 	_
84-55	11678-11680	60	_
84-56	11680-11681	°	_
84-57	11681-11682	,	_
84-58	11683-11688	field	_
84-59	11689-11691	of	_
84-60	11692-11696	view	_
84-61	11696-11697	 	_
84-62	11697-11698	=	_
84-63	11698-11699	 	_
84-64	11699-11702	220	_
84-65	11702-11703	 	_
84-66	11703-11705	mm	_
84-67	11705-11706	 	_
84-68	11706-11707	×	_
84-69	11707-11708	 	_
84-70	11708-11711	220	_
84-71	11711-11712	 	_
84-72	11712-11714	mm	_
84-73	11714-11715	,	_
84-74	11716-11722	matrix	_
84-75	11722-11723	 	_
84-76	11723-11724	=	_
84-77	11724-11725	 	_
84-78	11725-11728	256	_
84-79	11728-11729	 	_
84-80	11729-11730	×	_
84-81	11730-11731	 	_
84-82	11731-11734	256	_
84-83	11734-11735	,	_
84-84	11736-11738	32	_
84-85	11739-11745	slices	_
84-86	11746-11750	with	_
84-87	11751-11756	slice	_
84-88	11757-11766	thickness	_
84-89	11766-11767	 	_
84-90	11767-11768	=	_
84-91	11768-11769	 	_
84-92	11769-11770	4	_
84-93	11770-11771	 	_
84-94	11771-11773	mm	_
84-95	11774-11777	and	_
84-96	11778-11780	no	_
84-97	11781-11784	gap	_
84-98	11784-11785	.	_

#Text=Functional, blood oxygen level-dependent (BOLD) signals were then acquired with a single-shot gradient echo echo planar imaging (EPI) sequence.
85-1	11786-11796	Functional	_
85-2	11796-11797	,	_
85-3	11798-11803	blood	_
85-4	11804-11810	oxygen	_
85-5	11811-11826	level-dependent	_
85-6	11827-11828	(	_
85-7	11828-11832	BOLD	_
85-8	11832-11833	)	_
85-9	11834-11841	signals	_
85-10	11842-11846	were	_
85-11	11847-11851	then	_
85-12	11852-11860	acquired	_
85-13	11861-11865	with	_
85-14	11866-11867	a	_
85-15	11868-11879	single-shot	_
85-16	11880-11888	gradient	_
85-17	11889-11893	echo	_
85-18	11894-11898	echo	_
85-19	11899-11905	planar	_
85-20	11906-11913	imaging	_
85-21	11914-11915	(	_
85-22	11915-11918	EPI	_
85-23	11918-11919	)	_
85-24	11920-11928	sequence	_
85-25	11928-11929	.	_

#Text=Thirty-two axial slices parallel to the AC–PC line covering the whole brain were acquired with TR = 2000 ms, TE = 25ms, bandwidth = 2004 Hz/pixel, flip angle = 85°, field of view = 220 mm × 220mm, matrix = 64 × 64, 32 slices with slice thickness = 4 mm and no gap.
86-1	11930-11940	Thirty-two	_
86-2	11941-11946	axial	_
86-3	11947-11953	slices	_
86-4	11954-11962	parallel	_
86-5	11963-11965	to	_
86-6	11966-11969	the	_
86-7	11970-11975	AC–PC	_
86-8	11976-11980	line	_
86-9	11981-11989	covering	_
86-10	11990-11993	the	_
86-11	11994-11999	whole	_
86-12	12000-12005	brain	_
86-13	12006-12010	were	_
86-14	12011-12019	acquired	_
86-15	12020-12024	with	_
86-16	12025-12027	TR	_
86-17	12027-12028	 	_
86-18	12028-12029	=	_
86-19	12029-12030	 	_
86-20	12030-12034	2000	_
86-21	12034-12035	 	_
86-22	12035-12037	ms	_
86-23	12037-12038	,	_
86-24	12039-12041	TE	_
86-25	12041-12042	 	_
86-26	12042-12043	=	_
86-27	12043-12044	 	_
86-28	12044-12048	25ms	_
86-29	12048-12049	,	_
86-30	12050-12059	bandwidth	_
86-31	12059-12060	 	_
86-32	12060-12061	=	_
86-33	12061-12062	 	_
86-34	12062-12066	2004	_
86-35	12066-12067	 	_
86-36	12067-12069	Hz	_
86-37	12069-12070	/	_
86-38	12070-12075	pixel	_
86-39	12075-12076	,	_
86-40	12077-12081	flip	_
86-41	12082-12087	angle	_
86-42	12087-12088	 	_
86-43	12088-12089	=	_
86-44	12089-12090	 	_
86-45	12090-12092	85	_
86-46	12092-12093	°	_
86-47	12093-12094	,	_
86-48	12095-12100	field	_
86-49	12101-12103	of	_
86-50	12104-12108	view	_
86-51	12108-12109	 	_
86-52	12109-12110	=	_
86-53	12110-12111	 	_
86-54	12111-12114	220	_
86-55	12114-12115	 	_
86-56	12115-12117	mm	_
86-57	12117-12118	 	_
86-58	12118-12119	×	_
86-59	12119-12120	 	_
86-60	12120-12125	220mm	_
86-61	12125-12126	,	_
86-62	12127-12133	matrix	_
86-63	12133-12134	 	_
86-64	12134-12135	=	_
86-65	12135-12136	 	_
86-66	12136-12138	64	_
86-67	12138-12139	 	_
86-68	12139-12140	×	_
86-69	12140-12141	 	_
86-70	12141-12143	64	_
86-71	12143-12144	,	_
86-72	12145-12147	32	_
86-73	12148-12154	slices	_
86-74	12155-12159	with	_
86-75	12160-12165	slice	_
86-76	12166-12175	thickness	_
86-77	12175-12176	 	_
86-78	12176-12177	=	_
86-79	12177-12178	 	_
86-80	12178-12179	4	_
86-81	12179-12180	 	_
86-82	12180-12182	mm	_
86-83	12183-12186	and	_
86-84	12187-12189	no	_
86-85	12190-12193	gap	_
86-86	12193-12194	.	_

#Text=Spatial preprocessing
#Text=Data were analyzed with Statistical Parametric Mapping (SPM8, Wellcome Department of Imaging Neuroscience, University College London, U.K.).
87-1	12195-12202	Spatial	_
87-2	12203-12216	preprocessing	_
87-3	12217-12221	Data	_
87-4	12222-12226	were	_
87-5	12227-12235	analyzed	_
87-6	12236-12240	with	_
87-7	12241-12252	Statistical	_
87-8	12253-12263	Parametric	_
87-9	12264-12271	Mapping	_
87-10	12272-12273	(	_
87-11	12273-12277	SPM8	_
87-12	12277-12278	,	_
87-13	12279-12287	Wellcome	_
87-14	12288-12298	Department	_
87-15	12299-12301	of	_
87-16	12302-12309	Imaging	_
87-17	12310-12322	Neuroscience	_
87-18	12322-12323	,	_
87-19	12324-12334	University	_
87-20	12335-12342	College	_
87-21	12343-12349	London	_
87-22	12349-12350	,	_
87-23	12351-12354	U.K	_
87-24	12354-12355	.	_
87-25	12355-12356	)	_
87-26	12356-12357	.	_

#Text=Images from the first five TRs at the beginning of each trial were discarded to enable the signal to achieve steady-state equilibrium between RF pulsing and relaxation.
88-1	12358-12364	Images	_
88-2	12365-12369	from	_
88-3	12370-12373	the	_
88-4	12374-12379	first	_
88-5	12380-12384	five	_
88-6	12385-12388	TRs	_
88-7	12389-12391	at	_
88-8	12392-12395	the	_
88-9	12396-12405	beginning	_
88-10	12406-12408	of	_
88-11	12409-12413	each	_
88-12	12414-12419	trial	_
88-13	12420-12424	were	_
88-14	12425-12434	discarded	_
88-15	12435-12437	to	_
88-16	12438-12444	enable	_
88-17	12445-12448	the	_
88-18	12449-12455	signal	_
88-19	12456-12458	to	_
88-20	12459-12466	achieve	_
88-21	12467-12479	steady-state	_
88-22	12480-12491	equilibrium	_
88-23	12492-12499	between	_
88-24	12500-12502	RF	_
88-25	12503-12510	pulsing	_
88-26	12511-12514	and	_
88-27	12515-12525	relaxation	_
88-28	12525-12526	.	_

#Text=Standard image preprocessing was performed.
89-1	12527-12535	Standard	_
89-2	12536-12541	image	_
89-3	12542-12555	preprocessing	_
89-4	12556-12559	was	_
89-5	12560-12569	performed	_
89-6	12569-12570	.	_

#Text=Images of each individual subject were first realigned (motion corrected) and corrected for slice timing.
90-1	12571-12577	Images	_
90-2	12578-12580	of	_
90-3	12581-12585	each	_
90-4	12586-12596	individual	_
90-5	12597-12604	subject	_
90-6	12605-12609	were	_
90-7	12610-12615	first	_
90-8	12616-12625	realigned	_
90-9	12626-12627	(	_
90-10	12627-12633	motion	_
90-11	12634-12643	corrected	_
90-12	12643-12644	)	_
90-13	12645-12648	and	_
90-14	12649-12658	corrected	_
90-15	12659-12662	for	_
90-16	12663-12668	slice	_
90-17	12669-12675	timing	_
90-18	12675-12676	.	_

#Text=A mean functional image volume was constructed for each subject per run from the realigned image volumes.
91-1	12677-12678	A	_
91-2	12679-12683	mean	_
91-3	12684-12694	functional	_
91-4	12695-12700	image	_
91-5	12701-12707	volume	_
91-6	12708-12711	was	_
91-7	12712-12723	constructed	_
91-8	12724-12727	for	_
91-9	12728-12732	each	_
91-10	12733-12740	subject	_
91-11	12741-12744	per	_
91-12	12745-12748	run	_
91-13	12749-12753	from	_
91-14	12754-12757	the	_
91-15	12758-12767	realigned	_
91-16	12768-12773	image	_
91-17	12774-12781	volumes	_
91-18	12781-12782	.	_

#Text=These mean images were co-registered with the high-resolution structural image and then segmented for normalization with affine registration followed by nonlinear transformation.
92-1	12783-12788	These	_
92-2	12789-12793	mean	_
92-3	12794-12800	images	_
92-4	12801-12805	were	_
92-5	12806-12819	co-registered	_
92-6	12820-12824	with	_
92-7	12825-12828	the	_
92-8	12829-12844	high-resolution	_
92-9	12845-12855	structural	_
92-10	12856-12861	image	_
92-11	12862-12865	and	_
92-12	12866-12870	then	_
92-13	12871-12880	segmented	_
92-14	12881-12884	for	_
92-15	12885-12898	normalization	_
92-16	12899-12903	with	_
92-17	12904-12910	affine	_
92-18	12911-12923	registration	_
92-19	12924-12932	followed	_
92-20	12933-12935	by	_
92-21	12936-12945	nonlinear	_
92-22	12946-12960	transformation	_
92-23	12960-12961	.	_

#Text=The normalization parameters determined for the structure volume were then applied to the corresponding functional image volumes for each subject.
93-1	12962-12965	The	_
93-2	12966-12979	normalization	_
93-3	12980-12990	parameters	_
93-4	12991-13001	determined	_
93-5	13002-13005	for	_
93-6	13006-13009	the	_
93-7	13010-13019	structure	_
93-8	13020-13026	volume	_
93-9	13027-13031	were	_
93-10	13032-13036	then	_
93-11	13037-13044	applied	_
93-12	13045-13047	to	_
93-13	13048-13051	the	_
93-14	13052-13065	corresponding	_
93-15	13066-13076	functional	_
93-16	13077-13082	image	_
93-17	13083-13090	volumes	_
93-18	13091-13094	for	_
93-19	13095-13099	each	_
93-20	13100-13107	subject	_
93-21	13107-13108	.	_

#Text=Finally, the images were smoothed with a Gaussian kernel of 8 mm at Full Width at Half Maximum.
94-1	13109-13116	Finally	_
94-2	13116-13117	,	_
94-3	13118-13121	the	_
94-4	13122-13128	images	_
94-5	13129-13133	were	_
94-6	13134-13142	smoothed	_
94-7	13143-13147	with	_
94-8	13148-13149	a	_
94-9	13150-13158	Gaussian	_
94-10	13159-13165	kernel	_
94-11	13166-13168	of	_
94-12	13169-13170	8	_
94-13	13170-13171	 	_
94-14	13171-13173	mm	_
94-15	13174-13176	at	_
94-16	13177-13181	Full	_
94-17	13182-13187	Width	_
94-18	13188-13190	at	_
94-19	13191-13195	Half	_
94-20	13196-13203	Maximum	_
94-21	13203-13204	.	_

#Text=Independent component analysis
#Text=Preprocessed time series were analyzed with a group ICA algorithm (GIFT, http://icatb.sourceforge.net/, version 1.3i) to identify spatially independent and temporally coherent networks.
95-1	13205-13216	Independent	_
95-2	13217-13226	component	_
95-3	13227-13235	analysis	_
95-4	13236-13248	Preprocessed	_
95-5	13249-13253	time	_
95-6	13254-13260	series	_
95-7	13261-13265	were	_
95-8	13266-13274	analyzed	_
95-9	13275-13279	with	_
95-10	13280-13281	a	_
95-11	13282-13287	group	_
95-12	13288-13291	ICA	_
95-13	13292-13301	algorithm	_
95-14	13302-13303	(	_
95-15	13303-13307	GIFT	_
95-16	13307-13308	,	_
95-17	13309-13313	http	_
95-18	13313-13314	:	_
95-19	13314-13315	/	_
95-20	13315-13316	/	_
95-21	13316-13337	icatb.sourceforge.net	_
95-22	13337-13338	/	_
95-23	13338-13339	,	_
95-24	13340-13347	version	_
95-25	13348-13352	1.3i	_
95-26	13352-13353	)	_
95-27	13354-13356	to	_
95-28	13357-13365	identify	_
95-29	13366-13375	spatially	_
95-30	13376-13387	independent	_
95-31	13388-13391	and	_
95-32	13392-13402	temporally	_
95-33	13403-13411	coherent	_
95-34	13412-13420	networks	_
95-35	13420-13421	.	_

#Text=ICA identifies distinct groups of brain regions with the same temporal pattern of hemodynamic signal change.
96-1	13422-13425	ICA	_
96-2	13426-13436	identifies	_
96-3	13437-13445	distinct	_
96-4	13446-13452	groups	_
96-5	13453-13455	of	_
96-6	13456-13461	brain	_
96-7	13462-13469	regions	_
96-8	13470-13474	with	_
96-9	13475-13478	the	_
96-10	13479-13483	same	_
96-11	13484-13492	temporal	_
96-12	13493-13500	pattern	_
96-13	13501-13503	of	_
96-14	13504-13515	hemodynamic	_
96-15	13516-13522	signal	_
96-16	13523-13529	change	_
96-17	13529-13530	.	_

#Text=The data of CD (n = 100) and HC (n = 100) individuals were reduced through principal component analysis and separated into 30 maximally independent components (ICs) with an infomax algorithm.
97-1	13531-13534	The	_
97-2	13535-13539	data	_
97-3	13540-13542	of	_
97-4	13543-13545	CD	_
97-5	13546-13547	(	_
97-6	13547-13548	n	_
97-7	13548-13549	 	_
97-8	13549-13550	=	_
97-9	13550-13551	 	_
97-10	13551-13554	100	_
97-11	13554-13555	)	_
97-12	13556-13559	and	_
97-13	13560-13562	HC	_
97-14	13563-13564	(	_
97-15	13564-13565	n	_
97-16	13565-13566	 	_
97-17	13566-13567	=	_
97-18	13567-13568	 	_
97-19	13568-13571	100	_
97-20	13571-13572	)	_
97-21	13573-13584	individuals	_
97-22	13585-13589	were	_
97-23	13590-13597	reduced	_
97-24	13598-13605	through	_
97-25	13606-13615	principal	_
97-26	13616-13625	component	_
97-27	13626-13634	analysis	_
97-28	13635-13638	and	_
97-29	13639-13648	separated	_
97-30	13649-13653	into	_
97-31	13654-13656	30	_
97-32	13657-13666	maximally	_
97-33	13667-13678	independent	_
97-34	13679-13689	components	_
97-35	13690-13691	(	_
97-36	13691-13694	ICs	_
97-37	13694-13695	)	_
97-38	13696-13700	with	_
97-39	13701-13703	an	_
97-40	13704-13711	infomax	_
97-41	13712-13721	algorithm	_
97-42	13721-13722	.	_

#Text=The dimensionality was determined by the modified minimal description length (MDL) criteria as implemented in GIFT and averaged across subjects.
98-1	13723-13726	The	_
98-2	13727-13741	dimensionality	_
98-3	13742-13745	was	_
98-4	13746-13756	determined	_
98-5	13757-13759	by	_
98-6	13760-13763	the	_
98-7	13764-13772	modified	_
98-8	13773-13780	minimal	_
98-9	13781-13792	description	_
98-10	13793-13799	length	_
98-11	13800-13801	(	_
98-12	13801-13804	MDL	_
98-13	13804-13805	)	_
98-14	13806-13814	criteria	_
98-15	13815-13817	as	_
98-16	13818-13829	implemented	_
98-17	13830-13832	in	_
98-18	13833-13837	GIFT	_
98-19	13838-13841	and	_
98-20	13842-13850	averaged	_
98-21	13851-13857	across	_
98-22	13858-13866	subjects	_
98-23	13866-13867	.	_

#Text=A time course for each IC and its corresponding spatial map was obtained.
99-1	13868-13869	A	_
99-2	13870-13874	time	_
99-3	13875-13881	course	_
99-4	13882-13885	for	_
99-5	13886-13890	each	_
99-6	13891-13893	IC	_
99-7	13894-13897	and	_
99-8	13898-13901	its	_
99-9	13902-13915	corresponding	_
99-10	13916-13923	spatial	_
99-11	13924-13927	map	_
99-12	13928-13931	was	_
99-13	13932-13940	obtained	_
99-14	13940-13941	.	_

#Text=This analysis was repeated 20 times with ICASSO to assess the repeatability of ICs.
100-1	13942-13946	This	_
100-2	13947-13955	analysis	_
100-3	13956-13959	was	_
100-4	13960-13968	repeated	_
100-5	13969-13971	20	_
100-6	13972-13977	times	_
100-7	13978-13982	with	_
100-8	13983-13989	ICASSO	_
100-9	13990-13992	to	_
100-10	13993-13999	assess	_
100-11	14000-14003	the	_
100-12	14004-14017	repeatability	_
100-13	14018-14020	of	_
100-14	14021-14024	ICs	_
100-15	14024-14025	.	_

#Text=Finally, component time courses and spatial maps, which captured individual differences in the expression of the ICA-derived component, were back reconstructed for each participant.
101-1	14026-14033	Finally	_
101-2	14033-14034	,	_
101-3	14035-14044	component	_
101-4	14045-14049	time	_
101-5	14050-14057	courses	_
101-6	14058-14061	and	_
101-7	14062-14069	spatial	_
101-8	14070-14074	maps	_
101-9	14074-14075	,	_
101-10	14076-14081	which	_
101-11	14082-14090	captured	_
101-12	14091-14101	individual	_
101-13	14102-14113	differences	_
101-14	14114-14116	in	_
101-15	14117-14120	the	_
101-16	14121-14131	expression	_
101-17	14132-14134	of	_
101-18	14135-14138	the	_
101-19	14139-14150	ICA-derived	_
101-20	14151-14160	component	_
101-21	14160-14161	,	_
101-22	14162-14166	were	_
101-23	14167-14171	back	_
101-24	14172-14185	reconstructed	_
101-25	14186-14189	for	_
101-26	14190-14194	each	_
101-27	14195-14206	participant	_
101-28	14206-14207	.	_

#Text=Following our previous study, six ICs, including a motor cortical network for motor preparation and execution, a right fronto-parietal network for attentional monitoring, a left fronto-parietal network for response inhibition, a midline cortico-subcortical network for error processing, a cuneus-precuneus network for behavioral engagement, and a default-mode network (DMN) for self-referential processing, were included for further analyses.
102-1	14208-14217	Following	_
102-2	14218-14221	our	_
102-3	14222-14230	previous	_
102-4	14231-14236	study	_
102-5	14236-14237	,	_
102-6	14238-14241	six	_
102-7	14242-14245	ICs	_
102-8	14245-14246	,	_
102-9	14247-14256	including	_
102-10	14257-14258	a	_
102-11	14259-14264	motor	_
102-12	14265-14273	cortical	_
102-13	14274-14281	network	_
102-14	14282-14285	for	_
102-15	14286-14291	motor	_
102-16	14292-14303	preparation	_
102-17	14304-14307	and	_
102-18	14308-14317	execution	_
102-19	14317-14318	,	_
102-20	14319-14320	a	_
102-21	14321-14326	right	_
102-22	14327-14342	fronto-parietal	_
102-23	14343-14350	network	_
102-24	14351-14354	for	_
102-25	14355-14366	attentional	_
102-26	14367-14377	monitoring	_
102-27	14377-14378	,	_
102-28	14379-14380	a	_
102-29	14381-14385	left	_
102-30	14386-14401	fronto-parietal	_
102-31	14402-14409	network	_
102-32	14410-14413	for	_
102-33	14414-14422	response	_
102-34	14423-14433	inhibition	_
102-35	14433-14434	,	_
102-36	14435-14436	a	_
102-37	14437-14444	midline	_
102-38	14445-14464	cortico-subcortical	_
102-39	14465-14472	network	_
102-40	14473-14476	for	_
102-41	14477-14482	error	_
102-42	14483-14493	processing	_
102-43	14493-14494	,	_
102-44	14495-14496	a	_
102-45	14497-14513	cuneus-precuneus	_
102-46	14514-14521	network	_
102-47	14522-14525	for	_
102-48	14526-14536	behavioral	_
102-49	14537-14547	engagement	_
102-50	14547-14548	,	_
102-51	14549-14552	and	_
102-52	14553-14554	a	_
102-53	14555-14567	default-mode	_
102-54	14568-14575	network	_
102-55	14576-14577	(	_
102-56	14577-14580	DMN	_
102-57	14580-14581	)	_
102-58	14582-14585	for	_
102-59	14586-14602	self-referential	_
102-60	14603-14613	processing	_
102-61	14613-14614	,	_
102-62	14615-14619	were	_
102-63	14620-14628	included	_
102-64	14629-14632	for	_
102-65	14633-14640	further	_
102-66	14641-14649	analyses	_
102-67	14649-14650	.	_

#Text=We normalized back-reconstructed spatial maps of each IC into z-scores and averaged them across runs for each participant.
103-1	14651-14653	We	_
103-2	14654-14664	normalized	_
103-3	14665-14683	back-reconstructed	_
103-4	14684-14691	spatial	_
103-5	14692-14696	maps	_
103-6	14697-14699	of	_
103-7	14700-14704	each	_
103-8	14705-14707	IC	_
103-9	14708-14712	into	_
103-10	14713-14721	z-scores	_
103-11	14722-14725	and	_
103-12	14726-14734	averaged	_
103-13	14735-14739	them	_
103-14	14740-14746	across	_
103-15	14747-14751	runs	_
103-16	14752-14755	for	_
103-17	14756-14760	each	_
103-18	14761-14772	participant	_
103-19	14772-14773	.	_

#Text=A one-sample t test was applied to the “z maps” across all participants to define significant brain regions associated with each IC.
104-1	14774-14775	A	_
104-2	14776-14786	one-sample	_
104-3	14787-14788	t	_
104-4	14789-14793	test	_
104-5	14794-14797	was	_
104-6	14798-14805	applied	_
104-7	14806-14808	to	_
104-8	14809-14812	the	_
104-9	14813-14814	“	_
104-10	14814-14815	z	_
104-11	14816-14820	maps	_
104-12	14820-14821	”	_
104-13	14822-14828	across	_
104-14	14829-14832	all	_
104-15	14833-14845	participants	_
104-16	14846-14848	to	_
104-17	14849-14855	define	_
104-18	14856-14867	significant	_
104-19	14868-14873	brain	_
104-20	14874-14881	regions	_
104-21	14882-14892	associated	_
104-22	14893-14897	with	_
104-23	14898-14902	each	_
104-24	14903-14905	IC	_
104-25	14905-14906	.	_

#Text=Multivariate pattern analysis (MVPA) of the thalamic connectivity
#Text=Fig. 1 illustrates the analyses step-by-step with details described as follows.
105-1	14907-14919	Multivariate	_
105-2	14920-14927	pattern	_
105-3	14928-14936	analysis	_
105-4	14937-14938	(	_
105-5	14938-14942	MVPA	_
105-6	14942-14943	)	_
105-7	14944-14946	of	_
105-8	14947-14950	the	_
105-9	14951-14959	thalamic	_
105-10	14960-14972	connectivity	_
105-11	14973-14976	Fig	_
105-12	14976-14977	.	_
105-13	14978-14979	1	_
105-14	14980-14991	illustrates	_
105-15	14992-14995	the	_
105-16	14996-15004	analyses	_
105-17	15005-15017	step-by-step	_
105-18	15018-15022	with	_
105-19	15023-15030	details	_
105-20	15031-15040	described	_
105-21	15041-15043	as	_
105-22	15044-15051	follows	_
105-23	15051-15052	.	_

#Text=A multivariate pattern classifier was trained to identify CD from HC, followed by cross-validation using “leave-one-out”.
106-1	15053-15054	A	_
106-2	15055-15067	multivariate	_
106-3	15068-15075	pattern	_
106-4	15076-15086	classifier	_
106-5	15087-15090	was	_
106-6	15091-15098	trained	_
106-7	15099-15101	to	_
106-8	15102-15110	identify	_
106-9	15111-15113	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
106-10	15114-15118	from	_
106-11	15119-15121	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
106-12	15121-15122	,	_
106-13	15123-15131	followed	_
106-14	15132-15134	by	_
106-15	15135-15151	cross-validation	_
106-16	15152-15157	using	_
106-17	15158-15159	“	_
106-18	15159-15172	leave-one-out	_
106-19	15172-15173	”	_
106-20	15173-15174	.	_

#Text=Briefly, one CD or HC was left out as testing data while the remaining subjects were used to train the classifier.
107-1	15175-15182	Briefly	_
107-2	15182-15183	,	_
107-3	15184-15187	one	_
107-4	15188-15190	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
107-5	15191-15193	or	_
107-6	15194-15196	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
107-7	15197-15200	was	_
107-8	15201-15205	left	_
107-9	15206-15209	out	_
107-10	15210-15212	as	_
107-11	15213-15220	testing	_
107-12	15221-15225	data	_
107-13	15226-15231	while	_
107-14	15232-15235	the	_
107-15	15236-15245	remaining	_
107-16	15246-15254	subjects	_
107-17	15255-15259	were	_
107-18	15260-15264	used	_
107-19	15265-15267	to	_
107-20	15268-15273	train	_
107-21	15274-15277	the	_
107-22	15278-15288	classifier	_
107-23	15288-15289	.	_

#Text=This procedure was repeated until each of the 100 CD and 100 HC was selected once as the validation data.
108-1	15290-15294	This	_
108-2	15295-15304	procedure	_
108-3	15305-15308	was	_
108-4	15309-15317	repeated	_
108-5	15318-15323	until	_
108-6	15324-15328	each	_
108-7	15329-15331	of	_
108-8	15332-15335	the	_
108-9	15336-15339	100	_
108-10	15340-15342	CD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
108-11	15343-15346	and	_
108-12	15347-15350	100	_
108-13	15351-15353	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
108-14	15354-15357	was	_
108-15	15358-15366	selected	_
108-16	15367-15371	once	_
108-17	15372-15374	as	_
108-18	15375-15378	the	_
108-19	15379-15389	validation	_
108-20	15390-15394	data	_
108-21	15394-15395	.	_

#Text=A thalamus mask (698 voxels) was obtained from the Automated Anatomical Labeling atlas.
109-1	15396-15397	A	_
109-2	15398-15406	thalamus	_
109-3	15407-15411	mask	_
109-4	15412-15413	(	_
109-5	15413-15416	698	_
109-6	15417-15423	voxels	_
109-7	15423-15424	)	_
109-8	15425-15428	was	_
109-9	15429-15437	obtained	_
109-10	15438-15442	from	_
109-11	15443-15446	the	_
109-12	15447-15456	Automated	_
109-13	15457-15467	Anatomical	_
109-14	15468-15476	Labeling	_
109-15	15477-15482	atlas	_
109-16	15482-15483	.	_

#Text=For each participant, we extracted z values of thalamic voxels for all 6 ICs as a classification feature vector, resulting in a total of 698 × 6 = 4188 features.
110-1	15484-15487	For	_
110-2	15488-15492	each	_
110-3	15493-15504	participant	_
110-4	15504-15505	,	_
110-5	15506-15508	we	_
110-6	15509-15518	extracted	_
110-7	15519-15520	z	_
110-8	15521-15527	values	_
110-9	15528-15530	of	_
110-10	15531-15539	thalamic	_
110-11	15540-15546	voxels	_
110-12	15547-15550	for	_
110-13	15551-15554	all	_
110-14	15555-15556	6	_
110-15	15557-15560	ICs	_
110-16	15561-15563	as	_
110-17	15564-15565	a	_
110-18	15566-15580	classification	_
110-19	15581-15588	feature	_
110-20	15589-15595	vector	_
110-21	15595-15596	,	_
110-22	15597-15606	resulting	_
110-23	15607-15609	in	_
110-24	15610-15611	a	_
110-25	15612-15617	total	_
110-26	15618-15620	of	_
110-27	15621-15624	698	_
110-28	15624-15625	 	_
110-29	15625-15626	×	_
110-30	15626-15627	 	_
110-31	15627-15628	6	_
110-32	15628-15629	 	_
110-33	15629-15630	=	_
110-34	15630-15631	 	_
110-35	15631-15635	4188	_
110-36	15636-15644	features	_
110-37	15644-15645	.	_

#Text=The feature space was refined by retaining the most discriminating features, as assessed by feature-wise two-sample t tests of CD versus HC using training data only; features that differed between CD and HC at p < 0.05, uncorrected were included in the feature set for classification.
111-1	15646-15649	The	_
111-2	15650-15657	feature	_
111-3	15658-15663	space	_
111-4	15664-15667	was	_
111-5	15668-15675	refined	_
111-6	15676-15678	by	_
111-7	15679-15688	retaining	_
111-8	15689-15692	the	_
111-9	15693-15697	most	_
111-10	15698-15712	discriminating	_
111-11	15713-15721	features	_
111-12	15721-15722	,	_
111-13	15723-15725	as	_
111-14	15726-15734	assessed	_
111-15	15735-15737	by	_
111-16	15738-15750	feature-wise	_
111-17	15751-15761	two-sample	_
111-18	15762-15763	t	_
111-19	15764-15769	tests	_
111-20	15770-15772	of	_
111-21	15773-15775	CD	_
111-22	15776-15782	versus	_
111-23	15783-15785	HC	_
111-24	15786-15791	using	_
111-25	15792-15800	training	_
111-26	15801-15805	data	_
111-27	15806-15810	only	_
111-28	15810-15811	;	_
111-29	15812-15820	features	_
111-30	15821-15825	that	_
111-31	15826-15834	differed	_
111-32	15835-15842	between	_
111-33	15843-15845	CD	_
111-34	15846-15849	and	_
111-35	15850-15852	HC	_
111-36	15853-15855	at	_
111-37	15856-15857	p	_
111-38	15857-15858	 	_
111-39	15858-15859	<	_
111-40	15859-15860	 	_
111-41	15860-15864	0.05	_
111-42	15864-15865	,	_
111-43	15866-15877	uncorrected	_
111-44	15878-15882	were	_
111-45	15883-15891	included	_
111-46	15892-15894	in	_
111-47	15895-15898	the	_
111-48	15899-15906	feature	_
111-49	15907-15910	set	_
111-50	15911-15914	for	_
111-51	15915-15929	classification	_
111-52	15929-15930	.	_

#Text=Since a distinct set of features were selected from each set of training data, the final feature set differed slightly from iteration to iteration.
112-1	15931-15936	Since	_
112-2	15937-15938	a	_
112-3	15939-15947	distinct	_
112-4	15948-15951	set	_
112-5	15952-15954	of	_
112-6	15955-15963	features	_
112-7	15964-15968	were	_
112-8	15969-15977	selected	_
112-9	15978-15982	from	_
112-10	15983-15987	each	_
112-11	15988-15991	set	_
112-12	15992-15994	of	_
112-13	15995-16003	training	_
112-14	16004-16008	data	_
112-15	16008-16009	,	_
112-16	16010-16013	the	_
112-17	16014-16019	final	_
112-18	16020-16027	feature	_
112-19	16028-16031	set	_
112-20	16032-16040	differed	_
112-21	16041-16049	slightly	_
112-22	16050-16054	from	_
112-23	16055-16064	iteration	_
112-24	16065-16067	to	_
112-25	16068-16077	iteration	_
112-26	16077-16078	.	_

#Text=We thus used the frequency with which each feature was included in the classification sets across all iterations to represent its discriminative power.
113-1	16079-16081	We	_
113-2	16082-16086	thus	_
113-3	16087-16091	used	_
113-4	16092-16095	the	_
113-5	16096-16105	frequency	_
113-6	16106-16110	with	_
113-7	16111-16116	which	_
113-8	16117-16121	each	_
113-9	16122-16129	feature	_
113-10	16130-16133	was	_
113-11	16134-16142	included	_
113-12	16143-16145	in	_
113-13	16146-16149	the	_
113-14	16150-16164	classification	_
113-15	16165-16169	sets	_
113-16	16170-16176	across	_
113-17	16177-16180	all	_
113-18	16181-16191	iterations	_
113-19	16192-16194	to	_
113-20	16195-16204	represent	_
113-21	16205-16208	its	_
113-22	16209-16223	discriminative	_
113-23	16224-16229	power	_
113-24	16229-16230	.	_

#Text=We employed a support vector machine (SVM) classifier with a linear kernel function for classification, as in previous work of MVPA.
114-1	16231-16233	We	_
114-2	16234-16242	employed	_
114-3	16243-16244	a	_
114-4	16245-16252	support	_
114-5	16253-16259	vector	_
114-6	16260-16267	machine	_
114-7	16268-16269	(	_
114-8	16269-16272	SVM	_
114-9	16272-16273	)	_
114-10	16274-16284	classifier	_
114-11	16285-16289	with	_
114-12	16290-16291	a	_
114-13	16292-16298	linear	_
114-14	16299-16305	kernel	_
114-15	16306-16314	function	_
114-16	16315-16318	for	_
114-17	16319-16333	classification	_
114-18	16333-16334	,	_
114-19	16335-16337	as	_
114-20	16338-16340	in	_
114-21	16341-16349	previous	_
114-22	16350-16354	work	_
114-23	16355-16357	of	_
114-24	16358-16362	MVPA	_
114-25	16362-16363	.	_

#Text=Linear SVM helps to weigh down the effect of noisy features that are highly correlated.
115-1	16364-16370	Linear	_
115-2	16371-16374	SVM	_
115-3	16375-16380	helps	_
115-4	16381-16383	to	_
115-5	16384-16389	weigh	_
115-6	16390-16394	down	_
115-7	16395-16398	the	_
115-8	16399-16405	effect	_
115-9	16406-16408	of	_
115-10	16409-16414	noisy	_
115-11	16415-16423	features	_
115-12	16424-16428	that	_
115-13	16429-16432	are	_
115-14	16433-16439	highly	_
115-15	16440-16450	correlated	_
115-16	16450-16451	.	_

#Text=According to the results of cross-validation, we used the generalization rate, sensitivity and specificity to quantify the performance of our classifier.
116-1	16452-16461	According	_
116-2	16462-16464	to	_
116-3	16465-16468	the	_
116-4	16469-16476	results	_
116-5	16477-16479	of	_
116-6	16480-16496	cross-validation	_
116-7	16496-16497	,	_
116-8	16498-16500	we	_
116-9	16501-16505	used	_
116-10	16506-16509	the	_
116-11	16510-16524	generalization	_
116-12	16525-16529	rate	_
116-13	16529-16530	,	_
116-14	16531-16542	sensitivity	_
116-15	16543-16546	and	_
116-16	16547-16558	specificity	_
116-17	16559-16561	to	_
116-18	16562-16570	quantify	_
116-19	16571-16574	the	_
116-20	16575-16586	performance	_
116-21	16587-16589	of	_
116-22	16590-16593	our	_
116-23	16594-16604	classifier	_
116-24	16604-16605	.	_

#Text=The generalization rate represents the overall prediction rate of CD and HC combined, whereas the sensitivity and specificity each characterizes the prediction rates of CD and HC.
117-1	16606-16609	The	_
117-2	16610-16624	generalization	_
117-3	16625-16629	rate	_
117-4	16630-16640	represents	_
117-5	16641-16644	the	_
117-6	16645-16652	overall	_
117-7	16653-16663	prediction	_
117-8	16664-16668	rate	_
117-9	16669-16671	of	_
117-10	16672-16674	CD	_
117-11	16675-16678	and	_
117-12	16679-16681	HC	_
117-13	16682-16690	combined	_
117-14	16690-16691	,	_
117-15	16692-16699	whereas	_
117-16	16700-16703	the	_
117-17	16704-16715	sensitivity	_
117-18	16716-16719	and	_
117-19	16720-16731	specificity	_
117-20	16732-16736	each	_
117-21	16737-16750	characterizes	_
117-22	16751-16754	the	_
117-23	16755-16765	prediction	_
117-24	16766-16771	rates	_
117-25	16772-16774	of	_
117-26	16775-16777	CD	_
117-27	16778-16781	and	_
117-28	16782-16784	HC	_
117-29	16784-16785	.	_

#Text=We used permutation tests to examine the statistical significance of the observed classification accuracy.
118-1	16786-16788	We	_
118-2	16789-16793	used	_
118-3	16794-16805	permutation	_
118-4	16806-16811	tests	_
118-5	16812-16814	to	_
118-6	16815-16822	examine	_
118-7	16823-16826	the	_
118-8	16827-16838	statistical	_
118-9	16839-16851	significance	_
118-10	16852-16854	of	_
118-11	16855-16858	the	_
118-12	16859-16867	observed	_
118-13	16868-16882	classification	_
118-14	16883-16891	accuracy	_
118-15	16891-16892	.	_

#Text=In each permutation, the group label of the training data were randomly permuted prior to training and a generalization rate was computed.
119-1	16893-16895	In	_
119-2	16896-16900	each	_
119-3	16901-16912	permutation	_
119-4	16912-16913	,	_
119-5	16914-16917	the	_
119-6	16918-16923	group	_
119-7	16924-16929	label	_
119-8	16930-16932	of	_
119-9	16933-16936	the	_
119-10	16937-16945	training	_
119-11	16946-16950	data	_
119-12	16951-16955	were	_
119-13	16956-16964	randomly	_
119-14	16965-16973	permuted	_
119-15	16974-16979	prior	_
119-16	16980-16982	to	_
119-17	16983-16991	training	_
119-18	16992-16995	and	_
119-19	16996-16997	a	_
119-20	16998-17012	generalization	_
119-21	17013-17017	rate	_
119-22	17018-17021	was	_
119-23	17022-17030	computed	_
119-24	17030-17031	.	_

#Text=The permutation was repeated 1000 times to obtain a distribution of generalization rates, against which the accuracy in classification of the veridically labeled data was tested.
120-1	17032-17035	The	_
120-2	17036-17047	permutation	_
120-3	17048-17051	was	_
120-4	17052-17060	repeated	_
120-5	17061-17065	1000	_
120-6	17066-17071	times	_
120-7	17072-17074	to	_
120-8	17075-17081	obtain	_
120-9	17082-17083	a	_
120-10	17084-17096	distribution	_
120-11	17097-17099	of	_
120-12	17100-17114	generalization	_
120-13	17115-17120	rates	_
120-14	17120-17121	,	_
120-15	17122-17129	against	_
120-16	17130-17135	which	_
120-17	17136-17139	the	_
120-18	17140-17148	accuracy	_
120-19	17149-17151	in	_
120-20	17152-17166	classification	_
120-21	17167-17169	of	_
120-22	17170-17173	the	_
120-23	17174-17185	veridically	_
120-24	17186-17193	labeled	_
120-25	17194-17198	data	_
120-26	17199-17202	was	_
120-27	17203-17209	tested	_
120-28	17209-17210	.	_

#Text=In addition to the thalamus, we examined other AAL masks with a similar volume for comparison.
121-1	17211-17213	In	_
121-2	17214-17222	addition	_
121-3	17223-17225	to	_
121-4	17226-17229	the	_
121-5	17230-17238	thalamus	_
121-6	17238-17239	,	_
121-7	17240-17242	we	_
121-8	17243-17251	examined	_
121-9	17252-17257	other	_
121-10	17258-17261	AAL	_
121-11	17262-17267	masks	_
121-12	17268-17272	with	_
121-13	17273-17274	a	_
121-14	17275-17282	similar	_
121-15	17283-17289	volume	_
121-16	17290-17293	for	_
121-17	17294-17304	comparison	_
121-18	17304-17305	.	_

#Text=These regions included the paracentral lobule (695 voxels), the caudate (658 voxels), middle part of orbital frontal gyrus (694 voxels), parahippocampal gyrus (728 voxels), and inferior occipital gyrus (638 voxels), all with a volume close to the thalamus (698 voxels).
122-1	17306-17311	These	_
122-2	17312-17319	regions	_
122-3	17320-17328	included	_
122-4	17329-17332	the	_
122-5	17333-17344	paracentral	_
122-6	17345-17351	lobule	_
122-7	17352-17353	(	_
122-8	17353-17356	695	_
122-9	17357-17363	voxels	_
122-10	17363-17364	)	_
122-11	17364-17365	,	_
122-12	17366-17369	the	_
122-13	17370-17377	caudate	_
122-14	17378-17379	(	_
122-15	17379-17382	658	_
122-16	17383-17389	voxels	_
122-17	17389-17390	)	_
122-18	17390-17391	,	_
122-19	17392-17398	middle	_
122-20	17399-17403	part	_
122-21	17404-17406	of	_
122-22	17407-17414	orbital	_
122-23	17415-17422	frontal	_
122-24	17423-17428	gyrus	_
122-25	17429-17430	(	_
122-26	17430-17433	694	_
122-27	17434-17440	voxels	_
122-28	17440-17441	)	_
122-29	17441-17442	,	_
122-30	17443-17458	parahippocampal	_
122-31	17459-17464	gyrus	_
122-32	17465-17466	(	_
122-33	17466-17469	728	_
122-34	17470-17476	voxels	_
122-35	17476-17477	)	_
122-36	17477-17478	,	_
122-37	17479-17482	and	_
122-38	17483-17491	inferior	_
122-39	17492-17501	occipital	_
122-40	17502-17507	gyrus	_
122-41	17508-17509	(	_
122-42	17509-17512	638	_
122-43	17513-17519	voxels	_
122-44	17519-17520	)	_
122-45	17520-17521	,	_
122-46	17522-17525	all	_
122-47	17526-17530	with	_
122-48	17531-17532	a	_
122-49	17533-17539	volume	_
122-50	17540-17545	close	_
122-51	17546-17548	to	_
122-52	17549-17552	the	_
122-53	17553-17561	thalamus	_
122-54	17562-17563	(	_
122-55	17563-17566	698	_
122-56	17567-17573	voxels	_
122-57	17573-17574	)	_
122-58	17574-17575	.	_

#Text=Results
#Text=Behavioral performance
#Text=Table 2 shows behavioral measures of the SST.
123-1	17576-17583	Results	_
123-2	17584-17594	Behavioral	_
123-3	17595-17606	performance	_
123-4	17607-17612	Table	_
123-5	17613-17614	2	_
123-6	17615-17620	shows	_
123-7	17621-17631	behavioral	_
123-8	17632-17640	measures	_
123-9	17641-17643	of	_
123-10	17644-17647	the	_
123-11	17648-17651	SST	_
123-12	17651-17652	.	_

#Text=Both CD and HC succeeded in about half of the stop trials, indicating success of the staircase procedure in tracking their performance.
124-1	17653-17657	Both	_
124-2	17658-17660	CD	_
124-3	17661-17664	and	_
124-4	17665-17667	HC	_
124-5	17668-17677	succeeded	_
124-6	17678-17680	in	_
124-7	17681-17686	about	_
124-8	17687-17691	half	_
124-9	17692-17694	of	_
124-10	17695-17698	the	_
124-11	17699-17703	stop	_
124-12	17704-17710	trials	_
124-13	17710-17711	,	_
124-14	17712-17722	indicating	_
124-15	17723-17730	success	_
124-16	17731-17733	of	_
124-17	17734-17737	the	_
124-18	17738-17747	staircase	_
124-19	17748-17757	procedure	_
124-20	17758-17760	in	_
124-21	17761-17769	tracking	_
124-22	17770-17775	their	_
124-23	17776-17787	performance	_
124-24	17787-17788	.	_

#Text=Compared to HC, CD showed lower go response rate (p = 0.004; two-tailed two-sample t test) and less PES (p = 0.02).
125-1	17789-17797	Compared	_
125-2	17798-17800	to	_
125-3	17801-17803	HC	_
125-4	17803-17804	,	_
125-5	17805-17807	CD	_
125-6	17808-17814	showed	_
125-7	17815-17820	lower	_
125-8	17821-17823	go	_
125-9	17824-17832	response	_
125-10	17833-17837	rate	_
125-11	17838-17839	(	_
125-12	17839-17840	p	_
125-13	17840-17841	 	_
125-14	17841-17842	=	_
125-15	17842-17843	 	_
125-16	17843-17848	0.004	_
125-17	17848-17849	;	_
125-18	17850-17860	two-tailed	_
125-19	17861-17871	two-sample	_
125-20	17872-17873	t	_
125-21	17874-17878	test	_
125-22	17878-17879	)	_
125-23	17880-17883	and	_
125-24	17884-17888	less	_
125-25	17889-17892	PES	_
125-26	17893-17894	(	_
125-27	17894-17895	p	_
125-28	17895-17896	 	_
125-29	17896-17897	=	_
125-30	17897-17898	 	_
125-31	17898-17902	0.02	_
125-32	17902-17903	)	_
125-33	17903-17904	.	_

#Text=CD also showed prolonged SSRTs, but the difference did not reach statistical significance (p = 0.11).
126-1	17905-17907	CD	_
126-2	17908-17912	also	_
126-3	17913-17919	showed	_
126-4	17920-17929	prolonged	_
126-5	17930-17935	SSRTs	_
126-6	17935-17936	,	_
126-7	17937-17940	but	_
126-8	17941-17944	the	_
126-9	17945-17955	difference	_
126-10	17956-17959	did	_
126-11	17960-17963	not	_
126-12	17964-17969	reach	_
126-13	17970-17981	statistical	_
126-14	17982-17994	significance	_
126-15	17995-17996	(	_
126-16	17996-17997	p	_
126-17	17997-17998	 	_
126-18	17998-17999	=	_
126-19	17999-18000	 	_
126-20	18000-18004	0.11	_
126-21	18004-18005	)	_
126-22	18005-18006	.	_

#Text=The latter likely resulted from an under-estimation of the SSRT because the “RT” of a larger number of go error trials could not be considered in CD.
127-1	18007-18010	The	_
127-2	18011-18017	latter	_
127-3	18018-18024	likely	_
127-4	18025-18033	resulted	_
127-5	18034-18038	from	_
127-6	18039-18041	an	_
127-7	18042-18058	under-estimation	_
127-8	18059-18061	of	_
127-9	18062-18065	the	_
127-10	18066-18070	SSRT	_
127-11	18071-18078	because	_
127-12	18079-18082	the	_
127-13	18083-18084	“	_
127-14	18084-18086	RT	_
127-15	18086-18087	”	_
127-16	18088-18090	of	_
127-17	18091-18092	a	_
127-18	18093-18099	larger	_
127-19	18100-18106	number	_
127-20	18107-18109	of	_
127-21	18110-18112	go	_
127-22	18113-18118	error	_
127-23	18119-18125	trials	_
127-24	18126-18131	could	_
127-25	18132-18135	not	_
127-26	18136-18138	be	_
127-27	18139-18149	considered	_
127-28	18150-18152	in	_
127-29	18153-18155	CD	_
127-30	18155-18156	.	_

#Text=The two groups were otherwise not different in behavioral performance.
128-1	18157-18160	The	_
128-2	18161-18164	two	_
128-3	18165-18171	groups	_
128-4	18172-18176	were	_
128-5	18177-18186	otherwise	_
128-6	18187-18190	not	_
128-7	18191-18200	different	_
128-8	18201-18203	in	_
128-9	18204-18214	behavioral	_
128-10	18215-18226	performance	_
128-11	18226-18227	.	_

#Text=Altered thalamic connectivity in cocaine dependence
#Text=We verified the spatial congruency of the independent components identified from the current data set with those identified from our earlier work with spatial linear correlations.
129-1	18228-18235	Altered	_
129-2	18236-18244	thalamic	_
129-3	18245-18257	connectivity	_
129-4	18258-18260	in	_
129-5	18261-18268	cocaine	_
129-6	18269-18279	dependence	_
129-7	18280-18282	We	_
129-8	18283-18291	verified	_
129-9	18292-18295	the	_
129-10	18296-18303	spatial	_
129-11	18304-18314	congruency	_
129-12	18315-18317	of	_
129-13	18318-18321	the	_
129-14	18322-18333	independent	_
129-15	18334-18344	components	_
129-16	18345-18355	identified	_
129-17	18356-18360	from	_
129-18	18361-18364	the	_
129-19	18365-18372	current	_
129-20	18373-18377	data	_
129-21	18378-18381	set	_
129-22	18382-18386	with	_
129-23	18387-18392	those	_
129-24	18393-18403	identified	_
129-25	18404-18408	from	_
129-26	18409-18412	our	_
129-27	18413-18420	earlier	_
129-28	18421-18425	work	_
129-29	18426-18430	with	_
129-30	18431-18438	spatial	_
129-31	18439-18445	linear	_
129-32	18446-18458	correlations	_
129-33	18458-18459	.	_

#Text=These six networks are motor cortical network (IC024, r2 = 0.55), right frontoparietal network (IC009, r2 = 0.46), left frontoparietal network (IC027, r2 = 0.53), midline cortico-subcortical network (IC029, r2 = 0.17), cuneus-precuneus network (IC003, r2 = 0.65), and DMN (IC022, r2 = 0.44), as shown in Fig. 2.
130-1	18460-18465	These	_
130-2	18466-18469	six	_
130-3	18470-18478	networks	_
130-4	18479-18482	are	_
130-5	18483-18488	motor	_
130-6	18489-18497	cortical	_
130-7	18498-18505	network	_
130-8	18506-18507	(	_
130-9	18507-18512	IC024	_
130-10	18512-18513	,	_
130-11	18514-18516	r2	_
130-12	18516-18517	 	_
130-13	18517-18518	=	_
130-14	18518-18519	 	_
130-15	18519-18523	0.55	_
130-16	18523-18524	)	_
130-17	18524-18525	,	_
130-18	18526-18531	right	_
130-19	18532-18546	frontoparietal	_
130-20	18547-18554	network	_
130-21	18555-18556	(	_
130-22	18556-18561	IC009	_
130-23	18561-18562	,	_
130-24	18563-18565	r2	_
130-25	18565-18566	 	_
130-26	18566-18567	=	_
130-27	18567-18568	 	_
130-28	18568-18572	0.46	_
130-29	18572-18573	)	_
130-30	18573-18574	,	_
130-31	18575-18579	left	_
130-32	18580-18594	frontoparietal	_
130-33	18595-18602	network	_
130-34	18603-18604	(	_
130-35	18604-18609	IC027	_
130-36	18609-18610	,	_
130-37	18611-18613	r2	_
130-38	18613-18614	 	_
130-39	18614-18615	=	_
130-40	18615-18616	 	_
130-41	18616-18620	0.53	_
130-42	18620-18621	)	_
130-43	18621-18622	,	_
130-44	18623-18630	midline	_
130-45	18631-18650	cortico-subcortical	_
130-46	18651-18658	network	_
130-47	18659-18660	(	_
130-48	18660-18665	IC029	_
130-49	18665-18666	,	_
130-50	18667-18669	r2	_
130-51	18669-18670	 	_
130-52	18670-18671	=	_
130-53	18671-18672	 	_
130-54	18672-18676	0.17	_
130-55	18676-18677	)	_
130-56	18677-18678	,	_
130-57	18679-18695	cuneus-precuneus	_
130-58	18696-18703	network	_
130-59	18704-18705	(	_
130-60	18705-18710	IC003	_
130-61	18710-18711	,	_
130-62	18712-18714	r2	_
130-63	18714-18715	 	_
130-64	18715-18716	=	_
130-65	18716-18717	 	_
130-66	18717-18721	0.65	_
130-67	18721-18722	)	_
130-68	18722-18723	,	_
130-69	18724-18727	and	_
130-70	18728-18731	DMN	_
130-71	18732-18733	(	_
130-72	18733-18738	IC022	_
130-73	18738-18739	,	_
130-74	18740-18742	r2	_
130-75	18742-18743	 	_
130-76	18743-18744	=	_
130-77	18744-18745	 	_
130-78	18745-18749	0.44	_
130-79	18749-18750	)	_
130-80	18750-18751	,	_
130-81	18752-18754	as	_
130-82	18755-18760	shown	_
130-83	18761-18763	in	_
130-84	18764-18767	Fig	_
130-85	18767-18768	.	_
130-86	18769-18770	2	_
130-87	18770-18771	.	_

#Text=A total of 513 ± 10 features were selected at p < 0.05, uncorrected.
131-1	18772-18773	A	_
131-2	18774-18779	total	_
131-3	18780-18782	of	_
131-4	18783-18786	513	_
131-5	18786-18787	 	_
131-6	18787-18788	±	_
131-7	18788-18789	 	_
131-8	18789-18791	10	_
131-9	18792-18800	features	_
131-10	18801-18805	were	_
131-11	18806-18814	selected	_
131-12	18815-18817	at	_
131-13	18818-18819	p	_
131-14	18819-18820	 	_
131-15	18820-18821	<	_
131-16	18821-18822	 	_
131-17	18822-18826	0.05	_
131-18	18826-18827	,	_
131-19	18828-18839	uncorrected	_
131-20	18839-18840	.	_

#Text=In Fig. 3, we show the clusters of voxels of which the connectivity with the six ICs form the feature space for classification.
132-1	18841-18843	In	_
132-2	18844-18847	Fig	_
132-3	18847-18848	.	_
132-4	18849-18850	3	_
132-5	18850-18851	,	_
132-6	18852-18854	we	_
132-7	18855-18859	show	_
132-8	18860-18863	the	_
132-9	18864-18872	clusters	_
132-10	18873-18875	of	_
132-11	18876-18882	voxels	_
132-12	18883-18885	of	_
132-13	18886-18891	which	_
132-14	18892-18895	the	_
132-15	18896-18908	connectivity	_
132-16	18909-18913	with	_
132-17	18914-18917	the	_
132-18	18918-18921	six	_
132-19	18922-18925	ICs	_
132-20	18926-18930	form	_
132-21	18931-18934	the	_
132-22	18935-18942	feature	_
132-23	18943-18948	space	_
132-24	18949-18952	for	_
132-25	18953-18967	classification	_
132-26	18967-18968	.	_

#Text=With connectivity to the motor cortical network (IC024), a cluster in the area of bilateral ventrolateral nuclei (VL) possibly including mediodorsal nuclei (MD) distinguished CD from HC.
133-1	18969-18973	With	_
133-2	18974-18986	connectivity	_
133-3	18987-18989	to	_
133-4	18990-18993	the	_
133-5	18994-18999	motor	_
133-6	19000-19008	cortical	_
133-7	19009-19016	network	_
133-8	19017-19018	(	_
133-9	19018-19023	IC024	_
133-10	19023-19024	)	_
133-11	19024-19025	,	_
133-12	19026-19027	a	_
133-13	19028-19035	cluster	_
133-14	19036-19038	in	_
133-15	19039-19042	the	_
133-16	19043-19047	area	_
133-17	19048-19050	of	_
133-18	19051-19060	bilateral	_
133-19	19061-19074	ventrolateral	_
133-20	19075-19081	nuclei	_
133-21	19082-19083	(	_
133-22	19083-19085	VL	_
133-23	19085-19086	)	_
133-24	19087-19095	possibly	_
133-25	19096-19105	including	_
133-26	19106-19117	mediodorsal	_
133-27	19118-19124	nuclei	_
133-28	19125-19126	(	_
133-29	19126-19128	MD	_
133-30	19128-19129	)	_
133-31	19130-19143	distinguished	_
133-32	19144-19146	CD	_
133-33	19147-19151	from	_
133-34	19152-19154	HC	_
133-35	19154-19155	.	_

#Text=Compared to HC, CD showed significantly lower functional connectivity between this cluster and the motor cortical network (p = 0.0002, two-sample t test).
134-1	19156-19164	Compared	_
134-2	19165-19167	to	_
134-3	19168-19170	HC	_
134-4	19170-19171	,	_
134-5	19172-19174	CD	_
134-6	19175-19181	showed	_
134-7	19182-19195	significantly	_
134-8	19196-19201	lower	_
134-9	19202-19212	functional	_
134-10	19213-19225	connectivity	_
134-11	19226-19233	between	_
134-12	19234-19238	this	_
134-13	19239-19246	cluster	_
134-14	19247-19250	and	_
134-15	19251-19254	the	_
134-16	19255-19260	motor	_
134-17	19261-19269	cortical	_
134-18	19270-19277	network	_
134-19	19278-19279	(	_
134-20	19279-19280	p	_
134-21	19280-19281	 	_
134-22	19281-19282	=	_
134-23	19282-19283	 	_
134-24	19283-19289	0.0002	_
134-25	19289-19290	,	_
134-26	19291-19301	two-sample	_
134-27	19302-19303	t	_
134-28	19304-19308	test	_
134-29	19308-19309	)	_
134-30	19309-19310	.	_

#Text=With connectivity to the right frontoparietal network (IC009), three clusters, each in the area of the right and left ventroposterior lateral nuclei (VPL) and pulvinar (PUL), and left VL nucleus distinguished CD from HC.
135-1	19311-19315	With	_
135-2	19316-19328	connectivity	_
135-3	19329-19331	to	_
135-4	19332-19335	the	_
135-5	19336-19341	right	_
135-6	19342-19356	frontoparietal	_
135-7	19357-19364	network	_
135-8	19365-19366	(	_
135-9	19366-19371	IC009	_
135-10	19371-19372	)	_
135-11	19372-19373	,	_
135-12	19374-19379	three	_
135-13	19380-19388	clusters	_
135-14	19388-19389	,	_
135-15	19390-19394	each	_
135-16	19395-19397	in	_
135-17	19398-19401	the	_
135-18	19402-19406	area	_
135-19	19407-19409	of	_
135-20	19410-19413	the	_
135-21	19414-19419	right	_
135-22	19420-19423	and	_
135-23	19424-19428	left	_
135-24	19429-19444	ventroposterior	_
135-25	19445-19452	lateral	_
135-26	19453-19459	nuclei	_
135-27	19460-19461	(	_
135-28	19461-19464	VPL	_
135-29	19464-19465	)	_
135-30	19466-19469	and	_
135-31	19470-19478	pulvinar	_
135-32	19479-19480	(	_
135-33	19480-19483	PUL	_
135-34	19483-19484	)	_
135-35	19484-19485	,	_
135-36	19486-19489	and	_
135-37	19490-19494	left	_
135-38	19495-19497	VL	_
135-39	19498-19505	nucleus	_
135-40	19506-19519	distinguished	_
135-41	19520-19522	CD	_
135-42	19523-19527	from	_
135-43	19528-19530	HC	_
135-44	19530-19531	.	_

#Text=Compared to HC, CD showed significantly higher functional connectivity in the right VPL/PUL (p = 0.0001) and lower connectivity in the left VPL/PUL (p = 0.0002) and left VL (p = 0.0002).
136-1	19532-19540	Compared	_
136-2	19541-19543	to	_
136-3	19544-19546	HC	_
136-4	19546-19547	,	_
136-5	19548-19550	CD	_
136-6	19551-19557	showed	_
136-7	19558-19571	significantly	_
136-8	19572-19578	higher	_
136-9	19579-19589	functional	_
136-10	19590-19602	connectivity	_
136-11	19603-19605	in	_
136-12	19606-19609	the	_
136-13	19610-19615	right	_
136-14	19616-19619	VPL	_
136-15	19619-19620	/	_
136-16	19620-19623	PUL	_
136-17	19624-19625	(	_
136-18	19625-19626	p	_
136-19	19626-19627	 	_
136-20	19627-19628	=	_
136-21	19628-19629	 	_
136-22	19629-19635	0.0001	_
136-23	19635-19636	)	_
136-24	19637-19640	and	_
136-25	19641-19646	lower	_
136-26	19647-19659	connectivity	_
136-27	19660-19662	in	_
136-28	19663-19666	the	_
136-29	19667-19671	left	_
136-30	19672-19675	VPL	_
136-31	19675-19676	/	_
136-32	19676-19679	PUL	_
136-33	19680-19681	(	_
136-34	19681-19682	p	_
136-35	19682-19683	 	_
136-36	19683-19684	=	_
136-37	19684-19685	 	_
136-38	19685-19691	0.0002	_
136-39	19691-19692	)	_
136-40	19693-19696	and	_
136-41	19697-19701	left	_
136-42	19702-19704	VL	_
136-43	19705-19706	(	_
136-44	19706-19707	p	_
136-45	19707-19708	 	_
136-46	19708-19709	=	_
136-47	19709-19710	 	_
136-48	19710-19716	0.0002	_
136-49	19716-19717	)	_
136-50	19717-19718	.	_

#Text=With connectivity to the left frontoparietal network (IC027), clusters in the area of bilateral VL and right MD distinguished CD from HC.
137-1	19719-19723	With	_
137-2	19724-19736	connectivity	_
137-3	19737-19739	to	_
137-4	19740-19743	the	_
137-5	19744-19748	left	_
137-6	19749-19763	frontoparietal	_
137-7	19764-19771	network	_
137-8	19772-19773	(	_
137-9	19773-19778	IC027	_
137-10	19778-19779	)	_
137-11	19779-19780	,	_
137-12	19781-19789	clusters	_
137-13	19790-19792	in	_
137-14	19793-19796	the	_
137-15	19797-19801	area	_
137-16	19802-19804	of	_
137-17	19805-19814	bilateral	_
137-18	19815-19817	VL	_
137-19	19818-19821	and	_
137-20	19822-19827	right	_
137-21	19828-19830	MD	_
137-22	19831-19844	distinguished	_
137-23	19845-19847	CD	_
137-24	19848-19852	from	_
137-25	19853-19855	HC	_
137-26	19855-19856	.	_

#Text=Compared to HC, CD showed significant lower connectivity in bilateral VL (all p's < 0.00001) and higher connectivity in right MD (p = 0.0009).
138-1	19857-19865	Compared	_
138-2	19866-19868	to	_
138-3	19869-19871	HC	_
138-4	19871-19872	,	_
138-5	19873-19875	CD	_
138-6	19876-19882	showed	_
138-7	19883-19894	significant	_
138-8	19895-19900	lower	_
138-9	19901-19913	connectivity	_
138-10	19914-19916	in	_
138-11	19917-19926	bilateral	_
138-12	19927-19929	VL	_
138-13	19930-19931	(	_
138-14	19931-19934	all	_
138-15	19935-19938	p's	_
138-16	19938-19939	 	_
138-17	19939-19940	<	_
138-18	19940-19941	 	_
138-19	19941-19948	0.00001	_
138-20	19948-19949	)	_
138-21	19950-19953	and	_
138-22	19954-19960	higher	_
138-23	19961-19973	connectivity	_
138-24	19974-19976	in	_
138-25	19977-19982	right	_
138-26	19983-19985	MD	_
138-27	19986-19987	(	_
138-28	19987-19988	p	_
138-29	19988-19989	 	_
138-30	19989-19990	=	_
138-31	19990-19991	 	_
138-32	19991-19997	0.0009	_
138-33	19997-19998	)	_
138-34	19998-19999	.	_

#Text=With connectivity to the midline cortical-subcortical network (IC029), clusters in the area of bilateral MD distinguished CD from HC.
139-1	20000-20004	With	_
139-2	20005-20017	connectivity	_
139-3	20018-20020	to	_
139-4	20021-20024	the	_
139-5	20025-20032	midline	_
139-6	20033-20053	cortical-subcortical	_
139-7	20054-20061	network	_
139-8	20062-20063	(	_
139-9	20063-20068	IC029	_
139-10	20068-20069	)	_
139-11	20069-20070	,	_
139-12	20071-20079	clusters	_
139-13	20080-20082	in	_
139-14	20083-20086	the	_
139-15	20087-20091	area	_
139-16	20092-20094	of	_
139-17	20095-20104	bilateral	_
139-18	20105-20107	MD	_
139-19	20108-20121	distinguished	_
139-20	20122-20124	CD	_
139-21	20125-20129	from	_
139-22	20130-20132	HC	_
139-23	20132-20133	.	_

#Text=Compared to HC, CD showed higher connectivity in bilateral MD (all p's < 0.0001).
140-1	20134-20142	Compared	_
140-2	20143-20145	to	_
140-3	20146-20148	HC	_
140-4	20148-20149	,	_
140-5	20150-20152	CD	_
140-6	20153-20159	showed	_
140-7	20160-20166	higher	_
140-8	20167-20179	connectivity	_
140-9	20180-20182	in	_
140-10	20183-20192	bilateral	_
140-11	20193-20195	MD	_
140-12	20196-20197	(	_
140-13	20197-20200	all	_
140-14	20201-20204	p's	_
140-15	20204-20205	 	_
140-16	20205-20206	<	_
140-17	20206-20207	 	_
140-18	20207-20213	0.0001	_
140-19	20213-20214	)	_
140-20	20214-20215	.	_

#Text=With connectivity to the cuneus-precuneus network (IC003), clusters in the area of bilateral VPL distinguished CD from HC.
141-1	20216-20220	With	_
141-2	20221-20233	connectivity	_
141-3	20234-20236	to	_
141-4	20237-20240	the	_
141-5	20241-20257	cuneus-precuneus	_
141-6	20258-20265	network	_
141-7	20266-20267	(	_
141-8	20267-20272	IC003	_
141-9	20272-20273	)	_
141-10	20273-20274	,	_
141-11	20275-20283	clusters	_
141-12	20284-20286	in	_
141-13	20287-20290	the	_
141-14	20291-20295	area	_
141-15	20296-20298	of	_
141-16	20299-20308	bilateral	_
141-17	20309-20312	VPL	_
141-18	20313-20326	distinguished	_
141-19	20327-20329	CD	_
141-20	20330-20334	from	_
141-21	20335-20337	HC	_
141-22	20337-20338	.	_

#Text=Compared to HC, CD showed higher connectivity to VPL (all p's < 0.000001).
142-1	20339-20347	Compared	_
142-2	20348-20350	to	_
142-3	20351-20353	HC	_
142-4	20353-20354	,	_
142-5	20355-20357	CD	_
142-6	20358-20364	showed	_
142-7	20365-20371	higher	_
142-8	20372-20384	connectivity	_
142-9	20385-20387	to	_
142-10	20388-20391	VPL	_
142-11	20392-20393	(	_
142-12	20393-20396	all	_
142-13	20397-20400	p's	_
142-14	20400-20401	 	_
142-15	20401-20402	<	_
142-16	20402-20403	 	_
142-17	20403-20411	0.000001	_
142-18	20411-20412	)	_
142-19	20412-20413	.	_

#Text=With connectivity to the DMN (IC022), clusters in the right VL and bilateral MD distinguished CD from HC.
143-1	20414-20418	With	_
143-2	20419-20431	connectivity	_
143-3	20432-20434	to	_
143-4	20435-20438	the	_
143-5	20439-20442	DMN	_
143-6	20443-20444	(	_
143-7	20444-20449	IC022	_
143-8	20449-20450	)	_
143-9	20450-20451	,	_
143-10	20452-20460	clusters	_
143-11	20461-20463	in	_
143-12	20464-20467	the	_
143-13	20468-20473	right	_
143-14	20474-20476	VL	_
143-15	20477-20480	and	_
143-16	20481-20490	bilateral	_
143-17	20491-20493	MD	_
143-18	20494-20507	distinguished	_
143-19	20508-20510	CD	_
143-20	20511-20515	from	_
143-21	20516-20518	HC	_
143-22	20518-20519	.	_

#Text=Compared to HC, CD showed higher connectivity in these clusters (p = 0.002 and p = 0.001).
144-1	20520-20528	Compared	_
144-2	20529-20531	to	_
144-3	20532-20534	HC	_
144-4	20534-20535	,	_
144-5	20536-20538	CD	_
144-6	20539-20545	showed	_
144-7	20546-20552	higher	_
144-8	20553-20565	connectivity	_
144-9	20566-20568	in	_
144-10	20569-20574	these	_
144-11	20575-20583	clusters	_
144-12	20584-20585	(	_
144-13	20585-20586	p	_
144-14	20586-20587	 	_
144-15	20587-20588	=	_
144-16	20588-20589	 	_
144-17	20589-20594	0.002	_
144-18	20595-20598	and	_
144-19	20599-20600	p	_
144-20	20600-20601	 	_
144-21	20601-20602	=	_
144-22	20602-20603	 	_
144-23	20603-20608	0.001	_
144-24	20608-20609	)	_
144-25	20609-20610	.	_

#Text=Aggregation index analysis
#Text=To examine how well the thalamic voxels that distinguished CD and HC aggregate in clusters, we computed an aggregation index (AI) for each independent component for the thalamus and comparison regions (Table 3).
145-1	20611-20622	Aggregation	_
145-2	20623-20628	index	_
145-3	20629-20637	analysis	_
145-4	20638-20640	To	_
145-5	20641-20648	examine	_
145-6	20649-20652	how	_
145-7	20653-20657	well	_
145-8	20658-20661	the	_
145-9	20662-20670	thalamic	_
145-10	20671-20677	voxels	_
145-11	20678-20682	that	_
145-12	20683-20696	distinguished	_
145-13	20697-20699	CD	_
145-14	20700-20703	and	_
145-15	20704-20706	HC	_
145-16	20707-20716	aggregate	_
145-17	20717-20719	in	_
145-18	20720-20728	clusters	_
145-19	20728-20729	,	_
145-20	20730-20732	we	_
145-21	20733-20741	computed	_
145-22	20742-20744	an	_
145-23	20745-20756	aggregation	_
145-24	20757-20762	index	_
145-25	20763-20764	(	_
145-26	20764-20766	AI	_
145-27	20766-20767	)	_
145-28	20768-20771	for	_
145-29	20772-20776	each	_
145-30	20777-20788	independent	_
145-31	20789-20798	component	_
145-32	20799-20802	for	_
145-33	20803-20806	the	_
145-34	20807-20815	thalamus	_
145-35	20816-20819	and	_
145-36	20820-20830	comparison	_
145-37	20831-20838	regions	_
145-38	20839-20840	(	_
145-39	20840-20845	Table	_
145-40	20846-20847	3	_
145-41	20847-20848	)	_
145-42	20848-20849	.	_

#Text=The AI was computed as the total number of voxels that appear in a cluster ≥ 10 voxels divided by the total number of voxels.
146-1	20850-20853	The	_
146-2	20854-20856	AI	_
146-3	20857-20860	was	_
146-4	20861-20869	computed	_
146-5	20870-20872	as	_
146-6	20873-20876	the	_
146-7	20877-20882	total	_
146-8	20883-20889	number	_
146-9	20890-20892	of	_
146-10	20893-20899	voxels	_
146-11	20900-20904	that	_
146-12	20905-20911	appear	_
146-13	20912-20914	in	_
146-14	20915-20916	a	_
146-15	20917-20924	cluster	_
146-16	20925-20926	≥	_
146-17	20926-20927	 	_
146-18	20927-20929	10	_
146-19	20930-20936	voxels	_
146-20	20937-20944	divided	_
146-21	20945-20947	by	_
146-22	20948-20951	the	_
146-23	20952-20957	total	_
146-24	20958-20964	number	_
146-25	20965-20967	of	_
146-26	20968-20974	voxels	_
146-27	20974-20975	.	_

#Text=Thus, a higher AI indicated that more voxels aggregate in clusters.
147-1	20976-20980	Thus	_
147-2	20980-20981	,	_
147-3	20982-20983	a	_
147-4	20984-20990	higher	_
147-5	20991-20993	AI	_
147-6	20994-21003	indicated	_
147-7	21004-21008	that	_
147-8	21009-21013	more	_
147-9	21014-21020	voxels	_
147-10	21021-21030	aggregate	_
147-11	21031-21033	in	_
147-12	21034-21042	clusters	_
147-13	21042-21043	.	_

#Text=Thalamus showed a significantly higher AI than comparison regions, including the caudate (p = 0.03), middle orbital frontal gyrus (p = 0.02), parahippocampal gyrus (p = 0.008), and inferior occipital gyrus (p = 0.03), but not paracentral gyrus (p = 0.14).
148-1	21044-21052	Thalamus	_
148-2	21053-21059	showed	_
148-3	21060-21061	a	_
148-4	21062-21075	significantly	_
148-5	21076-21082	higher	_
148-6	21083-21085	AI	_
148-7	21086-21090	than	_
148-8	21091-21101	comparison	_
148-9	21102-21109	regions	_
148-10	21109-21110	,	_
148-11	21111-21120	including	_
148-12	21121-21124	the	_
148-13	21125-21132	caudate	_
148-14	21133-21134	(	_
148-15	21134-21135	p	_
148-16	21135-21136	 	_
148-17	21136-21137	=	_
148-18	21137-21138	 	_
148-19	21138-21142	0.03	_
148-20	21142-21143	)	_
148-21	21143-21144	,	_
148-22	21145-21151	middle	_
148-23	21152-21159	orbital	_
148-24	21160-21167	frontal	_
148-25	21168-21173	gyrus	_
148-26	21174-21175	(	_
148-27	21175-21176	p	_
148-28	21176-21177	 	_
148-29	21177-21178	=	_
148-30	21178-21179	 	_
148-31	21179-21183	0.02	_
148-32	21183-21184	)	_
148-33	21184-21185	,	_
148-34	21186-21201	parahippocampal	_
148-35	21202-21207	gyrus	_
148-36	21208-21209	(	_
148-37	21209-21210	p	_
148-38	21210-21211	 	_
148-39	21211-21212	=	_
148-40	21212-21213	 	_
148-41	21213-21218	0.008	_
148-42	21218-21219	)	_
148-43	21219-21220	,	_
148-44	21221-21224	and	_
148-45	21225-21233	inferior	_
148-46	21234-21243	occipital	_
148-47	21244-21249	gyrus	_
148-48	21250-21251	(	_
148-49	21251-21252	p	_
148-50	21252-21253	 	_
148-51	21253-21254	=	_
148-52	21254-21255	 	_
148-53	21255-21259	0.03	_
148-54	21259-21260	)	_
148-55	21260-21261	,	_
148-56	21262-21265	but	_
148-57	21266-21269	not	_
148-58	21270-21281	paracentral	_
148-59	21282-21287	gyrus	_
148-60	21288-21289	(	_
148-61	21289-21290	p	_
148-62	21290-21291	 	_
148-63	21291-21292	=	_
148-64	21292-21293	 	_
148-65	21293-21297	0.14	_
148-66	21297-21298	)	_
148-67	21298-21299	.	_

#Text=The results were similar when we redefined the cluster set size to ≥ 20 voxels (the caudate: p = 0.039; middle orbital frontal gyrus: p = 0.055; parahippocampal gyrus: p = 0.020; inferior occipital gyrus: p = 0.119; paracentral gyrus: p = 0.270), or ≥ 40 voxels (the caudate: p = 0.001; middle orbital frontal gyrus: p = 0.025; parahippocampal gyrus: p = 0.059; inferior occipital gyrus: p = 0.050; paracentral gyrus: p = 0.426).
149-1	21300-21303	The	_
149-2	21304-21311	results	_
149-3	21312-21316	were	_
149-4	21317-21324	similar	_
149-5	21325-21329	when	_
149-6	21330-21332	we	_
149-7	21333-21342	redefined	_
149-8	21343-21346	the	_
149-9	21347-21354	cluster	_
149-10	21355-21358	set	_
149-11	21359-21363	size	_
149-12	21364-21366	to	_
149-13	21367-21368	≥	_
149-14	21368-21369	 	_
149-15	21369-21371	20	_
149-16	21372-21378	voxels	_
149-17	21379-21380	(	_
149-18	21380-21383	the	_
149-19	21384-21391	caudate	_
149-20	21391-21392	:	_
149-21	21393-21394	p	_
149-22	21394-21395	 	_
149-23	21395-21396	=	_
149-24	21396-21397	 	_
149-25	21397-21402	0.039	_
149-26	21402-21403	;	_
149-27	21404-21410	middle	_
149-28	21411-21418	orbital	_
149-29	21419-21426	frontal	_
149-30	21427-21432	gyrus	_
149-31	21432-21433	:	_
149-32	21434-21435	p	_
149-33	21435-21436	 	_
149-34	21436-21437	=	_
149-35	21437-21438	 	_
149-36	21438-21443	0.055	_
149-37	21443-21444	;	_
149-38	21445-21460	parahippocampal	_
149-39	21461-21466	gyrus	_
149-40	21466-21467	:	_
149-41	21468-21469	p	_
149-42	21469-21470	 	_
149-43	21470-21471	=	_
149-44	21471-21472	 	_
149-45	21472-21477	0.020	_
149-46	21477-21478	;	_
149-47	21479-21487	inferior	_
149-48	21488-21497	occipital	_
149-49	21498-21503	gyrus	_
149-50	21503-21504	:	_
149-51	21505-21506	p	_
149-52	21506-21507	 	_
149-53	21507-21508	=	_
149-54	21508-21509	 	_
149-55	21509-21514	0.119	_
149-56	21514-21515	;	_
149-57	21516-21527	paracentral	_
149-58	21528-21533	gyrus	_
149-59	21533-21534	:	_
149-60	21535-21536	p	_
149-61	21536-21537	 	_
149-62	21537-21538	=	_
149-63	21538-21539	 	_
149-64	21539-21544	0.270	_
149-65	21544-21545	)	_
149-66	21545-21546	,	_
149-67	21547-21549	or	_
149-68	21550-21551	≥	_
149-69	21551-21552	 	_
149-70	21552-21554	40	_
149-71	21555-21561	voxels	_
149-72	21562-21563	(	_
149-73	21563-21566	the	_
149-74	21567-21574	caudate	_
149-75	21574-21575	:	_
149-76	21576-21577	p	_
149-77	21577-21578	 	_
149-78	21578-21579	=	_
149-79	21579-21580	 	_
149-80	21580-21585	0.001	_
149-81	21585-21586	;	_
149-82	21587-21593	middle	_
149-83	21594-21601	orbital	_
149-84	21602-21609	frontal	_
149-85	21610-21615	gyrus	_
149-86	21615-21616	:	_
149-87	21617-21618	p	_
149-88	21618-21619	 	_
149-89	21619-21620	=	_
149-90	21620-21621	 	_
149-91	21621-21626	0.025	_
149-92	21626-21627	;	_
149-93	21628-21643	parahippocampal	_
149-94	21644-21649	gyrus	_
149-95	21649-21650	:	_
149-96	21651-21652	p	_
149-97	21652-21653	 	_
149-98	21653-21654	=	_
149-99	21654-21655	 	_
149-100	21655-21660	0.059	_
149-101	21660-21661	;	_
149-102	21662-21670	inferior	_
149-103	21671-21680	occipital	_
149-104	21681-21686	gyrus	_
149-105	21686-21687	:	_
149-106	21688-21689	p	_
149-107	21689-21690	 	_
149-108	21690-21691	=	_
149-109	21691-21692	 	_
149-110	21692-21697	0.050	_
149-111	21697-21698	;	_
149-112	21699-21710	paracentral	_
149-113	21711-21716	gyrus	_
149-114	21716-21717	:	_
149-115	21718-21719	p	_
149-116	21719-21720	 	_
149-117	21720-21721	=	_
149-118	21721-21722	 	_
149-119	21722-21727	0.426	_
149-120	21727-21728	)	_
149-121	21728-21729	.	_

#Text=In no cases were the AIs of any of the comparison regions higher than that of the thalamus.
150-1	21730-21732	In	_
150-2	21733-21735	no	_
150-3	21736-21741	cases	_
150-4	21742-21746	were	_
150-5	21747-21750	the	_
150-6	21751-21754	AIs	_
150-7	21755-21757	of	_
150-8	21758-21761	any	_
150-9	21762-21764	of	_
150-10	21765-21768	the	_
150-11	21769-21779	comparison	_
150-12	21780-21787	regions	_
150-13	21788-21794	higher	_
150-14	21795-21799	than	_
150-15	21800-21804	that	_
150-16	21805-21807	of	_
150-17	21808-21811	the	_
150-18	21812-21820	thalamus	_
150-19	21820-21821	.	_

#Text=Correlation with performance outcomes and clinical assessments
#Text=Thalamic cortical connectivity is critical to cognitive control in the stop signal task.
151-1	21822-21833	Correlation	_
151-2	21834-21838	with	_
151-3	21839-21850	performance	_
151-4	21851-21859	outcomes	_
151-5	21860-21863	and	_
151-6	21864-21872	clinical	_
151-7	21873-21884	assessments	_
151-8	21885-21893	Thalamic	_
151-9	21894-21902	cortical	_
151-10	21903-21915	connectivity	_
151-11	21916-21918	is	_
151-12	21919-21927	critical	_
151-13	21928-21930	to	_
151-14	21931-21940	cognitive	_
151-15	21941-21948	control	_
151-16	21949-21951	in	_
151-17	21952-21955	the	_
151-18	21956-21960	stop	_
151-19	21961-21967	signal	_
151-20	21968-21972	task	_
151-21	21972-21973	.	_

#Text=We previously showed that, compared to HC, CD showed prolonged SSRT and diminished PES.
152-1	21974-21976	We	_
152-2	21977-21987	previously	_
152-3	21988-21994	showed	_
152-4	21995-21999	that	_
152-5	21999-22000	,	_
152-6	22001-22009	compared	_
152-7	22010-22012	to	_
152-8	22013-22015	HC	_
152-9	22015-22016	,	_
152-10	22017-22019	CD	_
152-11	22020-22026	showed	_
152-12	22027-22036	prolonged	_
152-13	22037-22041	SSRT	_
152-14	22042-22045	and	_
152-15	22046-22056	diminished	_
152-16	22057-22060	PES	_
152-17	22060-22061	.	_

#Text=Thus, we examined whether thalamic connectivity to each of the independent component of cognitive control is related to SSRT and PES.
153-1	22062-22066	Thus	_
153-2	22066-22067	,	_
153-3	22068-22070	we	_
153-4	22071-22079	examined	_
153-5	22080-22087	whether	_
153-6	22088-22096	thalamic	_
153-7	22097-22109	connectivity	_
153-8	22110-22112	to	_
153-9	22113-22117	each	_
153-10	22118-22120	of	_
153-11	22121-22124	the	_
153-12	22125-22136	independent	_
153-13	22137-22146	component	_
153-14	22147-22149	of	_
153-15	22150-22159	cognitive	_
153-16	22160-22167	control	_
153-17	22168-22170	is	_
153-18	22171-22178	related	_
153-19	22179-22181	to	_
153-20	22182-22186	SSRT	_
153-21	22187-22190	and	_
153-22	22191-22194	PES	_
153-23	22194-22195	.	_

#Text=We derived the z scores of connectivity (connectivity strength) between each independent network and corresponding cluster for individual participants.
154-1	22196-22198	We	_
154-2	22199-22206	derived	_
154-3	22207-22210	the	_
154-4	22211-22212	z	_
154-5	22213-22219	scores	_
154-6	22220-22222	of	_
154-7	22223-22235	connectivity	_
154-8	22236-22237	(	_
154-9	22237-22249	connectivity	_
154-10	22250-22258	strength	_
154-11	22258-22259	)	_
154-12	22260-22267	between	_
154-13	22268-22272	each	_
154-14	22273-22284	independent	_
154-15	22285-22292	network	_
154-16	22293-22296	and	_
154-17	22297-22310	corresponding	_
154-18	22311-22318	cluster	_
154-19	22319-22322	for	_
154-20	22323-22333	individual	_
154-21	22334-22346	participants	_
154-22	22346-22347	.	_

#Text=Pearson regression across subjects showed positive correlations between SSRT and right MD connectivity to the left frontoparietal network in CD (p = 0.007, r = 0.27) but not HC (p = 0.39, r = 0.09) and between PES and left MD connectivity to the DMN network in HC (p = 0.05, r = 0.20) but not CD (p = 0.68, r = − 0.04).
155-1	22348-22355	Pearson	_
155-2	22356-22366	regression	_
155-3	22367-22373	across	_
155-4	22374-22382	subjects	_
155-5	22383-22389	showed	_
155-6	22390-22398	positive	_
155-7	22399-22411	correlations	_
155-8	22412-22419	between	_
155-9	22420-22424	SSRT	_
155-10	22425-22428	and	_
155-11	22429-22434	right	_
155-12	22435-22437	MD	_
155-13	22438-22450	connectivity	_
155-14	22451-22453	to	_
155-15	22454-22457	the	_
155-16	22458-22462	left	_
155-17	22463-22477	frontoparietal	_
155-18	22478-22485	network	_
155-19	22486-22488	in	_
155-20	22489-22491	CD	_
155-21	22492-22493	(	_
155-22	22493-22494	p	_
155-23	22494-22495	 	_
155-24	22495-22496	=	_
155-25	22496-22497	 	_
155-26	22497-22502	0.007	_
155-27	22502-22503	,	_
155-28	22504-22505	r	_
155-29	22505-22506	 	_
155-30	22506-22507	=	_
155-31	22507-22508	 	_
155-32	22508-22512	0.27	_
155-33	22512-22513	)	_
155-34	22514-22517	but	_
155-35	22518-22521	not	_
155-36	22522-22524	HC	_
155-37	22525-22526	(	_
155-38	22526-22527	p	_
155-39	22527-22528	 	_
155-40	22528-22529	=	_
155-41	22529-22530	 	_
155-42	22530-22534	0.39	_
155-43	22534-22535	,	_
155-44	22536-22537	r	_
155-45	22537-22538	 	_
155-46	22538-22539	=	_
155-47	22539-22540	 	_
155-48	22540-22544	0.09	_
155-49	22544-22545	)	_
155-50	22546-22549	and	_
155-51	22550-22557	between	_
155-52	22558-22561	PES	_
155-53	22562-22565	and	_
155-54	22566-22570	left	_
155-55	22571-22573	MD	_
155-56	22574-22586	connectivity	_
155-57	22587-22589	to	_
155-58	22590-22593	the	_
155-59	22594-22597	DMN	_
155-60	22598-22605	network	_
155-61	22606-22608	in	_
155-62	22609-22611	HC	_
155-63	22612-22613	(	_
155-64	22613-22614	p	_
155-65	22614-22615	 	_
155-66	22615-22616	=	_
155-67	22616-22617	 	_
155-68	22617-22621	0.05	_
155-69	22621-22622	,	_
155-70	22623-22624	r	_
155-71	22624-22625	 	_
155-72	22625-22626	=	_
155-73	22626-22627	 	_
155-74	22627-22631	0.20	_
155-75	22631-22632	)	_
155-76	22633-22636	but	_
155-77	22637-22640	not	_
155-78	22641-22643	CD	_
155-79	22644-22645	(	_
155-80	22645-22646	p	_
155-81	22646-22647	 	_
155-82	22647-22648	=	_
155-83	22648-22649	 	_
155-84	22649-22653	0.68	_
155-85	22653-22654	,	_
155-86	22655-22656	r	_
155-87	22656-22657	 	_
155-88	22657-22658	=	_
155-89	22658-22659	 	_
155-90	22659-22660	−	_
155-91	22660-22661	 	_
155-92	22661-22665	0.04	_
155-93	22665-22666	)	_
155-94	22666-22667	.	_

#Text=Conversely, a negative correlations was observed between SSRT and left MD connectivity to the DMN in HC (p = 0.01, r = − 0.25) but not CD (p = 0.55, r = 0.06).
156-1	22668-22678	Conversely	_
156-2	22678-22679	,	_
156-3	22680-22681	a	_
156-4	22682-22690	negative	_
156-5	22691-22703	correlations	_
156-6	22704-22707	was	_
156-7	22708-22716	observed	_
156-8	22717-22724	between	_
156-9	22725-22729	SSRT	_
156-10	22730-22733	and	_
156-11	22734-22738	left	_
156-12	22739-22741	MD	_
156-13	22742-22754	connectivity	_
156-14	22755-22757	to	_
156-15	22758-22761	the	_
156-16	22762-22765	DMN	_
156-17	22766-22768	in	_
156-18	22769-22771	HC	_
156-19	22772-22773	(	_
156-20	22773-22774	p	_
156-21	22774-22775	 	_
156-22	22775-22776	=	_
156-23	22776-22777	 	_
156-24	22777-22781	0.01	_
156-25	22781-22782	,	_
156-26	22783-22784	r	_
156-27	22784-22785	 	_
156-28	22785-22786	=	_
156-29	22786-22787	 	_
156-30	22787-22788	−	_
156-31	22788-22789	 	_
156-32	22789-22793	0.25	_
156-33	22793-22794	)	_
156-34	22795-22798	but	_
156-35	22799-22802	not	_
156-36	22803-22805	CD	_
156-37	22806-22807	(	_
156-38	22807-22808	p	_
156-39	22808-22809	 	_
156-40	22809-22810	=	_
156-41	22810-22811	 	_
156-42	22811-22815	0.55	_
156-43	22815-22816	,	_
156-44	22817-22818	r	_
156-45	22818-22819	 	_
156-46	22819-22820	=	_
156-47	22820-22821	 	_
156-48	22821-22825	0.06	_
156-49	22825-22826	)	_
156-50	22826-22827	.	_

#Text=Further, the linear regressions between SSRT and left MD connectivity to the DMN were significantly different in slope between CD and HC (p < 0.05).
157-1	22828-22835	Further	_
157-2	22835-22836	,	_
157-3	22837-22840	the	_
157-4	22841-22847	linear	_
157-5	22848-22859	regressions	_
157-6	22860-22867	between	_
157-7	22868-22872	SSRT	_
157-8	22873-22876	and	_
157-9	22877-22881	left	_
157-10	22882-22884	MD	_
157-11	22885-22897	connectivity	_
157-12	22898-22900	to	_
157-13	22901-22904	the	_
157-14	22905-22908	DMN	_
157-15	22909-22913	were	_
157-16	22914-22927	significantly	_
157-17	22928-22937	different	_
157-18	22938-22940	in	_
157-19	22941-22946	slope	_
157-20	22947-22954	between	_
157-21	22955-22957	CD	_
157-22	22958-22961	and	_
157-23	22962-22964	HC	_
157-24	22965-22966	(	_
157-25	22966-22967	p	_
157-26	22967-22968	 	_
157-27	22968-22969	<	_
157-28	22969-22970	 	_
157-29	22970-22974	0.05	_
157-30	22974-22975	)	_
157-31	22975-22976	.	_

#Text=Left VL connectivity to left frontoparietal network positively correlated with CCQ score on the scan day (p = 0.006, r = 0.27) and left VPL/PUL connectivity to right frontoparietal network positively correlated to the amount of cocaine (grams) per use (p = 0.05, r = 0.2).
158-1	22977-22981	Left	_
158-2	22982-22984	VL	_
158-3	22985-22997	connectivity	_
158-4	22998-23000	to	_
158-5	23001-23005	left	_
158-6	23006-23020	frontoparietal	_
158-7	23021-23028	network	_
158-8	23029-23039	positively	_
158-9	23040-23050	correlated	_
158-10	23051-23055	with	_
158-11	23056-23059	CCQ	_
158-12	23060-23065	score	_
158-13	23066-23068	on	_
158-14	23069-23072	the	_
158-15	23073-23077	scan	_
158-16	23078-23081	day	_
158-17	23082-23083	(	_
158-18	23083-23084	p	_
158-19	23084-23085	 	_
158-20	23085-23086	=	_
158-21	23086-23087	 	_
158-22	23087-23092	0.006	_
158-23	23092-23093	,	_
158-24	23094-23095	r	_
158-25	23095-23096	 	_
158-26	23096-23097	=	_
158-27	23097-23098	 	_
158-28	23098-23102	0.27	_
158-29	23102-23103	)	_
158-30	23104-23107	and	_
158-31	23108-23112	left	_
158-32	23113-23116	VPL	_
158-33	23116-23117	/	_
158-34	23117-23120	PUL	_
158-35	23121-23133	connectivity	_
158-36	23134-23136	to	_
158-37	23137-23142	right	_
158-38	23143-23157	frontoparietal	_
158-39	23158-23165	network	_
158-40	23166-23176	positively	_
158-41	23177-23187	correlated	_
158-42	23188-23190	to	_
158-43	23191-23194	the	_
158-44	23195-23201	amount	_
158-45	23202-23204	of	_
158-46	23205-23212	cocaine	_
158-47	23213-23214	(	_
158-48	23214-23219	grams	_
158-49	23219-23220	)	_
158-50	23221-23224	per	_
158-51	23225-23228	use	_
158-52	23229-23230	(	_
158-53	23230-23231	p	_
158-54	23231-23232	 	_
158-55	23232-23233	=	_
158-56	23233-23234	 	_
158-57	23234-23238	0.05	_
158-58	23238-23239	,	_
158-59	23240-23241	r	_
158-60	23241-23242	 	_
158-61	23242-23243	=	_
158-62	23243-23244	 	_
158-63	23244-23247	0.2	_
158-64	23247-23248	)	_
158-65	23248-23249	.	_

#Text=Conversely, right VPL connectivity to the cuneus-precuneus network negatively correlated with the duration of abstinence (days) prior to scan (p = 0.01, r = − 0.26) and left VL connectivity to the right frontoparietal network negatively correlated with the years of cocaine use (p = 0.05, r = − 0.2).
159-1	23250-23260	Conversely	_
159-2	23260-23261	,	_
159-3	23262-23267	right	_
159-4	23268-23271	VPL	_
159-5	23272-23284	connectivity	_
159-6	23285-23287	to	_
159-7	23288-23291	the	_
159-8	23292-23308	cuneus-precuneus	_
159-9	23309-23316	network	_
159-10	23317-23327	negatively	_
159-11	23328-23338	correlated	_
159-12	23339-23343	with	_
159-13	23344-23347	the	_
159-14	23348-23356	duration	_
159-15	23357-23359	of	_
159-16	23360-23370	abstinence	_
159-17	23371-23372	(	_
159-18	23372-23376	days	_
159-19	23376-23377	)	_
159-20	23378-23383	prior	_
159-21	23384-23386	to	_
159-22	23387-23391	scan	_
159-23	23392-23393	(	_
159-24	23393-23394	p	_
159-25	23394-23395	 	_
159-26	23395-23396	=	_
159-27	23396-23397	 	_
159-28	23397-23401	0.01	_
159-29	23401-23402	,	_
159-30	23403-23404	r	_
159-31	23404-23405	 	_
159-32	23405-23406	=	_
159-33	23406-23407	 	_
159-34	23407-23408	−	_
159-35	23408-23409	 	_
159-36	23409-23413	0.26	_
159-37	23413-23414	)	_
159-38	23415-23418	and	_
159-39	23419-23423	left	_
159-40	23424-23426	VL	_
159-41	23427-23439	connectivity	_
159-42	23440-23442	to	_
159-43	23443-23446	the	_
159-44	23447-23452	right	_
159-45	23453-23467	frontoparietal	_
159-46	23468-23475	network	_
159-47	23476-23486	negatively	_
159-48	23487-23497	correlated	_
159-49	23498-23502	with	_
159-50	23503-23506	the	_
159-51	23507-23512	years	_
159-52	23513-23515	of	_
159-53	23516-23523	cocaine	_
159-54	23524-23527	use	_
159-55	23528-23529	(	_
159-56	23529-23530	p	_
159-57	23530-23531	 	_
159-58	23531-23532	=	_
159-59	23532-23533	 	_
159-60	23533-23537	0.05	_
159-61	23537-23538	,	_
159-62	23539-23540	r	_
159-63	23540-23541	 	_
159-64	23541-23542	=	_
159-65	23542-23543	 	_
159-66	23543-23544	−	_
159-67	23544-23545	 	_
159-68	23545-23548	0.2	_
159-69	23548-23549	)	_
159-70	23549-23550	.	_

#Text=None of the connectivity strengths was correlated with days of cocaine use (all p's > 0.1) or daily amount of cocaine use (grams) in the month prior to admission (all p's > 0.07), or years of cocaine use (all p's > 0.05), in CD.
160-1	23551-23555	None	_
160-2	23556-23558	of	_
160-3	23559-23562	the	_
160-4	23563-23575	connectivity	_
160-5	23576-23585	strengths	_
160-6	23586-23589	was	_
160-7	23590-23600	correlated	_
160-8	23601-23605	with	_
160-9	23606-23610	days	_
160-10	23611-23613	of	_
160-11	23614-23621	cocaine	_
160-12	23622-23625	use	_
160-13	23626-23627	(	_
160-14	23627-23630	all	_
160-15	23631-23634	p's	_
160-16	23634-23635	 	_
160-17	23635-23636	>	_
160-18	23636-23637	 	_
160-19	23637-23640	0.1	_
160-20	23640-23641	)	_
160-21	23642-23644	or	_
160-22	23645-23650	daily	_
160-23	23651-23657	amount	_
160-24	23658-23660	of	_
160-25	23661-23668	cocaine	_
160-26	23669-23672	use	_
160-27	23673-23674	(	_
160-28	23674-23679	grams	_
160-29	23679-23680	)	_
160-30	23681-23683	in	_
160-31	23684-23687	the	_
160-32	23688-23693	month	_
160-33	23694-23699	prior	_
160-34	23700-23702	to	_
160-35	23703-23712	admission	_
160-36	23713-23714	(	_
160-37	23714-23717	all	_
160-38	23718-23721	p's	_
160-39	23721-23722	 	_
160-40	23722-23723	>	_
160-41	23723-23724	 	_
160-42	23724-23728	0.07	_
160-43	23728-23729	)	_
160-44	23729-23730	,	_
160-45	23731-23733	or	_
160-46	23734-23739	years	_
160-47	23740-23742	of	_
160-48	23743-23750	cocaine	_
160-49	23751-23754	use	_
160-50	23755-23756	(	_
160-51	23756-23759	all	_
160-52	23760-23763	p's	_
160-53	23763-23764	 	_
160-54	23764-23765	>	_
160-55	23765-23766	 	_
160-56	23766-23770	0.05	_
160-57	23770-23771	)	_
160-58	23771-23772	,	_
160-59	23773-23775	in	_
160-60	23776-23778	CD	_
160-61	23778-23779	.	_

#Text=The connectivity strengths also did not correlate with years of alcohol use (all p's > 0.06), years of marijuana use (all p's > 0.1), BDI score (all p's > 0.1), STAI state anxiety score (all p's > 0.1), STAI trait anxiety score (all p's > 0.07).
161-1	23780-23783	The	_
161-2	23784-23796	connectivity	_
161-3	23797-23806	strengths	_
161-4	23807-23811	also	_
161-5	23812-23815	did	_
161-6	23816-23819	not	_
161-7	23820-23829	correlate	_
161-8	23830-23834	with	_
161-9	23835-23840	years	_
161-10	23841-23843	of	_
161-11	23844-23851	alcohol	_
161-12	23852-23855	use	_
161-13	23856-23857	(	_
161-14	23857-23860	all	_
161-15	23861-23864	p's	_
161-16	23864-23865	 	_
161-17	23865-23866	>	_
161-18	23866-23867	 	_
161-19	23867-23871	0.06	_
161-20	23871-23872	)	_
161-21	23872-23873	,	_
161-22	23874-23879	years	_
161-23	23880-23882	of	_
161-24	23883-23892	marijuana	_
161-25	23893-23896	use	_
161-26	23897-23898	(	_
161-27	23898-23901	all	_
161-28	23902-23905	p's	_
161-29	23905-23906	 	_
161-30	23906-23907	>	_
161-31	23907-23908	 	_
161-32	23908-23911	0.1	_
161-33	23911-23912	)	_
161-34	23912-23913	,	_
161-35	23914-23917	BDI	_
161-36	23918-23923	score	_
161-37	23924-23925	(	_
161-38	23925-23928	all	_
161-39	23929-23932	p's	_
161-40	23932-23933	 	_
161-41	23933-23934	>	_
161-42	23934-23935	 	_
161-43	23935-23938	0.1	_
161-44	23938-23939	)	_
161-45	23939-23940	,	_
161-46	23941-23945	STAI	_
161-47	23946-23951	state	_
161-48	23952-23959	anxiety	_
161-49	23960-23965	score	_
161-50	23966-23967	(	_
161-51	23967-23970	all	_
161-52	23971-23974	p's	_
161-53	23974-23975	 	_
161-54	23975-23976	>	_
161-55	23976-23977	 	_
161-56	23977-23980	0.1	_
161-57	23980-23981	)	_
161-58	23981-23982	,	_
161-59	23983-23987	STAI	_
161-60	23988-23993	trait	_
161-61	23994-24001	anxiety	_
161-62	24002-24007	score	_
161-63	24008-24009	(	_
161-64	24009-24012	all	_
161-65	24013-24016	p's	_
161-66	24016-24017	 	_
161-67	24017-24018	>	_
161-68	24018-24019	 	_
161-69	24019-24023	0.07	_
161-70	24023-24024	)	_
161-71	24024-24025	.	_

#Text=None of the correlations with outcome measures of the SST or with clinical variables were significant, when corrected for multiple comparisons.
162-1	24026-24030	None	_
162-2	24031-24033	of	_
162-3	24034-24037	the	_
162-4	24038-24050	correlations	_
162-5	24051-24055	with	_
162-6	24056-24063	outcome	_
162-7	24064-24072	measures	_
162-8	24073-24075	of	_
162-9	24076-24079	the	_
162-10	24080-24083	SST	_
162-11	24084-24086	or	_
162-12	24087-24091	with	_
162-13	24092-24100	clinical	_
162-14	24101-24110	variables	_
162-15	24111-24115	were	_
162-16	24116-24127	significant	_
162-17	24127-24128	,	_
162-18	24129-24133	when	_
162-19	24134-24143	corrected	_
162-20	24144-24147	for	_
162-21	24148-24156	multiple	_
162-22	24157-24168	comparisons	_
162-23	24168-24169	.	_

#Text=Classification results
#Text=With leave-one-out cross-validation, the linear SVM classifier achieved a mean accuracy of 72% (76% for CD and 68% for HC, and F1 score = 73%) across 200 iterations (p = 0.001, permutation test; Fig. 4).
163-1	24170-24184	Classification	_
163-2	24185-24192	results	_
163-3	24193-24197	With	_
163-4	24198-24211	leave-one-out	_
163-5	24212-24228	cross-validation	_
163-6	24228-24229	,	_
163-7	24230-24233	the	_
163-8	24234-24240	linear	_
163-9	24241-24244	SVM	_
163-10	24245-24255	classifier	_
163-11	24256-24264	achieved	_
163-12	24265-24266	a	_
163-13	24267-24271	mean	_
163-14	24272-24280	accuracy	_
163-15	24281-24283	of	_
163-16	24284-24287	72%	_
163-17	24288-24289	(	_
163-18	24289-24292	76%	_
163-19	24293-24296	for	_
163-20	24297-24299	CD	_
163-21	24300-24303	and	_
163-22	24304-24307	68%	_
163-23	24308-24311	for	_
163-24	24312-24314	HC	_
163-25	24314-24315	,	_
163-26	24316-24319	and	_
163-27	24320-24322	F1	_
163-28	24323-24328	score	_
163-29	24328-24329	 	_
163-30	24329-24330	=	_
163-31	24330-24331	 	_
163-32	24331-24334	73%	_
163-33	24334-24335	)	_
163-34	24336-24342	across	_
163-35	24343-24346	200	_
163-36	24347-24357	iterations	_
163-37	24358-24359	(	_
163-38	24359-24360	p	_
163-39	24360-24361	 	_
163-40	24361-24362	=	_
163-41	24362-24363	 	_
163-42	24363-24368	0.001	_
163-43	24368-24369	,	_
163-44	24370-24381	permutation	_
163-45	24382-24386	test	_
163-46	24386-24387	;	_
163-47	24388-24391	Fig	_
163-48	24391-24392	.	_
163-49	24393-24394	4	_
163-50	24394-24395	)	_
163-51	24395-24396	.	_

#Text=On the other hand, SVM classification accuracies of the control regions were all less than 60%, and p-values of permutation tests were not significant (Table 4).
164-1	24397-24399	On	_
164-2	24400-24403	the	_
164-3	24404-24409	other	_
164-4	24410-24414	hand	_
164-5	24414-24415	,	_
164-6	24416-24419	SVM	_
164-7	24420-24434	classification	_
164-8	24435-24445	accuracies	_
164-9	24446-24448	of	_
164-10	24449-24452	the	_
164-11	24453-24460	control	_
164-12	24461-24468	regions	_
164-13	24469-24473	were	_
164-14	24474-24477	all	_
164-15	24478-24482	less	_
164-16	24483-24487	than	_
164-17	24488-24491	60%	_
164-18	24491-24492	,	_
164-19	24493-24496	and	_
164-20	24497-24505	p-values	_
164-21	24506-24508	of	_
164-22	24509-24520	permutation	_
164-23	24521-24526	tests	_
164-24	24527-24531	were	_
164-25	24532-24535	not	_
164-26	24536-24547	significant	_
164-27	24548-24549	(	_
164-28	24549-24554	Table	_
164-29	24555-24556	4	_
164-30	24556-24557	)	_
164-31	24557-24558	.	_

#Text=Further, compared to the control regions, the thalamus showed significantly higher accuracy rates in classification (p = 0.004; two-sample t test; Table 4).
165-1	24559-24566	Further	_
165-2	24566-24567	,	_
165-3	24568-24576	compared	_
165-4	24577-24579	to	_
165-5	24580-24583	the	_
165-6	24584-24591	control	_
165-7	24592-24599	regions	_
165-8	24599-24600	,	_
165-9	24601-24604	the	_
165-10	24605-24613	thalamus	_
165-11	24614-24620	showed	_
165-12	24621-24634	significantly	_
165-13	24635-24641	higher	_
165-14	24642-24650	accuracy	_
165-15	24651-24656	rates	_
165-16	24657-24659	in	_
165-17	24660-24674	classification	_
165-18	24675-24676	(	_
165-19	24676-24677	p	_
165-20	24677-24678	 	_
165-21	24678-24679	=	_
165-22	24679-24680	 	_
165-23	24680-24685	0.004	_
165-24	24685-24686	;	_
165-25	24687-24697	two-sample	_
165-26	24698-24699	t	_
165-27	24700-24704	test	_
165-28	24704-24705	;	_
165-29	24706-24711	Table	_
165-30	24712-24713	4	_
165-31	24713-24714	)	_
165-32	24714-24715	.	_

#Text=Discussion
#Text=With MVPA of thalamic connectivity to the six independent functional networks, the current study demonstrated that CD can be distinguished from HC with a higher (72%) accuracy, relative to comparison regions with similar volumes (53% to 58%).
166-1	24716-24726	Discussion	_
166-2	24727-24731	With	_
166-3	24732-24736	MVPA	_
166-4	24737-24739	of	_
166-5	24740-24748	thalamic	_
166-6	24749-24761	connectivity	_
166-7	24762-24764	to	_
166-8	24765-24768	the	_
166-9	24769-24772	six	_
166-10	24773-24784	independent	_
166-11	24785-24795	functional	_
166-12	24796-24804	networks	_
166-13	24804-24805	,	_
166-14	24806-24809	the	_
166-15	24810-24817	current	_
166-16	24818-24823	study	_
166-17	24824-24836	demonstrated	_
166-18	24837-24841	that	_
166-19	24842-24844	CD	_
166-20	24845-24848	can	_
166-21	24849-24851	be	_
166-22	24852-24865	distinguished	_
166-23	24866-24870	from	_
166-24	24871-24873	HC	_
166-25	24874-24878	with	_
166-26	24879-24880	a	_
166-27	24881-24887	higher	_
166-28	24888-24889	(	_
166-29	24889-24892	72%	_
166-30	24892-24893	)	_
166-31	24894-24902	accuracy	_
166-32	24902-24903	,	_
166-33	24904-24912	relative	_
166-34	24913-24915	to	_
166-35	24916-24926	comparison	_
166-36	24927-24934	regions	_
166-37	24935-24939	with	_
166-38	24940-24947	similar	_
166-39	24948-24955	volumes	_
166-40	24956-24957	(	_
166-41	24957-24960	53%	_
166-42	24961-24963	to	_
166-43	24964-24967	58%	_
166-44	24967-24968	)	_
166-45	24968-24969	.	_

#Text=Of note, because the testing and training samples are distinct for each validating iteration, this accuracy rate reflects a true estimate of the power of thalamic connectivity in distinguishing CD from HC.
167-1	24970-24972	Of	_
167-2	24973-24977	note	_
167-3	24977-24978	,	_
167-4	24979-24986	because	_
167-5	24987-24990	the	_
167-6	24991-24998	testing	_
167-7	24999-25002	and	_
167-8	25003-25011	training	_
167-9	25012-25019	samples	_
167-10	25020-25023	are	_
167-11	25024-25032	distinct	_
167-12	25033-25036	for	_
167-13	25037-25041	each	_
167-14	25042-25052	validating	_
167-15	25053-25062	iteration	_
167-16	25062-25063	,	_
167-17	25064-25068	this	_
167-18	25069-25077	accuracy	_
167-19	25078-25082	rate	_
167-20	25083-25091	reflects	_
167-21	25092-25093	a	_
167-22	25094-25098	true	_
167-23	25099-25107	estimate	_
167-24	25108-25110	of	_
167-25	25111-25114	the	_
167-26	25115-25120	power	_
167-27	25121-25123	of	_
167-28	25124-25132	thalamic	_
167-29	25133-25145	connectivity	_
167-30	25146-25148	in	_
167-31	25149-25163	distinguishing	_
167-32	25164-25166	CD	_
167-33	25167-25171	from	_
167-34	25172-25174	HC	_
167-35	25174-25175	.	_

#Text=Moreover, a higher number of the identified voxels aggregate in clusters in the thalamus, in contrast to the comparison regions, indicating that these connectivities are non-random and reflect the altered functional architecture of the thalamus in cocaine addiction.
168-1	25176-25184	Moreover	_
168-2	25184-25185	,	_
168-3	25186-25187	a	_
168-4	25188-25194	higher	_
168-5	25195-25201	number	_
168-6	25202-25204	of	_
168-7	25205-25208	the	_
168-8	25209-25219	identified	_
168-9	25220-25226	voxels	_
168-10	25227-25236	aggregate	_
168-11	25237-25239	in	_
168-12	25240-25248	clusters	_
168-13	25249-25251	in	_
168-14	25252-25255	the	_
168-15	25256-25264	thalamus	_
168-16	25264-25265	,	_
168-17	25266-25268	in	_
168-18	25269-25277	contrast	_
168-19	25278-25280	to	_
168-20	25281-25284	the	_
168-21	25285-25295	comparison	_
168-22	25296-25303	regions	_
168-23	25303-25304	,	_
168-24	25305-25315	indicating	_
168-25	25316-25320	that	_
168-26	25321-25326	these	_
168-27	25327-25341	connectivities	_
168-28	25342-25345	are	_
168-29	25346-25356	non-random	_
168-30	25357-25360	and	_
168-31	25361-25368	reflect	_
168-32	25369-25372	the	_
168-33	25373-25380	altered	_
168-34	25381-25391	functional	_
168-35	25392-25404	architecture	_
168-36	25405-25407	of	_
168-37	25408-25411	the	_
168-38	25412-25420	thalamus	_
168-39	25421-25423	in	_
168-40	25424-25431	cocaine	_
168-41	25432-25441	addiction	_
168-42	25441-25442	.	_

#Text=Together, these results suggest that thalamic connectivities to the functional networks of cognitive control represent a useful circuit maker of cocaine dependence.
169-1	25443-25451	Together	_
169-2	25451-25452	,	_
169-3	25453-25458	these	_
169-4	25459-25466	results	_
169-5	25467-25474	suggest	_
169-6	25475-25479	that	_
169-7	25480-25488	thalamic	_
169-8	25489-25503	connectivities	_
169-9	25504-25506	to	_
169-10	25507-25510	the	_
169-11	25511-25521	functional	_
169-12	25522-25530	networks	_
169-13	25531-25533	of	_
169-14	25534-25543	cognitive	_
169-15	25544-25551	control	_
169-16	25552-25561	represent	_
169-17	25562-25563	a	_
169-18	25564-25570	useful	_
169-19	25571-25578	circuit	_
169-20	25579-25584	maker	_
169-21	25585-25587	of	_
169-22	25588-25595	cocaine	_
169-23	25596-25606	dependence	_
169-24	25606-25607	.	_

#Text=A recent study employed a linear classifier to distinguish cocaine-dependent from non-drug-abusing men on the basis of independent component networks of a SST.
170-1	25608-25609	A	_
170-2	25610-25616	recent	_
170-3	25617-25622	study	_
170-4	25623-25631	employed	_
170-5	25632-25633	a	_
170-6	25634-25640	linear	_
170-7	25641-25651	classifier	_
170-8	25652-25654	to	_
170-9	25655-25666	distinguish	_
170-10	25667-25684	cocaine-dependent	_
170-11	25685-25689	from	_
170-12	25690-25706	non-drug-abusing	_
170-13	25707-25710	men	_
170-14	25711-25713	on	_
170-15	25714-25717	the	_
170-16	25718-25723	basis	_
170-17	25724-25726	of	_
170-18	25727-25738	independent	_
170-19	25739-25748	component	_
170-20	25749-25757	networks	_
170-21	25758-25760	of	_
170-22	25761-25762	a	_
170-23	25763-25766	SST	_
170-24	25766-25767	.	_

#Text=The authors identified 15 task-related networks attributed to motor, visual, cognitive and affective processes and used the statistical associations of these components with trial types for group classification.
171-1	25768-25771	The	_
171-2	25772-25779	authors	_
171-3	25780-25790	identified	_
171-4	25791-25793	15	_
171-5	25794-25806	task-related	_
171-6	25807-25815	networks	_
171-7	25816-25826	attributed	_
171-8	25827-25829	to	_
171-9	25830-25835	motor	_
171-10	25835-25836	,	_
171-11	25837-25843	visual	_
171-12	25843-25844	,	_
171-13	25845-25854	cognitive	_
171-14	25855-25858	and	_
171-15	25859-25868	affective	_
171-16	25869-25878	processes	_
171-17	25879-25882	and	_
171-18	25883-25887	used	_
171-19	25888-25891	the	_
171-20	25892-25903	statistical	_
171-21	25904-25916	associations	_
171-22	25917-25919	of	_
171-23	25920-25925	these	_
171-24	25926-25936	components	_
171-25	25937-25941	with	_
171-26	25942-25947	trial	_
171-27	25948-25953	types	_
171-28	25954-25957	for	_
171-29	25958-25963	group	_
171-30	25964-25978	classification	_
171-31	25978-25979	.	_

#Text=Along with this earlier work, the current results support a critical role of altered cognitive control in characterizing cocaine addiction and, by describing the neural substrates, extend the literature in new directions.
172-1	25980-25985	Along	_
172-2	25986-25990	with	_
172-3	25991-25995	this	_
172-4	25996-26003	earlier	_
172-5	26004-26008	work	_
172-6	26008-26009	,	_
172-7	26010-26013	the	_
172-8	26014-26021	current	_
172-9	26022-26029	results	_
172-10	26030-26037	support	_
172-11	26038-26039	a	_
172-12	26040-26048	critical	_
172-13	26049-26053	role	_
172-14	26054-26056	of	_
172-15	26057-26064	altered	_
172-16	26065-26074	cognitive	_
172-17	26075-26082	control	_
172-18	26083-26085	in	_
172-19	26086-26100	characterizing	_
172-20	26101-26108	cocaine	_
172-21	26109-26118	addiction	_
172-22	26119-26122	and	_
172-23	26122-26123	,	_
172-24	26124-26126	by	_
172-25	26127-26137	describing	_
172-26	26138-26141	the	_
172-27	26142-26148	neural	_
172-28	26149-26159	substrates	_
172-29	26159-26160	,	_
172-30	26161-26167	extend	_
172-31	26168-26171	the	_
172-32	26172-26182	literature	_
172-33	26183-26185	in	_
172-34	26186-26189	new	_
172-35	26190-26200	directions	_
172-36	26200-26201	.	_

#Text=Altered thalamic connectivity for cognitive control
#Text=With connectivity to the motor cortical, bilateral frontoparietal, and default-mode networks, clusters in the area of the ventrolateral thalamic nuclei (VL) distinguished CD and HC.
173-1	26202-26209	Altered	_
173-2	26210-26218	thalamic	_
173-3	26219-26231	connectivity	_
173-4	26232-26235	for	_
173-5	26236-26245	cognitive	_
173-6	26246-26253	control	_
173-7	26254-26258	With	_
173-8	26259-26271	connectivity	_
173-9	26272-26274	to	_
173-10	26275-26278	the	_
173-11	26279-26284	motor	_
173-12	26285-26293	cortical	_
173-13	26293-26294	,	_
173-14	26295-26304	bilateral	_
173-15	26305-26319	frontoparietal	_
173-16	26319-26320	,	_
173-17	26321-26324	and	_
173-18	26325-26337	default-mode	_
173-19	26338-26346	networks	_
173-20	26346-26347	,	_
173-21	26348-26356	clusters	_
173-22	26357-26359	in	_
173-23	26360-26363	the	_
173-24	26364-26368	area	_
173-25	26369-26371	of	_
173-26	26372-26375	the	_
173-27	26376-26389	ventrolateral	_
173-28	26390-26398	thalamic	_
173-29	26399-26405	nuclei	_
173-30	26406-26407	(	_
173-31	26407-26409	VL	_
173-32	26409-26410	)	_
173-33	26411-26424	distinguished	_
173-34	26425-26427	CD	_
173-35	26428-26431	and	_
173-36	26432-26434	HC	_
173-37	26434-26435	.	_

#Text=Compared to HC, CD showed decreased VL connectivity to the motor cortical and frontoparietal networks and increased connectivity to the DMN.
174-1	26436-26444	Compared	_
174-2	26445-26447	to	_
174-3	26448-26450	HC	_
174-4	26450-26451	,	_
174-5	26452-26454	CD	_
174-6	26455-26461	showed	_
174-7	26462-26471	decreased	_
174-8	26472-26474	VL	_
174-9	26475-26487	connectivity	_
174-10	26488-26490	to	_
174-11	26491-26494	the	_
174-12	26495-26500	motor	_
174-13	26501-26509	cortical	_
174-14	26510-26513	and	_
174-15	26514-26528	frontoparietal	_
174-16	26529-26537	networks	_
174-17	26538-26541	and	_
174-18	26542-26551	increased	_
174-19	26552-26564	connectivity	_
174-20	26565-26567	to	_
174-21	26568-26571	the	_
174-22	26572-26575	DMN	_
174-23	26575-26576	.	_

#Text=CD and HC were also distinguished by mediodorsal nucleus (MD) connectivity to the left frontoparietal, midline cortico-subcortical, and DMN.
175-1	26577-26579	CD	_
175-2	26580-26583	and	_
175-3	26584-26586	HC	_
175-4	26587-26591	were	_
175-5	26592-26596	also	_
175-6	26597-26610	distinguished	_
175-7	26611-26613	by	_
175-8	26614-26625	mediodorsal	_
175-9	26626-26633	nucleus	_
175-10	26634-26635	(	_
175-11	26635-26637	MD	_
175-12	26637-26638	)	_
175-13	26639-26651	connectivity	_
175-14	26652-26654	to	_
175-15	26655-26658	the	_
175-16	26659-26663	left	_
175-17	26664-26678	frontoparietal	_
175-18	26678-26679	,	_
175-19	26680-26687	midline	_
175-20	26688-26707	cortico-subcortical	_
175-21	26707-26708	,	_
175-22	26709-26712	and	_
175-23	26713-26716	DMN	_
175-24	26716-26717	.	_

#Text=Compared to HC, CD showed increased connectivity to all three functional networks.
176-1	26718-26726	Compared	_
176-2	26727-26729	to	_
176-3	26730-26732	HC	_
176-4	26732-26733	,	_
176-5	26734-26736	CD	_
176-6	26737-26743	showed	_
176-7	26744-26753	increased	_
176-8	26754-26766	connectivity	_
176-9	26767-26769	to	_
176-10	26770-26773	all	_
176-11	26774-26779	three	_
176-12	26780-26790	functional	_
176-13	26791-26799	networks	_
176-14	26799-26800	.	_

#Text=These findings are broadly consistent with cognitive motor dysfunction as a result of cocaine misuse.
177-1	26801-26806	These	_
177-2	26807-26815	findings	_
177-3	26816-26819	are	_
177-4	26820-26827	broadly	_
177-5	26828-26838	consistent	_
177-6	26839-26843	with	_
177-7	26844-26853	cognitive	_
177-8	26854-26859	motor	_
177-9	26860-26871	dysfunction	_
177-10	26872-26874	as	_
177-11	26875-26876	a	_
177-12	26877-26883	result	_
177-13	26884-26886	of	_
177-14	26887-26894	cocaine	_
177-15	26895-26901	misuse	_
177-16	26901-26902	.	_

#Text=The frontoparietal networks play a ubiquitous role in human cognitive functioning.
178-1	26903-26906	The	_
178-2	26907-26921	frontoparietal	_
178-3	26922-26930	networks	_
178-4	26931-26935	play	_
178-5	26936-26937	a	_
178-6	26938-26948	ubiquitous	_
178-7	26949-26953	role	_
178-8	26954-26956	in	_
178-9	26957-26962	human	_
178-10	26963-26972	cognitive	_
178-11	26973-26984	functioning	_
178-12	26984-26985	.	_

#Text=Frontoparietal dysfunction has been identified in cocaine addicts in multiple experimental domains.
179-1	26986-27000	Frontoparietal	_
179-2	27001-27012	dysfunction	_
179-3	27013-27016	has	_
179-4	27017-27021	been	_
179-5	27022-27032	identified	_
179-6	27033-27035	in	_
179-7	27036-27043	cocaine	_
179-8	27044-27051	addicts	_
179-9	27052-27054	in	_
179-10	27055-27063	multiple	_
179-11	27064-27076	experimental	_
179-12	27077-27084	domains	_
179-13	27084-27085	.	_

#Text=The current findings showed that connectivity of the anterior and lateral pulvinar (PUL) and the ventroposterior lateral nuclei (VPL) to the right frontoparietal network and connectivity of the MD and left VL to the left frontoparietal network distinguished CD from HC.
180-1	27086-27089	The	_
180-2	27090-27097	current	_
180-3	27098-27106	findings	_
180-4	27107-27113	showed	_
180-5	27114-27118	that	_
180-6	27119-27131	connectivity	_
180-7	27132-27134	of	_
180-8	27135-27138	the	_
180-9	27139-27147	anterior	_
180-10	27148-27151	and	_
180-11	27152-27159	lateral	_
180-12	27160-27168	pulvinar	_
180-13	27169-27170	(	_
180-14	27170-27173	PUL	_
180-15	27173-27174	)	_
180-16	27175-27178	and	_
180-17	27179-27182	the	_
180-18	27183-27198	ventroposterior	_
180-19	27199-27206	lateral	_
180-20	27207-27213	nuclei	_
180-21	27214-27215	(	_
180-22	27215-27218	VPL	_
180-23	27218-27219	)	_
180-24	27220-27222	to	_
180-25	27223-27226	the	_
180-26	27227-27232	right	_
180-27	27233-27247	frontoparietal	_
180-28	27248-27255	network	_
180-29	27256-27259	and	_
180-30	27260-27272	connectivity	_
180-31	27273-27275	of	_
180-32	27276-27279	the	_
180-33	27280-27282	MD	_
180-34	27283-27286	and	_
180-35	27287-27291	left	_
180-36	27292-27294	VL	_
180-37	27295-27297	to	_
180-38	27298-27301	the	_
180-39	27302-27306	left	_
180-40	27307-27321	frontoparietal	_
180-41	27322-27329	network	_
180-42	27330-27343	distinguished	_
180-43	27344-27346	CD	_
180-44	27347-27351	from	_
180-45	27352-27354	HC	_
180-46	27354-27355	.	_

#Text=The right and left frontoparietal networks are each involved in attentional monitoring and response inhibition in the SST.
181-1	27356-27359	The	_
181-2	27360-27365	right	_
181-3	27366-27369	and	_
181-4	27370-27374	left	_
181-5	27375-27389	frontoparietal	_
181-6	27390-27398	networks	_
181-7	27399-27402	are	_
181-8	27403-27407	each	_
181-9	27408-27416	involved	_
181-10	27417-27419	in	_
181-11	27420-27431	attentional	_
181-12	27432-27442	monitoring	_
181-13	27443-27446	and	_
181-14	27447-27455	response	_
181-15	27456-27466	inhibition	_
181-16	27467-27469	in	_
181-17	27470-27473	the	_
181-18	27474-27477	SST	_
181-19	27477-27478	.	_

#Text=Thus, the findings are consistent with the role of the PUL in attentional processing and binding of perceptual information, as shown in imaging and lesion studies.
182-1	27479-27483	Thus	_
182-2	27483-27484	,	_
182-3	27485-27488	the	_
182-4	27489-27497	findings	_
182-5	27498-27501	are	_
182-6	27502-27512	consistent	_
182-7	27513-27517	with	_
182-8	27518-27521	the	_
182-9	27522-27526	role	_
182-10	27527-27529	of	_
182-11	27530-27533	the	_
182-12	27534-27537	PUL	_
182-13	27538-27540	in	_
182-14	27541-27552	attentional	_
182-15	27553-27563	processing	_
182-16	27564-27567	and	_
182-17	27568-27575	binding	_
182-18	27576-27578	of	_
182-19	27579-27589	perceptual	_
182-20	27590-27601	information	_
182-21	27601-27602	,	_
182-22	27603-27605	as	_
182-23	27606-27611	shown	_
182-24	27612-27614	in	_
182-25	27615-27622	imaging	_
182-26	27623-27626	and	_
182-27	27627-27633	lesion	_
182-28	27634-27641	studies	_
182-29	27641-27642	.	_

#Text=On the other hand, the right VL was associated with response inhibition, with activation negatively correlated with the SSRT, an outcome measure of response inhibition in the SST.
183-1	27643-27645	On	_
183-2	27646-27649	the	_
183-3	27650-27655	other	_
183-4	27656-27660	hand	_
183-5	27660-27661	,	_
183-6	27662-27665	the	_
183-7	27666-27671	right	_
183-8	27672-27674	VL	_
183-9	27675-27678	was	_
183-10	27679-27689	associated	_
183-11	27690-27694	with	_
183-12	27695-27703	response	_
183-13	27704-27714	inhibition	_
183-14	27714-27715	,	_
183-15	27716-27720	with	_
183-16	27721-27731	activation	_
183-17	27732-27742	negatively	_
183-18	27743-27753	correlated	_
183-19	27754-27758	with	_
183-20	27759-27762	the	_
183-21	27763-27767	SSRT	_
183-22	27767-27768	,	_
183-23	27769-27771	an	_
183-24	27772-27779	outcome	_
183-25	27780-27787	measure	_
183-26	27788-27790	of	_
183-27	27791-27799	response	_
183-28	27800-27810	inhibition	_
183-29	27811-27813	in	_
183-30	27814-27817	the	_
183-31	27818-27821	SST	_
183-32	27821-27822	.	_

#Text=Previous work implicates altered error processing and error-related learning in CD.
184-1	27823-27831	Previous	_
184-2	27832-27836	work	_
184-3	27837-27847	implicates	_
184-4	27848-27855	altered	_
184-5	27856-27861	error	_
184-6	27862-27872	processing	_
184-7	27873-27876	and	_
184-8	27877-27890	error-related	_
184-9	27891-27899	learning	_
184-10	27900-27902	in	_
184-11	27903-27905	CD	_
184-12	27905-27906	.	_

#Text=Consistently, the current findings showed altered connectivity of the dorsal MD to midline cortical-subcortical network, which is involved in error processing in the SST.
185-1	27907-27919	Consistently	_
185-2	27919-27920	,	_
185-3	27921-27924	the	_
185-4	27925-27932	current	_
185-5	27933-27941	findings	_
185-6	27942-27948	showed	_
185-7	27949-27956	altered	_
185-8	27957-27969	connectivity	_
185-9	27970-27972	of	_
185-10	27973-27976	the	_
185-11	27977-27983	dorsal	_
185-12	27984-27986	MD	_
185-13	27987-27989	to	_
185-14	27990-27997	midline	_
185-15	27998-28018	cortical-subcortical	_
185-16	28019-28026	network	_
185-17	28026-28027	,	_
185-18	28028-28033	which	_
185-19	28034-28036	is	_
185-20	28037-28045	involved	_
185-21	28046-28048	in	_
185-22	28049-28054	error	_
185-23	28055-28065	processing	_
185-24	28066-28068	in	_
185-25	28069-28072	the	_
185-26	28073-28076	SST	_
185-27	28076-28077	.	_

#Text=Further, error-related activations elevated in the MD during early compared to late cocaine abstinence, whereas decreased error-related MD activation later during abstinence predicted relapse and time to relapse.
186-1	28078-28085	Further	_
186-2	28085-28086	,	_
186-3	28087-28100	error-related	_
186-4	28101-28112	activations	_
186-5	28113-28121	elevated	_
186-6	28122-28124	in	_
186-7	28125-28128	the	_
186-8	28129-28131	MD	_
186-9	28132-28138	during	_
186-10	28139-28144	early	_
186-11	28145-28153	compared	_
186-12	28154-28156	to	_
186-13	28157-28161	late	_
186-14	28162-28169	cocaine	_
186-15	28170-28180	abstinence	_
186-16	28180-28181	,	_
186-17	28182-28189	whereas	_
186-18	28190-28199	decreased	_
186-19	28200-28213	error-related	_
186-20	28214-28216	MD	_
186-21	28217-28227	activation	_
186-22	28228-28233	later	_
186-23	28234-28240	during	_
186-24	28241-28251	abstinence	_
186-25	28252-28261	predicted	_
186-26	28262-28269	relapse	_
186-27	28270-28273	and	_
186-28	28274-28278	time	_
186-29	28279-28281	to	_
186-30	28282-28289	relapse	_
186-31	28289-28290	.	_

#Text=Although it remains premature to link changes in regional activation and connectivity, these findings support thalamic cortical mechanisms as an important etiological process of cocaine addiction.
187-1	28291-28299	Although	_
187-2	28300-28302	it	_
187-3	28303-28310	remains	_
187-4	28311-28320	premature	_
187-5	28321-28323	to	_
187-6	28324-28328	link	_
187-7	28329-28336	changes	_
187-8	28337-28339	in	_
187-9	28340-28348	regional	_
187-10	28349-28359	activation	_
187-11	28360-28363	and	_
187-12	28364-28376	connectivity	_
187-13	28376-28377	,	_
187-14	28378-28383	these	_
187-15	28384-28392	findings	_
187-16	28393-28400	support	_
187-17	28401-28409	thalamic	_
187-18	28410-28418	cortical	_
187-19	28419-28429	mechanisms	_
187-20	28430-28432	as	_
187-21	28433-28435	an	_
187-22	28436-28445	important	_
187-23	28446-28457	etiological	_
187-24	28458-28465	process	_
187-25	28466-28468	of	_
187-26	28469-28476	cocaine	_
187-27	28477-28486	addiction	_
187-28	28486-28487	.	_

#Text=A more recent study suggested reduced functional connectivity between the MD and the anterior cingulate cortex (ACC) in CD compared to HC, which seems inconsistent with the current findings.
188-1	28488-28489	A	_
188-2	28490-28494	more	_
188-3	28495-28501	recent	_
188-4	28502-28507	study	_
188-5	28508-28517	suggested	_
188-6	28518-28525	reduced	_
188-7	28526-28536	functional	_
188-8	28537-28549	connectivity	_
188-9	28550-28557	between	_
188-10	28558-28561	the	_
188-11	28562-28564	MD	_
188-12	28565-28568	and	_
188-13	28569-28572	the	_
188-14	28573-28581	anterior	_
188-15	28582-28591	cingulate	_
188-16	28592-28598	cortex	_
188-17	28599-28600	(	_
188-18	28600-28603	ACC	_
188-19	28603-28604	)	_
188-20	28605-28607	in	_
188-21	28608-28610	CD	_
188-22	28611-28619	compared	_
188-23	28620-28622	to	_
188-24	28623-28625	HC	_
188-25	28625-28626	,	_
188-26	28627-28632	which	_
188-27	28633-28638	seems	_
188-28	28639-28651	inconsistent	_
188-29	28652-28656	with	_
188-30	28657-28660	the	_
188-31	28661-28668	current	_
188-32	28669-28677	findings	_
188-33	28677-28678	.	_

#Text=However, the latter study examined resting state functional connectivity while the current work focused on task-related connectivity.
189-1	28679-28686	However	_
189-2	28686-28687	,	_
189-3	28688-28691	the	_
189-4	28692-28698	latter	_
189-5	28699-28704	study	_
189-6	28705-28713	examined	_
189-7	28714-28721	resting	_
189-8	28722-28727	state	_
189-9	28728-28738	functional	_
189-10	28739-28751	connectivity	_
189-11	28752-28757	while	_
189-12	28758-28761	the	_
189-13	28762-28769	current	_
189-14	28770-28774	work	_
189-15	28775-28782	focused	_
189-16	28783-28785	on	_
189-17	28786-28798	task-related	_
189-18	28799-28811	connectivity	_
189-19	28811-28812	.	_

#Text=Importantly, Verdejo-Garcia et al. observed reduced connectivity between the MD and rostral ACC, while the ACC of the midline cortical-subcortical network sits at a dorsal location.
190-1	28813-28824	Importantly	_
190-2	28824-28825	,	_
190-3	28826-28840	Verdejo-Garcia	_
190-4	28841-28843	et	_
190-5	28844-28846	al	_
190-6	28846-28847	.	_
190-7	28848-28856	observed	_
190-8	28857-28864	reduced	_
190-9	28865-28877	connectivity	_
190-10	28878-28885	between	_
190-11	28886-28889	the	_
190-12	28890-28892	MD	_
190-13	28893-28896	and	_
190-14	28897-28904	rostral	_
190-15	28905-28908	ACC	_
190-16	28908-28909	,	_
190-17	28910-28915	while	_
190-18	28916-28919	the	_
190-19	28920-28923	ACC	_
190-20	28924-28926	of	_
190-21	28927-28930	the	_
190-22	28931-28938	midline	_
190-23	28939-28959	cortical-subcortical	_
190-24	28960-28967	network	_
190-25	28968-28972	sits	_
190-26	28973-28975	at	_
190-27	28976-28977	a	_
190-28	28978-28984	dorsal	_
190-29	28985-28993	location	_
190-30	28993-28994	.	_

#Text=Dorsal and rostral ACC play different roles in cognitive control and connect with different brain regions.
191-1	28995-29001	Dorsal	_
191-2	29002-29005	and	_
191-3	29006-29013	rostral	_
191-4	29014-29017	ACC	_
191-5	29018-29022	play	_
191-6	29023-29032	different	_
191-7	29033-29038	roles	_
191-8	29039-29041	in	_
191-9	29042-29051	cognitive	_
191-10	29052-29059	control	_
191-11	29060-29063	and	_
191-12	29064-29071	connect	_
191-13	29072-29076	with	_
191-14	29077-29086	different	_
191-15	29087-29092	brain	_
191-16	29093-29100	regions	_
191-17	29100-29101	.	_

#Text=Both ACC regions respond to errors, but the dorsal ACC may also play an evaluative role by assessing feedbacks for cognitive control.
192-1	29102-29106	Both	_
192-2	29107-29110	ACC	_
192-3	29111-29118	regions	_
192-4	29119-29126	respond	_
192-5	29127-29129	to	_
192-6	29130-29136	errors	_
192-7	29136-29137	,	_
192-8	29138-29141	but	_
192-9	29142-29145	the	_
192-10	29146-29152	dorsal	_
192-11	29153-29156	ACC	_
192-12	29157-29160	may	_
192-13	29161-29165	also	_
192-14	29166-29170	play	_
192-15	29171-29173	an	_
192-16	29174-29184	evaluative	_
192-17	29185-29189	role	_
192-18	29190-29192	by	_
192-19	29193-29202	assessing	_
192-20	29203-29212	feedbacks	_
192-21	29213-29216	for	_
192-22	29217-29226	cognitive	_
192-23	29227-29234	control	_
192-24	29234-29235	.	_

#Text=Our previous studies suggested that activity of the cuneus-precuneus network may reflect behavioral engagement of the participants.
193-1	29236-29239	Our	_
193-2	29240-29248	previous	_
193-3	29249-29256	studies	_
193-4	29257-29266	suggested	_
193-5	29267-29271	that	_
193-6	29272-29280	activity	_
193-7	29281-29283	of	_
193-8	29284-29287	the	_
193-9	29288-29304	cuneus-precuneus	_
193-10	29305-29312	network	_
193-11	29313-29316	may	_
193-12	29317-29324	reflect	_
193-13	29325-29335	behavioral	_
193-14	29336-29346	engagement	_
193-15	29347-29349	of	_
193-16	29350-29353	the	_
193-17	29354-29366	participants	_
193-18	29366-29367	.	_

#Text=Here, the connectivity between the VPL nucleus and cuneus-precuneus network was altered by cocaine use, with less negative connectivity in CD than HC, in accord with previous reports of anatomical connectivity between the precuneus and VPL nucleus.
194-1	29368-29372	Here	_
194-2	29372-29373	,	_
194-3	29374-29377	the	_
194-4	29378-29390	connectivity	_
194-5	29391-29398	between	_
194-6	29399-29402	the	_
194-7	29403-29406	VPL	_
194-8	29407-29414	nucleus	_
194-9	29415-29418	and	_
194-10	29419-29435	cuneus-precuneus	_
194-11	29436-29443	network	_
194-12	29444-29447	was	_
194-13	29448-29455	altered	_
194-14	29456-29458	by	_
194-15	29459-29466	cocaine	_
194-16	29467-29470	use	_
194-17	29470-29471	,	_
194-18	29472-29476	with	_
194-19	29477-29481	less	_
194-20	29482-29490	negative	_
194-21	29491-29503	connectivity	_
194-22	29504-29506	in	_
194-23	29507-29509	CD	_
194-24	29510-29514	than	_
194-25	29515-29517	HC	_
194-26	29517-29518	,	_
194-27	29519-29521	in	_
194-28	29522-29528	accord	_
194-29	29529-29533	with	_
194-30	29534-29542	previous	_
194-31	29543-29550	reports	_
194-32	29551-29553	of	_
194-33	29554-29564	anatomical	_
194-34	29565-29577	connectivity	_
194-35	29578-29585	between	_
194-36	29586-29589	the	_
194-37	29590-29599	precuneus	_
194-38	29600-29603	and	_
194-39	29604-29607	VPL	_
194-40	29608-29615	nucleus	_
194-41	29615-29616	.	_

#Text=The DMN refers to a set of brain regions that decreases activations during cognitive challenges and increases activations during resting, mind wandering, and self-referential processing.
195-1	29617-29620	The	_
195-2	29621-29624	DMN	_
195-3	29625-29631	refers	_
195-4	29632-29634	to	_
195-5	29635-29636	a	_
195-6	29637-29640	set	_
195-7	29641-29643	of	_
195-8	29644-29649	brain	_
195-9	29650-29657	regions	_
195-10	29658-29662	that	_
195-11	29663-29672	decreases	_
195-12	29673-29684	activations	_
195-13	29685-29691	during	_
195-14	29692-29701	cognitive	_
195-15	29702-29712	challenges	_
195-16	29713-29716	and	_
195-17	29717-29726	increases	_
195-18	29727-29738	activations	_
195-19	29739-29745	during	_
195-20	29746-29753	resting	_
195-21	29753-29754	,	_
195-22	29755-29759	mind	_
195-23	29760-29769	wandering	_
195-24	29769-29770	,	_
195-25	29771-29774	and	_
195-26	29775-29791	self-referential	_
195-27	29792-29802	processing	_
195-28	29802-29803	.	_

#Text=An earlier study with high field fMRI demonstrated coactivation of MD and the pregenual ACC, a key brain region of the DMN.
196-1	29804-29806	An	_
196-2	29807-29814	earlier	_
196-3	29815-29820	study	_
196-4	29821-29825	with	_
196-5	29826-29830	high	_
196-6	29831-29836	field	_
196-7	29837-29841	fMRI	_
196-8	29842-29854	demonstrated	_
196-9	29855-29867	coactivation	_
196-10	29868-29870	of	_
196-11	29871-29873	MD	_
196-12	29874-29877	and	_
196-13	29878-29881	the	_
196-14	29882-29891	pregenual	_
196-15	29892-29895	ACC	_
196-16	29895-29896	,	_
196-17	29897-29898	a	_
196-18	29899-29902	key	_
196-19	29903-29908	brain	_
196-20	29909-29915	region	_
196-21	29916-29918	of	_
196-22	29919-29922	the	_
196-23	29923-29926	DMN	_
196-24	29926-29927	.	_

#Text=Our findings suggested that the MD altered its connectivity to the DMN, consistent with recent findings of DMN dysfunction in drug addiction.
197-1	29928-29931	Our	_
197-2	29932-29940	findings	_
197-3	29941-29950	suggested	_
197-4	29951-29955	that	_
197-5	29956-29959	the	_
197-6	29960-29962	MD	_
197-7	29963-29970	altered	_
197-8	29971-29974	its	_
197-9	29975-29987	connectivity	_
197-10	29988-29990	to	_
197-11	29991-29994	the	_
197-12	29995-29998	DMN	_
197-13	29998-29999	,	_
197-14	30000-30010	consistent	_
197-15	30011-30015	with	_
197-16	30016-30022	recent	_
197-17	30023-30031	findings	_
197-18	30032-30034	of	_
197-19	30035-30038	DMN	_
197-20	30039-30050	dysfunction	_
197-21	30051-30053	in	_
197-22	30054-30058	drug	_
197-23	30059-30068	addiction	_
197-24	30068-30069	.	_

#Text=For instance, cocaine dependence was associated with altered error-preceding activity of the DMN, a deficit that correlated with the years of cocaine use and could be remediated with methylphenidate.
198-1	30070-30073	For	_
198-2	30074-30082	instance	_
198-3	30082-30083	,	_
198-4	30084-30091	cocaine	_
198-5	30092-30102	dependence	_
198-6	30103-30106	was	_
198-7	30107-30117	associated	_
198-8	30118-30122	with	_
198-9	30123-30130	altered	_
198-10	30131-30146	error-preceding	_
198-11	30147-30155	activity	_
198-12	30156-30158	of	_
198-13	30159-30162	the	_
198-14	30163-30166	DMN	_
198-15	30166-30167	,	_
198-16	30168-30169	a	_
198-17	30170-30177	deficit	_
198-18	30178-30182	that	_
198-19	30183-30193	correlated	_
198-20	30194-30198	with	_
198-21	30199-30202	the	_
198-22	30203-30208	years	_
198-23	30209-30211	of	_
198-24	30212-30219	cocaine	_
198-25	30220-30223	use	_
198-26	30224-30227	and	_
198-27	30228-30233	could	_
198-28	30234-30236	be	_
198-29	30237-30247	remediated	_
198-30	30248-30252	with	_
198-31	30253-30268	methylphenidate	_
198-32	30268-30269	.	_

#Text=Here, right VL and bilateral MD connectivity to the DMN distinguished CD from HC.
199-1	30270-30274	Here	_
199-2	30274-30275	,	_
199-3	30276-30281	right	_
199-4	30282-30284	VL	_
199-5	30285-30288	and	_
199-6	30289-30298	bilateral	_
199-7	30299-30301	MD	_
199-8	30302-30314	connectivity	_
199-9	30315-30317	to	_
199-10	30318-30321	the	_
199-11	30322-30325	DMN	_
199-12	30326-30339	distinguished	_
199-13	30340-30342	CD	_
199-14	30343-30347	from	_
199-15	30348-30350	HC	_
199-16	30350-30351	.	_

#Text=Broad methodological implications
#Text=The current results speak to the utility of thalamic functional connectivity in relation to cognitive control in distinguishing CD from HC.
200-1	30352-30357	Broad	_
200-2	30358-30372	methodological	_
200-3	30373-30385	implications	_
200-4	30386-30389	The	_
200-5	30390-30397	current	_
200-6	30398-30405	results	_
200-7	30406-30411	speak	_
200-8	30412-30414	to	_
200-9	30415-30418	the	_
200-10	30419-30426	utility	_
200-11	30427-30429	of	_
200-12	30430-30438	thalamic	_
200-13	30439-30449	functional	_
200-14	30450-30462	connectivity	_
200-15	30463-30465	in	_
200-16	30466-30474	relation	_
200-17	30475-30477	to	_
200-18	30478-30487	cognitive	_
200-19	30488-30495	control	_
200-20	30496-30498	in	_
200-21	30499-30513	distinguishing	_
200-22	30514-30516	CD	_
200-23	30517-30521	from	_
200-24	30522-30524	HC	_
200-25	30524-30525	.	_

#Text=As described earlier, the thalamus is heterogeneous in functions and mediates multiple cognitive and affective processes in addition to cognitive control.
201-1	30526-30528	As	_
201-2	30529-30538	described	_
201-3	30539-30546	earlier	_
201-4	30546-30547	,	_
201-5	30548-30551	the	_
201-6	30552-30560	thalamus	_
201-7	30561-30563	is	_
201-8	30564-30577	heterogeneous	_
201-9	30578-30580	in	_
201-10	30581-30590	functions	_
201-11	30591-30594	and	_
201-12	30595-30603	mediates	_
201-13	30604-30612	multiple	_
201-14	30613-30622	cognitive	_
201-15	30623-30626	and	_
201-16	30627-30636	affective	_
201-17	30637-30646	processes	_
201-18	30647-30649	in	_
201-19	30650-30658	addition	_
201-20	30659-30661	to	_
201-21	30662-30671	cognitive	_
201-22	30672-30679	control	_
201-23	30679-30680	.	_

#Text=Thus, studies using other task-related or even resting state imaging data will provide additional information needed to characterize thalamic processes compromised in cocaine addiction and to fully determine group membership in an analogous data analytic scheme.
202-1	30681-30685	Thus	_
202-2	30685-30686	,	_
202-3	30687-30694	studies	_
202-4	30695-30700	using	_
202-5	30701-30706	other	_
202-6	30707-30719	task-related	_
202-7	30720-30722	or	_
202-8	30723-30727	even	_
202-9	30728-30735	resting	_
202-10	30736-30741	state	_
202-11	30742-30749	imaging	_
202-12	30750-30754	data	_
202-13	30755-30759	will	_
202-14	30760-30767	provide	_
202-15	30768-30778	additional	_
202-16	30779-30790	information	_
202-17	30791-30797	needed	_
202-18	30798-30800	to	_
202-19	30801-30813	characterize	_
202-20	30814-30822	thalamic	_
202-21	30823-30832	processes	_
202-22	30833-30844	compromised	_
202-23	30845-30847	in	_
202-24	30848-30855	cocaine	_
202-25	30856-30865	addiction	_
202-26	30866-30869	and	_
202-27	30870-30872	to	_
202-28	30873-30878	fully	_
202-29	30879-30888	determine	_
202-30	30889-30894	group	_
202-31	30895-30905	membership	_
202-32	30906-30908	in	_
202-33	30909-30911	an	_
202-34	30912-30921	analogous	_
202-35	30922-30926	data	_
202-36	30927-30935	analytic	_
202-37	30936-30942	scheme	_
202-38	30942-30943	.	_

#Text=In these future studies, one would be able to investigate whether the thalamic subnuclei as identified across different behavioral tasks or states would conform to similar anatomical boundaries and yet partake in various cognitive and affective processes by interacting with different functional neural networks.
203-1	30944-30946	In	_
203-2	30947-30952	these	_
203-3	30953-30959	future	_
203-4	30960-30967	studies	_
203-5	30967-30968	,	_
203-6	30969-30972	one	_
203-7	30973-30978	would	_
203-8	30979-30981	be	_
203-9	30982-30986	able	_
203-10	30987-30989	to	_
203-11	30990-31001	investigate	_
203-12	31002-31009	whether	_
203-13	31010-31013	the	_
203-14	31014-31022	thalamic	_
203-15	31023-31032	subnuclei	_
203-16	31033-31035	as	_
203-17	31036-31046	identified	_
203-18	31047-31053	across	_
203-19	31054-31063	different	_
203-20	31064-31074	behavioral	_
203-21	31075-31080	tasks	_
203-22	31081-31083	or	_
203-23	31084-31090	states	_
203-24	31091-31096	would	_
203-25	31097-31104	conform	_
203-26	31105-31107	to	_
203-27	31108-31115	similar	_
203-28	31116-31126	anatomical	_
203-29	31127-31137	boundaries	_
203-30	31138-31141	and	_
203-31	31142-31145	yet	_
203-32	31146-31153	partake	_
203-33	31154-31156	in	_
203-34	31157-31164	various	_
203-35	31165-31174	cognitive	_
203-36	31175-31178	and	_
203-37	31179-31188	affective	_
203-38	31189-31198	processes	_
203-39	31199-31201	by	_
203-40	31202-31213	interacting	_
203-41	31214-31218	with	_
203-42	31219-31228	different	_
203-43	31229-31239	functional	_
203-44	31240-31246	neural	_
203-45	31247-31255	networks	_
203-46	31255-31256	.	_

#Text=Leave-one-out versus k-fold cross validation
#Text=Besides “leave-one-out” as employed in the current study, k-fold (usually 10-fold) cross validation is another commonly used cross validation approach.
204-1	31257-31270	Leave-one-out	_
204-2	31271-31277	versus	_
204-3	31278-31284	k-fold	_
204-4	31285-31290	cross	_
204-5	31291-31301	validation	_
204-6	31302-31309	Besides	_
204-7	31310-31311	“	_
204-8	31311-31324	leave-one-out	_
204-9	31324-31325	”	_
204-10	31326-31328	as	_
204-11	31329-31337	employed	_
204-12	31338-31340	in	_
204-13	31341-31344	the	_
204-14	31345-31352	current	_
204-15	31353-31358	study	_
204-16	31358-31359	,	_
204-17	31360-31366	k-fold	_
204-18	31367-31368	(	_
204-19	31368-31375	usually	_
204-20	31376-31378	10	_
204-21	31378-31379	-	_
204-22	31379-31383	fold	_
204-23	31383-31384	)	_
204-24	31385-31390	cross	_
204-25	31391-31401	validation	_
204-26	31402-31404	is	_
204-27	31405-31412	another	_
204-28	31413-31421	commonly	_
204-29	31422-31426	used	_
204-30	31427-31432	cross	_
204-31	31433-31443	validation	_
204-32	31444-31452	approach	_
204-33	31452-31453	.	_

#Text=On one hand, because the training sets differ in only one observation, leave-one-out approach involves a higher variance compared with 10-fold cross validation.
205-1	31454-31456	On	_
205-2	31457-31460	one	_
205-3	31461-31465	hand	_
205-4	31465-31466	,	_
205-5	31467-31474	because	_
205-6	31475-31478	the	_
205-7	31479-31487	training	_
205-8	31488-31492	sets	_
205-9	31493-31499	differ	_
205-10	31500-31502	in	_
205-11	31503-31507	only	_
205-12	31508-31511	one	_
205-13	31512-31523	observation	_
205-14	31523-31524	,	_
205-15	31525-31538	leave-one-out	_
205-16	31539-31547	approach	_
205-17	31548-31556	involves	_
205-18	31557-31558	a	_
205-19	31559-31565	higher	_
205-20	31566-31574	variance	_
205-21	31575-31583	compared	_
205-22	31584-31588	with	_
205-23	31589-31591	10	_
205-24	31591-31592	-	_
205-25	31592-31596	fold	_
205-26	31597-31602	cross	_
205-27	31603-31613	validation	_
205-28	31613-31614	.	_

#Text=On the other hand, leave-one-out approach yields close to unbiased estimates of the test error, since each training set contains n − 1 observations, which is almost as many as the number of observations in the full data set.
206-1	31615-31617	On	_
206-2	31618-31621	the	_
206-3	31622-31627	other	_
206-4	31628-31632	hand	_
206-5	31632-31633	,	_
206-6	31634-31647	leave-one-out	_
206-7	31648-31656	approach	_
206-8	31657-31663	yields	_
206-9	31664-31669	close	_
206-10	31670-31672	to	_
206-11	31673-31681	unbiased	_
206-12	31682-31691	estimates	_
206-13	31692-31694	of	_
206-14	31695-31698	the	_
206-15	31699-31703	test	_
206-16	31704-31709	error	_
206-17	31709-31710	,	_
206-18	31711-31716	since	_
206-19	31717-31721	each	_
206-20	31722-31730	training	_
206-21	31731-31734	set	_
206-22	31735-31743	contains	_
206-23	31744-31745	n	_
206-24	31746-31747	−	_
206-25	31748-31749	1	_
206-26	31750-31762	observations	_
206-27	31762-31763	,	_
206-28	31764-31769	which	_
206-29	31770-31772	is	_
206-30	31773-31779	almost	_
206-31	31780-31782	as	_
206-32	31783-31787	many	_
206-33	31788-31790	as	_
206-34	31791-31794	the	_
206-35	31795-31801	number	_
206-36	31802-31804	of	_
206-37	31805-31817	observations	_
206-38	31818-31820	in	_
206-39	31821-31824	the	_
206-40	31825-31829	full	_
206-41	31830-31834	data	_
206-42	31835-31838	set	_
206-43	31838-31839	.	_

#Text=One previous study compared these two cross validation approaches using 13 different data sets and observed that they have very similar results.
207-1	31840-31843	One	_
207-2	31844-31852	previous	_
207-3	31853-31858	study	_
207-4	31859-31867	compared	_
207-5	31868-31873	these	_
207-6	31874-31877	two	_
207-7	31878-31883	cross	_
207-8	31884-31894	validation	_
207-9	31895-31905	approaches	_
207-10	31906-31911	using	_
207-11	31912-31914	13	_
207-12	31915-31924	different	_
207-13	31925-31929	data	_
207-14	31930-31934	sets	_
207-15	31935-31938	and	_
207-16	31939-31947	observed	_
207-17	31948-31952	that	_
207-18	31953-31957	they	_
207-19	31958-31962	have	_
207-20	31963-31967	very	_
207-21	31968-31975	similar	_
207-22	31976-31983	results	_
207-23	31983-31984	.	_

#Text=Limitations of the study and conclusions
#Text=A number of limitations need to be considered.
208-1	31985-31996	Limitations	_
208-2	31997-31999	of	_
208-3	32000-32003	the	_
208-4	32004-32009	study	_
208-5	32010-32013	and	_
208-6	32014-32025	conclusions	_
208-7	32026-32027	A	_
208-8	32028-32034	number	_
208-9	32035-32037	of	_
208-10	32038-32049	limitations	_
208-11	32050-32054	need	_
208-12	32055-32057	to	_
208-13	32058-32060	be	_
208-14	32061-32071	considered	_
208-15	32071-32072	.	_

#Text=First, none of the thalamic connectivities that distinguish CD from HC appeared to correlate with clinical variables or outcome measures of the SST, following correction for multiple comparisons.
209-1	32073-32078	First	_
209-2	32078-32079	,	_
209-3	32080-32084	none	_
209-4	32085-32087	of	_
209-5	32088-32091	the	_
209-6	32092-32100	thalamic	_
209-7	32101-32115	connectivities	_
209-8	32116-32120	that	_
209-9	32121-32132	distinguish	_
209-10	32133-32135	CD	_
209-11	32136-32140	from	_
209-12	32141-32143	HC	_
209-13	32144-32152	appeared	_
209-14	32153-32155	to	_
209-15	32156-32165	correlate	_
209-16	32166-32170	with	_
209-17	32171-32179	clinical	_
209-18	32180-32189	variables	_
209-19	32190-32192	or	_
209-20	32193-32200	outcome	_
209-21	32201-32209	measures	_
209-22	32210-32212	of	_
209-23	32213-32216	the	_
209-24	32217-32220	SST	_
209-25	32220-32221	,	_
209-26	32222-32231	following	_
209-27	32232-32242	correction	_
209-28	32243-32246	for	_
209-29	32247-32255	multiple	_
209-30	32256-32267	comparisons	_
209-31	32267-32268	.	_

#Text=Therefore, the current work supports thalamic cortical dysfunction as a neural marker of cocaine addiction, but the functional significance is unclear.
210-1	32269-32278	Therefore	_
210-2	32278-32279	,	_
210-3	32280-32283	the	_
210-4	32284-32291	current	_
210-5	32292-32296	work	_
210-6	32297-32305	supports	_
210-7	32306-32314	thalamic	_
210-8	32315-32323	cortical	_
210-9	32324-32335	dysfunction	_
210-10	32336-32338	as	_
210-11	32339-32340	a	_
210-12	32341-32347	neural	_
210-13	32348-32354	marker	_
210-14	32355-32357	of	_
210-15	32358-32365	cocaine	_
210-16	32366-32375	addiction	_
210-17	32375-32376	,	_
210-18	32377-32380	but	_
210-19	32381-32384	the	_
210-20	32385-32395	functional	_
210-21	32396-32408	significance	_
210-22	32409-32411	is	_
210-23	32412-32419	unclear	_
210-24	32419-32420	.	_

#Text=On the other hand, it is not uncommon that neural phenotypes do not readily associate with clinical characteristics in psychiatric conditions.
211-1	32421-32423	On	_
211-2	32424-32427	the	_
211-3	32428-32433	other	_
211-4	32434-32438	hand	_
211-5	32438-32439	,	_
211-6	32440-32442	it	_
211-7	32443-32445	is	_
211-8	32446-32449	not	_
211-9	32450-32458	uncommon	_
211-10	32459-32463	that	_
211-11	32464-32470	neural	_
211-12	32471-32481	phenotypes	_
211-13	32482-32484	do	_
211-14	32485-32488	not	_
211-15	32489-32496	readily	_
211-16	32497-32506	associate	_
211-17	32507-32511	with	_
211-18	32512-32520	clinical	_
211-19	32521-32536	characteristics	_
211-20	32537-32539	in	_
211-21	32540-32551	psychiatric	_
211-22	32552-32562	conditions	_
211-23	32562-32563	.	_

#Text=This discrepancy may suggest the importance in going beyond clinical evaluations in understanding the etiology of mental illness.
212-1	32564-32568	This	_
212-2	32569-32580	discrepancy	_
212-3	32581-32584	may	_
212-4	32585-32592	suggest	_
212-5	32593-32596	the	_
212-6	32597-32607	importance	_
212-7	32608-32610	in	_
212-8	32611-32616	going	_
212-9	32617-32623	beyond	_
212-10	32624-32632	clinical	_
212-11	32633-32644	evaluations	_
212-12	32645-32647	in	_
212-13	32648-32661	understanding	_
212-14	32662-32665	the	_
212-15	32666-32674	etiology	_
212-16	32675-32677	of	_
212-17	32678-32684	mental	_
212-18	32685-32692	illness	_
212-19	32692-32693	.	_

#Text=Second, we did not examine gender differences in the patterns of thalamic connectivity because of the moderate and unbalanced sample size.
213-1	32694-32700	Second	_
213-2	32700-32701	,	_
213-3	32702-32704	we	_
213-4	32705-32708	did	_
213-5	32709-32712	not	_
213-6	32713-32720	examine	_
213-7	32721-32727	gender	_
213-8	32728-32739	differences	_
213-9	32740-32742	in	_
213-10	32743-32746	the	_
213-11	32747-32755	patterns	_
213-12	32756-32758	of	_
213-13	32759-32767	thalamic	_
213-14	32768-32780	connectivity	_
213-15	32781-32788	because	_
213-16	32789-32791	of	_
213-17	32792-32795	the	_
213-18	32796-32804	moderate	_
213-19	32805-32808	and	_
213-20	32809-32819	unbalanced	_
213-21	32820-32826	sample	_
213-22	32827-32831	size	_
213-23	32831-32832	.	_

#Text=The enormity of the feature space generated in such analyses can also be extremely challenging.
214-1	32833-32836	The	_
214-2	32837-32845	enormity	_
214-3	32846-32848	of	_
214-4	32849-32852	the	_
214-5	32853-32860	feature	_
214-6	32861-32866	space	_
214-7	32867-32876	generated	_
214-8	32877-32879	in	_
214-9	32880-32884	such	_
214-10	32885-32893	analyses	_
214-11	32894-32897	can	_
214-12	32898-32902	also	_
214-13	32903-32905	be	_
214-14	32906-32915	extremely	_
214-15	32916-32927	challenging	_
214-16	32927-32928	.	_

#Text=Third, ICA was performed before cross validation, which may result in bias in classification.
215-1	32929-32934	Third	_
215-2	32934-32935	,	_
215-3	32936-32939	ICA	_
215-4	32940-32943	was	_
215-5	32944-32953	performed	_
215-6	32954-32960	before	_
215-7	32961-32966	cross	_
215-8	32967-32977	validation	_
215-9	32977-32978	,	_
215-10	32979-32984	which	_
215-11	32985-32988	may	_
215-12	32989-32995	result	_
215-13	32996-32998	in	_
215-14	32999-33003	bias	_
215-15	33004-33006	in	_
215-16	33007-33021	classification	_
215-17	33021-33022	.	_

#Text=On the other hand, the differences in group ICA results between a sample of 200 and 199 (leave-one-out) subjects should be very limited.
216-1	33023-33025	On	_
216-2	33026-33029	the	_
216-3	33030-33035	other	_
216-4	33036-33040	hand	_
216-5	33040-33041	,	_
216-6	33042-33045	the	_
216-7	33046-33057	differences	_
216-8	33058-33060	in	_
216-9	33061-33066	group	_
216-10	33067-33070	ICA	_
216-11	33071-33078	results	_
216-12	33079-33086	between	_
216-13	33087-33088	a	_
216-14	33089-33095	sample	_
216-15	33096-33098	of	_
216-16	33099-33102	200	_
216-17	33103-33106	and	_
216-18	33107-33110	199	_
216-19	33111-33112	(	_
216-20	33112-33125	leave-one-out	_
216-21	33125-33126	)	_
216-22	33127-33135	subjects	_
216-23	33136-33142	should	_
216-24	33143-33145	be	_
216-25	33146-33150	very	_
216-26	33151-33158	limited	_
216-27	33158-33159	.	_

#Text=Fourth, many studies have parcellated the thalamus on the basis of diffusion tensor imaging.
217-1	33160-33166	Fourth	_
217-2	33166-33167	,	_
217-3	33168-33172	many	_
217-4	33173-33180	studies	_
217-5	33181-33185	have	_
217-6	33186-33197	parcellated	_
217-7	33198-33201	the	_
217-8	33202-33210	thalamus	_
217-9	33211-33213	on	_
217-10	33214-33217	the	_
217-11	33218-33223	basis	_
217-12	33224-33226	of	_
217-13	33227-33236	diffusion	_
217-14	33237-33243	tensor	_
217-15	33244-33251	imaging	_
217-16	33251-33252	.	_

#Text=Future work is warranted to compare the findings from these different parcellation schemes.
218-1	33253-33259	Future	_
218-2	33260-33264	work	_
218-3	33265-33267	is	_
218-4	33268-33277	warranted	_
218-5	33278-33280	to	_
218-6	33281-33288	compare	_
218-7	33289-33292	the	_
218-8	33293-33301	findings	_
218-9	33302-33306	from	_
218-10	33307-33312	these	_
218-11	33313-33322	different	_
218-12	33323-33335	parcellation	_
218-13	33336-33343	schemes	_
218-14	33343-33344	.	_

#Text=Fifth, this is a cross-sectional study.
219-1	33345-33350	Fifth	_
219-2	33350-33351	,	_
219-3	33352-33356	this	_
219-4	33357-33359	is	_
219-5	33360-33361	a	_
219-6	33362-33377	cross-sectional	_
219-7	33378-33383	study	_
219-8	33383-33384	.	_

#Text=Whether and how thalamic functional connectivities may predict trajectories of drug use warrants more investigation.
220-1	33385-33392	Whether	_
220-2	33393-33396	and	_
220-3	33397-33400	how	_
220-4	33401-33409	thalamic	_
220-5	33410-33420	functional	_
220-6	33421-33435	connectivities	_
220-7	33436-33439	may	_
220-8	33440-33447	predict	_
220-9	33448-33460	trajectories	_
220-10	33461-33463	of	_
220-11	33464-33468	drug	_
220-12	33469-33472	use	_
220-13	33473-33481	warrants	_
220-14	33482-33486	more	_
220-15	33487-33500	investigation	_
220-16	33500-33501	.	_

#Text=In summary, MVPA demonstrated thalamic functional connectivities as a potential diagnostic circuit marker of cocaine addiction.
221-1	33502-33504	In	_
221-2	33505-33512	summary	_
221-3	33512-33513	,	_
221-4	33514-33518	MVPA	_
221-5	33519-33531	demonstrated	_
221-6	33532-33540	thalamic	_
221-7	33541-33551	functional	_
221-8	33552-33566	connectivities	_
221-9	33567-33569	as	_
221-10	33570-33571	a	_
221-11	33572-33581	potential	_
221-12	33582-33592	diagnostic	_
221-13	33593-33600	circuit	_
221-14	33601-33607	marker	_
221-15	33608-33610	of	_
221-16	33611-33618	cocaine	_
221-17	33619-33628	addiction	_
221-18	33628-33629	.	_

#Text=The intricate patterns of thalamic subregional connectivities that distinguish cocaine-addicted from non-addicted individuals confirm the utility of this computational approach in psychiatric neuroscience research.
222-1	33630-33633	The	_
222-2	33634-33643	intricate	_
222-3	33644-33652	patterns	_
222-4	33653-33655	of	_
222-5	33656-33664	thalamic	_
222-6	33665-33676	subregional	_
222-7	33677-33691	connectivities	_
222-8	33692-33696	that	_
222-9	33697-33708	distinguish	_
222-10	33709-33725	cocaine-addicted	_
222-11	33726-33730	from	_
222-12	33731-33743	non-addicted	_
222-13	33744-33755	individuals	_
222-14	33756-33763	confirm	_
222-15	33764-33767	the	_
222-16	33768-33775	utility	_
222-17	33776-33778	of	_
222-18	33779-33783	this	_
222-19	33784-33797	computational	_
222-20	33798-33806	approach	_
222-21	33807-33809	in	_
222-22	33810-33821	psychiatric	_
222-23	33822-33834	neuroscience	_
222-24	33835-33843	research	_
222-25	33843-33844	.	_

#Text=Disclosures
#Text=All authors report that they have no conflicts of interest over the past five years to report as related to the subject of the report.
223-1	33845-33856	Disclosures	_
223-2	33857-33860	All	_
223-3	33861-33868	authors	_
223-4	33869-33875	report	_
223-5	33876-33880	that	_
223-6	33881-33885	they	_
223-7	33886-33890	have	_
223-8	33891-33893	no	_
223-9	33894-33903	conflicts	_
223-10	33904-33906	of	_
223-11	33907-33915	interest	_
223-12	33916-33920	over	_
223-13	33921-33924	the	_
223-14	33925-33929	past	_
223-15	33930-33934	five	_
223-16	33935-33940	years	_
223-17	33941-33943	to	_
223-18	33944-33950	report	_
223-19	33951-33953	as	_
223-20	33954-33961	related	_
223-21	33962-33964	to	_
223-22	33965-33968	the	_
223-23	33969-33976	subject	_
223-24	33977-33979	of	_
223-25	33980-33983	the	_
223-26	33984-33990	report	_
223-27	33990-33991	.	_

#Text=Dr.
224-1	33992-33994	Dr	_
224-2	33994-33995	.	_

#Text=Potenza has consulted for Ironwood, Lundbeck, Boehringer Ingelheim, Shire, INSYS, Lightlake Therapeutics and RiverMend Health; has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, the National Center for Responsible Gaming, Pfizer, and Psyadon Pharmaceuticals; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; has consulted for gambling, legal and educational entities on issues related to impulse control and addictive disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has edited journals and journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.
225-1	33996-34003	Potenza	_
225-2	34004-34007	has	_
225-3	34008-34017	consulted	_
225-4	34018-34021	for	_
225-5	34022-34030	Ironwood	_
225-6	34030-34031	,	_
225-7	34032-34040	Lundbeck	_
225-8	34040-34041	,	_
225-9	34042-34052	Boehringer	_
225-10	34053-34062	Ingelheim	_
225-11	34062-34063	,	_
225-12	34064-34069	Shire	_
225-13	34069-34070	,	_
225-14	34071-34076	INSYS	_
225-15	34076-34077	,	_
225-16	34078-34087	Lightlake	_
225-17	34088-34100	Therapeutics	_
225-18	34101-34104	and	_
225-19	34105-34114	RiverMend	_
225-20	34115-34121	Health	_
225-21	34121-34122	;	_
225-22	34123-34126	has	_
225-23	34127-34135	received	_
225-24	34136-34144	research	_
225-25	34145-34152	support	_
225-26	34153-34157	from	_
225-27	34158-34161	the	_
225-28	34162-34170	National	_
225-29	34171-34181	Institutes	_
225-30	34182-34184	of	_
225-31	34185-34191	Health	_
225-32	34191-34192	,	_
225-33	34193-34202	Veteran's	_
225-34	34203-34217	Administration	_
225-35	34217-34218	,	_
225-36	34219-34226	Mohegan	_
225-37	34227-34230	Sun	_
225-38	34231-34237	Casino	_
225-39	34237-34238	,	_
225-40	34239-34242	the	_
225-41	34243-34251	National	_
225-42	34252-34258	Center	_
225-43	34259-34262	for	_
225-44	34263-34274	Responsible	_
225-45	34275-34281	Gaming	_
225-46	34281-34282	,	_
225-47	34283-34289	Pfizer	_
225-48	34289-34290	,	_
225-49	34291-34294	and	_
225-50	34295-34302	Psyadon	_
225-51	34303-34318	Pharmaceuticals	_
225-52	34318-34319	;	_
225-53	34320-34323	has	_
225-54	34324-34336	participated	_
225-55	34337-34339	in	_
225-56	34340-34347	surveys	_
225-57	34347-34348	,	_
225-58	34349-34357	mailings	_
225-59	34358-34360	or	_
225-60	34361-34370	telephone	_
225-61	34371-34384	consultations	_
225-62	34385-34392	related	_
225-63	34393-34395	to	_
225-64	34396-34400	drug	_
225-65	34401-34410	addiction	_
225-66	34410-34411	,	_
225-67	34412-34419	impulse	_
225-68	34420-34427	control	_
225-69	34428-34437	disorders	_
225-70	34438-34440	or	_
225-71	34441-34446	other	_
225-72	34447-34453	health	_
225-73	34454-34460	topics	_
225-74	34460-34461	;	_
225-75	34462-34465	has	_
225-76	34466-34475	consulted	_
225-77	34476-34479	for	_
225-78	34480-34488	gambling	_
225-79	34488-34489	,	_
225-80	34490-34495	legal	_
225-81	34496-34499	and	_
225-82	34500-34511	educational	_
225-83	34512-34520	entities	_
225-84	34521-34523	on	_
225-85	34524-34530	issues	_
225-86	34531-34538	related	_
225-87	34539-34541	to	_
225-88	34542-34549	impulse	_
225-89	34550-34557	control	_
225-90	34558-34561	and	_
225-91	34562-34571	addictive	_
225-92	34572-34581	disorders	_
225-93	34581-34582	;	_
225-94	34583-34591	provides	_
225-95	34592-34600	clinical	_
225-96	34601-34605	care	_
225-97	34606-34608	in	_
225-98	34609-34612	the	_
225-99	34613-34624	Connecticut	_
225-100	34625-34635	Department	_
225-101	34636-34638	of	_
225-102	34639-34645	Mental	_
225-103	34646-34652	Health	_
225-104	34653-34656	and	_
225-105	34657-34666	Addiction	_
225-106	34667-34675	Services	_
225-107	34676-34683	Problem	_
225-108	34684-34692	Gambling	_
225-109	34693-34701	Services	_
225-110	34702-34709	Program	_
225-111	34709-34710	;	_
225-112	34711-34714	has	_
225-113	34715-34724	performed	_
225-114	34725-34730	grant	_
225-115	34731-34738	reviews	_
225-116	34739-34742	for	_
225-117	34743-34746	the	_
225-118	34747-34755	National	_
225-119	34756-34766	Institutes	_
225-120	34767-34769	of	_
225-121	34770-34776	Health	_
225-122	34777-34780	and	_
225-123	34781-34786	other	_
225-124	34787-34795	agencies	_
225-125	34795-34796	;	_
225-126	34797-34800	has	_
225-127	34801-34807	edited	_
225-128	34808-34816	journals	_
225-129	34817-34820	and	_
225-130	34821-34828	journal	_
225-131	34829-34837	sections	_
225-132	34837-34838	;	_
225-133	34839-34842	has	_
225-134	34843-34848	given	_
225-135	34849-34857	academic	_
225-136	34858-34866	lectures	_
225-137	34867-34869	in	_
225-138	34870-34875	grand	_
225-139	34876-34882	rounds	_
225-140	34882-34883	,	_
225-141	34884-34887	CME	_
225-142	34888-34894	events	_
225-143	34895-34898	and	_
225-144	34899-34904	other	_
225-145	34905-34913	clinical	_
225-146	34914-34916	or	_
225-147	34917-34927	scientific	_
225-148	34928-34934	venues	_
225-149	34934-34935	;	_
225-150	34936-34939	and	_
225-151	34940-34943	has	_
225-152	34944-34953	generated	_
225-153	34954-34959	books	_
225-154	34960-34962	or	_
225-155	34963-34967	book	_
225-156	34968-34976	chapters	_
225-157	34977-34980	for	_
225-158	34981-34991	publishers	_
225-159	34992-34994	of	_
225-160	34995-35001	mental	_
225-161	35002-35008	health	_
225-162	35009-35014	texts	_
225-163	35014-35015	.	_

#Text=References
#Text=Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers
#Text=The role of the human pulvinar in visual attention and action: evidence from temporal-order judgment, saccade decision, and antisaccade tasks
#Text=Spatial and temporal deficits are regionally dissociable in patients with pulvinar lesions
#Text=Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use
#Text=Nonlinear spatial normalization using basis functions
#Text=Lower activation in the right frontoparietal network during a counting Stroop task in a cocaine-dependent group
#Text=An inventory for measuring depression
#Text=Investigations into resting-state connectivity using independent component analysis
#Text=Deficits in default mode network activity preceding error in cocaine dependent individuals
#Text=Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging
#Text=An information maximisation approach to blind separation and blind deconvolution
#Text=The time-course of preparation with regular and irregular foreperiods
#Text=Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: a multicenter study
#Text=Toward discovery science of human brain function
#Text=Decoding the perception of pain from fMRI using multivariate pattern analysis
#Text=The brain's default network: anatomy, function, and relevance to disease
#Text=Dorsal anterior cingulate cortex: a role in reward-based decision making
#Text=A method for making group inferences from functional MRI data using independent component analysis
#Text=A review of group ICA for fMRI data and ICA for joint inference of imaging, genetic, and ERP data
#Text=The precuneus: a review of its functional anatomy and behavioural correlates
#Text=Efficient leave-one-out cross-validation of kernel fisher discriminant classifiers
#Text=Altered functional connectivity of the insular cortex across prefrontal networks in cocaine addiction
#Text=Global connectivity of prefrontal cortex predicts cognitive control and intelligence
#Text=Engagement of large-scale networks is related to individual differences in inhibitory control
#Text=Frontoparietal cortical networks for directing attention and the eye to visual locations: identical, independent, or overlapping neural systems?
226-1	35016-35026	References	_
226-2	35027-35036	Diffusion	_
226-3	35037-35043	tensor	_
226-4	35044-35051	imaging	_
226-5	35052-35060	reliably	_
226-6	35061-35075	differentiates	_
226-7	35076-35084	patients	_
226-8	35085-35089	with	_
226-9	35090-35103	schizophrenia	_
226-10	35104-35108	from	_
226-11	35109-35116	healthy	_
226-12	35117-35127	volunteers	_
226-13	35128-35131	The	_
226-14	35132-35136	role	_
226-15	35137-35139	of	_
226-16	35140-35143	the	_
226-17	35144-35149	human	_
226-18	35150-35158	pulvinar	_
226-19	35159-35161	in	_
226-20	35162-35168	visual	_
226-21	35169-35178	attention	_
226-22	35179-35182	and	_
226-23	35183-35189	action	_
226-24	35189-35190	:	_
226-25	35191-35199	evidence	_
226-26	35200-35204	from	_
226-27	35205-35219	temporal-order	_
226-28	35220-35228	judgment	_
226-29	35228-35229	,	_
226-30	35230-35237	saccade	_
226-31	35238-35246	decision	_
226-32	35246-35247	,	_
226-33	35248-35251	and	_
226-34	35252-35263	antisaccade	_
226-35	35264-35269	tasks	_
226-36	35270-35277	Spatial	_
226-37	35278-35281	and	_
226-38	35282-35290	temporal	_
226-39	35291-35299	deficits	_
226-40	35300-35303	are	_
226-41	35304-35314	regionally	_
226-42	35315-35326	dissociable	_
226-43	35327-35329	in	_
226-44	35330-35338	patients	_
226-45	35339-35343	with	_
226-46	35344-35352	pulvinar	_
226-47	35353-35360	lesions	_
226-48	35361-35369	Location	_
226-49	35369-35370	,	_
226-50	35371-35379	location	_
226-51	35379-35380	:	_
226-52	35381-35386	using	_
226-53	35387-35397	functional	_
226-54	35398-35406	magnetic	_
226-55	35407-35416	resonance	_
226-56	35417-35424	imaging	_
226-57	35425-35427	to	_
226-58	35428-35436	pinpoint	_
226-59	35437-35442	brain	_
226-60	35443-35454	differences	_
226-61	35455-35463	relevant	_
226-62	35464-35466	to	_
226-63	35467-35476	stimulant	_
226-64	35477-35480	use	_
226-65	35481-35490	Nonlinear	_
226-66	35491-35498	spatial	_
226-67	35499-35512	normalization	_
226-68	35513-35518	using	_
226-69	35519-35524	basis	_
226-70	35525-35534	functions	_
226-71	35535-35540	Lower	_
226-72	35541-35551	activation	_
226-73	35552-35554	in	_
226-74	35555-35558	the	_
226-75	35559-35564	right	_
226-76	35565-35579	frontoparietal	_
226-77	35580-35587	network	_
226-78	35588-35594	during	_
226-79	35595-35596	a	_
226-80	35597-35605	counting	_
226-81	35606-35612	Stroop	_
226-82	35613-35617	task	_
226-83	35618-35620	in	_
226-84	35621-35622	a	_
226-85	35623-35640	cocaine-dependent	_
226-86	35641-35646	group	_
226-87	35647-35649	An	_
226-88	35650-35659	inventory	_
226-89	35660-35663	for	_
226-90	35664-35673	measuring	_
226-91	35674-35684	depression	_
226-92	35685-35699	Investigations	_
226-93	35700-35704	into	_
226-94	35705-35718	resting-state	_
226-95	35719-35731	connectivity	_
226-96	35732-35737	using	_
226-97	35738-35749	independent	_
226-98	35750-35759	component	_
226-99	35760-35768	analysis	_
226-100	35769-35777	Deficits	_
226-101	35778-35780	in	_
226-102	35781-35788	default	_
226-103	35789-35793	mode	_
226-104	35794-35801	network	_
226-105	35802-35810	activity	_
226-106	35811-35820	preceding	_
226-107	35821-35826	error	_
226-108	35827-35829	in	_
226-109	35830-35837	cocaine	_
226-110	35838-35847	dependent	_
226-111	35848-35859	individuals	_
226-112	35860-35872	Non-invasive	_
226-113	35873-35880	mapping	_
226-114	35881-35883	of	_
226-115	35884-35895	connections	_
226-116	35896-35903	between	_
226-117	35904-35909	human	_
226-118	35910-35918	thalamus	_
226-119	35919-35922	and	_
226-120	35923-35929	cortex	_
226-121	35930-35935	using	_
226-122	35936-35945	diffusion	_
226-123	35946-35953	imaging	_
226-124	35954-35956	An	_
226-125	35957-35968	information	_
226-126	35969-35981	maximisation	_
226-127	35982-35990	approach	_
226-128	35991-35993	to	_
226-129	35994-35999	blind	_
226-130	36000-36010	separation	_
226-131	36011-36014	and	_
226-132	36015-36020	blind	_
226-133	36021-36034	deconvolution	_
226-134	36035-36038	The	_
226-135	36039-36050	time-course	_
226-136	36051-36053	of	_
226-137	36054-36065	preparation	_
226-138	36066-36070	with	_
226-139	36071-36078	regular	_
226-140	36079-36082	and	_
226-141	36083-36092	irregular	_
226-142	36093-36104	foreperiods	_
226-143	36105-36123	Connectivity-based	_
226-144	36124-36136	parcellation	_
226-145	36137-36139	of	_
226-146	36140-36143	the	_
226-147	36144-36152	thalamus	_
226-148	36153-36155	in	_
226-149	36156-36164	multiple	_
226-150	36165-36174	sclerosis	_
226-151	36175-36178	and	_
226-152	36179-36182	its	_
226-153	36183-36195	implications	_
226-154	36196-36199	for	_
226-155	36200-36209	cognitive	_
226-156	36210-36220	impairment	_
226-157	36220-36221	:	_
226-158	36222-36223	a	_
226-159	36224-36235	multicenter	_
226-160	36236-36241	study	_
226-161	36242-36248	Toward	_
226-162	36249-36258	discovery	_
226-163	36259-36266	science	_
226-164	36267-36269	of	_
226-165	36270-36275	human	_
226-166	36276-36281	brain	_
226-167	36282-36290	function	_
226-168	36291-36299	Decoding	_
226-169	36300-36303	the	_
226-170	36304-36314	perception	_
226-171	36315-36317	of	_
226-172	36318-36322	pain	_
226-173	36323-36327	from	_
226-174	36328-36332	fMRI	_
226-175	36333-36338	using	_
226-176	36339-36351	multivariate	_
226-177	36352-36359	pattern	_
226-178	36360-36368	analysis	_
226-179	36369-36372	The	_
226-180	36373-36380	brain's	_
226-181	36381-36388	default	_
226-182	36389-36396	network	_
226-183	36396-36397	:	_
226-184	36398-36405	anatomy	_
226-185	36405-36406	,	_
226-186	36407-36415	function	_
226-187	36415-36416	,	_
226-188	36417-36420	and	_
226-189	36421-36430	relevance	_
226-190	36431-36433	to	_
226-191	36434-36441	disease	_
226-192	36442-36448	Dorsal	_
226-193	36449-36457	anterior	_
226-194	36458-36467	cingulate	_
226-195	36468-36474	cortex	_
226-196	36474-36475	:	_
226-197	36476-36477	a	_
226-198	36478-36482	role	_
226-199	36483-36485	in	_
226-200	36486-36498	reward-based	_
226-201	36499-36507	decision	_
226-202	36508-36514	making	_
226-203	36515-36516	A	_
226-204	36517-36523	method	_
226-205	36524-36527	for	_
226-206	36528-36534	making	_
226-207	36535-36540	group	_
226-208	36541-36551	inferences	_
226-209	36552-36556	from	_
226-210	36557-36567	functional	_
226-211	36568-36571	MRI	_
226-212	36572-36576	data	_
226-213	36577-36582	using	_
226-214	36583-36594	independent	_
226-215	36595-36604	component	_
226-216	36605-36613	analysis	_
226-217	36614-36615	A	_
226-218	36616-36622	review	_
226-219	36623-36625	of	_
226-220	36626-36631	group	_
226-221	36632-36635	ICA	_
226-222	36636-36639	for	_
226-223	36640-36644	fMRI	_
226-224	36645-36649	data	_
226-225	36650-36653	and	_
226-226	36654-36657	ICA	_
226-227	36658-36661	for	_
226-228	36662-36667	joint	_
226-229	36668-36677	inference	_
226-230	36678-36680	of	_
226-231	36681-36688	imaging	_
226-232	36688-36689	,	_
226-233	36690-36697	genetic	_
226-234	36697-36698	,	_
226-235	36699-36702	and	_
226-236	36703-36706	ERP	_
226-237	36707-36711	data	_
226-238	36712-36715	The	_
226-239	36716-36725	precuneus	_
226-240	36725-36726	:	_
226-241	36727-36728	a	_
226-242	36729-36735	review	_
226-243	36736-36738	of	_
226-244	36739-36742	its	_
226-245	36743-36753	functional	_
226-246	36754-36761	anatomy	_
226-247	36762-36765	and	_
226-248	36766-36777	behavioural	_
226-249	36778-36788	correlates	_
226-250	36789-36798	Efficient	_
226-251	36799-36812	leave-one-out	_
226-252	36813-36829	cross-validation	_
226-253	36830-36832	of	_
226-254	36833-36839	kernel	_
226-255	36840-36846	fisher	_
226-256	36847-36859	discriminant	_
226-257	36860-36871	classifiers	_
226-258	36872-36879	Altered	_
226-259	36880-36890	functional	_
226-260	36891-36903	connectivity	_
226-261	36904-36906	of	_
226-262	36907-36910	the	_
226-263	36911-36918	insular	_
226-264	36919-36925	cortex	_
226-265	36926-36932	across	_
226-266	36933-36943	prefrontal	_
226-267	36944-36952	networks	_
226-268	36953-36955	in	_
226-269	36956-36963	cocaine	_
226-270	36964-36973	addiction	_
226-271	36974-36980	Global	_
226-272	36981-36993	connectivity	_
226-273	36994-36996	of	_
226-274	36997-37007	prefrontal	_
226-275	37008-37014	cortex	_
226-276	37015-37023	predicts	_
226-277	37024-37033	cognitive	_
226-278	37034-37041	control	_
226-279	37042-37045	and	_
226-280	37046-37058	intelligence	_
226-281	37059-37069	Engagement	_
226-282	37070-37072	of	_
226-283	37073-37084	large-scale	_
226-284	37085-37093	networks	_
226-285	37094-37096	is	_
226-286	37097-37104	related	_
226-287	37105-37107	to	_
226-288	37108-37118	individual	_
226-289	37119-37130	differences	_
226-290	37131-37133	in	_
226-291	37134-37144	inhibitory	_
226-292	37145-37152	control	_
226-293	37153-37167	Frontoparietal	_
226-294	37168-37176	cortical	_
226-295	37177-37185	networks	_
226-296	37186-37189	for	_
226-297	37190-37199	directing	_
226-298	37200-37209	attention	_
226-299	37210-37213	and	_
226-300	37214-37217	the	_
226-301	37218-37221	eye	_
226-302	37222-37224	to	_
226-303	37225-37231	visual	_
226-304	37232-37241	locations	_
226-305	37241-37242	:	_
226-306	37243-37252	identical	_
226-307	37252-37253	,	_
226-308	37254-37265	independent	_
226-309	37265-37266	,	_
226-310	37267-37269	or	_
226-311	37270-37281	overlapping	_
226-312	37282-37288	neural	_
226-313	37289-37296	systems	_
226-314	37296-37297	?	_

#Text=Multi-voxel pattern analysis of fMRI data predicts clinical symptom severity
#Text=Disease state prediction from resting state functional connectivity
#Text=Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database
#Text=In search of the point of no return: the control of response processes
#Text=Impulsivity as a determinant and consequence of drug use: a review of underlying processes
#Text=Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease
#Text=Changes of functional and effective connectivity in smoking replenishment on deprived heavy smokers: a resting-state FMRI study
#Text=Cocaine addiction related reproducible brain regions of abnormal default-mode network functional connectivity: A group ICA study with different model orders
#Text=Prediction of individual brain maturity using fMRI
#Text=Thalamus segmentation from diffusion tensor magnetic resonance imaging
#Text=Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition
#Text=Stop-signal reaction-time task performance: role of prefrontal cortex and subthalamic nucleus
#Text=Investigating the predictive value of whole-brain structural MR scans in autism: a pattern classification approach
#Text=Neural network activation during a stop-signal task discriminates cocaine-dependent from non-drug-abusing men
#Text=The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers
#Text=Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline
#Text=Exploring the relationship between depressive and anxiety symptoms and neuronal response to alcohol cues
#Text=Marijuana craving in the brain
#Text=Structured Clinical Interview for DSM-IV (SCID)
#Text=Error-processing deficits in patients with cocaine dependence
#Text=DAT genotype modulates brain and behavioral responses elicited by cigarette cues
#Text=Orientation decoding depends on maps, not columns
#Text=Spatial registration and normalization of images
#Text=Pattern classification of sad facial processing: toward the development of neurobiological markers in depression
#Text=The role of cognitive control in cocaine dependence
#Text=Acute effects of cocaine on the neurobiology of cognitive control
#Text=The effect of practice on a sustained attention task in cocaine abusers
#Text=Anterior cingulate cortex hypoactivations to an emotionally salient task in cocaine addiction
#Text=Permutation tests for classification: towards statistical significance in image-based studies
#Text=Neuroimaging evidence of altered fronto-cortical and striatal function after prolonged cocaine self-administration in the rat
#Text=Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity
#Text=Loss of functional specificity in the dorsal striatum of chronic cocaine users
#Text=The association between frontal-striatal connectivity and sensorimotor control in cocaine users
#Text=Decoding neuronal ensembles in the human hippocampus
#Text=Multivariate pattern analysis of fMRI: the early beginnings
#Text=Distributed and overlapping representations of faces and objects in ventral temporal cortex
#Text=Predicting the orientation of invisible stimuli from activity in human primary visual cortex
#Text=Decoding mental states from brain activity in humans
#Text=Dissociable processes of cognitive control during error and non-error conflicts: a study of the stop signal task
#Text=Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI
#Text=Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity
#Text=Post-error behavior in active cocaine users: poor awareness of errors in the presence of intact performance adjustments
#Text=Validating the independent components of neuroimaging time series via clustering and visualization
#Text=Conflict anticipation in alcohol dependence - A model-based fMRI study of stop signal task
#Text=A cerebellar thalamic cortical circuit for error-related cognitive control
#Text=Impaired Bayesian learning for cognitive control in cocaine dependence
#Text=Frontoparietal network involved in successful retrieval from episodic memory.
227-1	37298-37309	Multi-voxel	_
227-2	37310-37317	pattern	_
227-3	37318-37326	analysis	_
227-4	37327-37329	of	_
227-5	37330-37334	fMRI	_
227-6	37335-37339	data	_
227-7	37340-37348	predicts	_
227-8	37349-37357	clinical	_
227-9	37358-37365	symptom	_
227-10	37366-37374	severity	_
227-11	37375-37382	Disease	_
227-12	37383-37388	state	_
227-13	37389-37399	prediction	_
227-14	37400-37404	from	_
227-15	37405-37412	resting	_
227-16	37413-37418	state	_
227-17	37419-37429	functional	_
227-18	37430-37442	connectivity	_
227-19	37443-37452	Automatic	_
227-20	37453-37467	classification	_
227-21	37468-37470	of	_
227-22	37471-37479	patients	_
227-23	37480-37484	with	_
227-24	37485-37496	Alzheimer's	_
227-25	37497-37504	disease	_
227-26	37505-37509	from	_
227-27	37510-37520	structural	_
227-28	37521-37524	MRI	_
227-29	37524-37525	:	_
227-30	37526-37527	a	_
227-31	37528-37538	comparison	_
227-32	37539-37541	of	_
227-33	37542-37545	ten	_
227-34	37546-37553	methods	_
227-35	37554-37559	using	_
227-36	37560-37563	the	_
227-37	37564-37568	ADNI	_
227-38	37569-37577	database	_
227-39	37578-37580	In	_
227-40	37581-37587	search	_
227-41	37588-37590	of	_
227-42	37591-37594	the	_
227-43	37595-37600	point	_
227-44	37601-37603	of	_
227-45	37604-37606	no	_
227-46	37607-37613	return	_
227-47	37613-37614	:	_
227-48	37615-37618	the	_
227-49	37619-37626	control	_
227-50	37627-37629	of	_
227-51	37630-37638	response	_
227-52	37639-37648	processes	_
227-53	37649-37660	Impulsivity	_
227-54	37661-37663	as	_
227-55	37664-37665	a	_
227-56	37666-37677	determinant	_
227-57	37678-37681	and	_
227-58	37682-37693	consequence	_
227-59	37694-37696	of	_
227-60	37697-37701	drug	_
227-61	37702-37705	use	_
227-62	37705-37706	:	_
227-63	37707-37708	a	_
227-64	37709-37715	review	_
227-65	37716-37718	of	_
227-66	37719-37729	underlying	_
227-67	37730-37739	processes	_
227-68	37740-37749	Automated	_
227-69	37750-37753	MRI	_
227-70	37754-37762	measures	_
227-71	37763-37771	identify	_
227-72	37772-37783	individuals	_
227-73	37784-37788	with	_
227-74	37789-37793	mild	_
227-75	37794-37803	cognitive	_
227-76	37804-37814	impairment	_
227-77	37815-37818	and	_
227-78	37819-37830	Alzheimer's	_
227-79	37831-37838	disease	_
227-80	37839-37846	Changes	_
227-81	37847-37849	of	_
227-82	37850-37860	functional	_
227-83	37861-37864	and	_
227-84	37865-37874	effective	_
227-85	37875-37887	connectivity	_
227-86	37888-37890	in	_
227-87	37891-37898	smoking	_
227-88	37899-37912	replenishment	_
227-89	37913-37915	on	_
227-90	37916-37924	deprived	_
227-91	37925-37930	heavy	_
227-92	37931-37938	smokers	_
227-93	37938-37939	:	_
227-94	37940-37941	a	_
227-95	37942-37955	resting-state	_
227-96	37956-37960	FMRI	_
227-97	37961-37966	study	_
227-98	37967-37974	Cocaine	_
227-99	37975-37984	addiction	_
227-100	37985-37992	related	_
227-101	37993-38005	reproducible	_
227-102	38006-38011	brain	_
227-103	38012-38019	regions	_
227-104	38020-38022	of	_
227-105	38023-38031	abnormal	_
227-106	38032-38044	default-mode	_
227-107	38045-38052	network	_
227-108	38053-38063	functional	_
227-109	38064-38076	connectivity	_
227-110	38076-38077	:	_
227-111	38078-38079	A	_
227-112	38080-38085	group	_
227-113	38086-38089	ICA	_
227-114	38090-38095	study	_
227-115	38096-38100	with	_
227-116	38101-38110	different	_
227-117	38111-38116	model	_
227-118	38117-38123	orders	_
227-119	38124-38134	Prediction	_
227-120	38135-38137	of	_
227-121	38138-38148	individual	_
227-122	38149-38154	brain	_
227-123	38155-38163	maturity	_
227-124	38164-38169	using	_
227-125	38170-38174	fMRI	_
227-126	38175-38183	Thalamus	_
227-127	38184-38196	segmentation	_
227-128	38197-38201	from	_
227-129	38202-38211	diffusion	_
227-130	38212-38218	tensor	_
227-131	38219-38227	magnetic	_
227-132	38228-38237	resonance	_
227-133	38238-38245	imaging	_
227-134	38246-38256	Functional	_
227-135	38257-38269	connectivity	_
227-136	38270-38280	delineates	_
227-137	38281-38289	distinct	_
227-138	38290-38295	roles	_
227-139	38296-38298	of	_
227-140	38299-38302	the	_
227-141	38303-38311	inferior	_
227-142	38312-38319	frontal	_
227-143	38320-38326	cortex	_
227-144	38327-38330	and	_
227-145	38331-38347	presupplementary	_
227-146	38348-38353	motor	_
227-147	38354-38358	area	_
227-148	38359-38361	in	_
227-149	38362-38366	stop	_
227-150	38367-38373	signal	_
227-151	38374-38384	inhibition	_
227-152	38385-38396	Stop-signal	_
227-153	38397-38410	reaction-time	_
227-154	38411-38415	task	_
227-155	38416-38427	performance	_
227-156	38427-38428	:	_
227-157	38429-38433	role	_
227-158	38434-38436	of	_
227-159	38437-38447	prefrontal	_
227-160	38448-38454	cortex	_
227-161	38455-38458	and	_
227-162	38459-38470	subthalamic	_
227-163	38471-38478	nucleus	_
227-164	38479-38492	Investigating	_
227-165	38493-38496	the	_
227-166	38497-38507	predictive	_
227-167	38508-38513	value	_
227-168	38514-38516	of	_
227-169	38517-38528	whole-brain	_
227-170	38529-38539	structural	_
227-171	38540-38542	MR	_
227-172	38543-38548	scans	_
227-173	38549-38551	in	_
227-174	38552-38558	autism	_
227-175	38558-38559	:	_
227-176	38560-38561	a	_
227-177	38562-38569	pattern	_
227-178	38570-38584	classification	_
227-179	38585-38593	approach	_
227-180	38594-38600	Neural	_
227-181	38601-38608	network	_
227-182	38609-38619	activation	_
227-183	38620-38626	during	_
227-184	38627-38628	a	_
227-185	38629-38640	stop-signal	_
227-186	38641-38645	task	_
227-187	38646-38659	discriminates	_
227-188	38660-38677	cocaine-dependent	_
227-189	38678-38682	from	_
227-190	38683-38699	non-drug-abusing	_
227-191	38700-38703	men	_
227-192	38704-38707	The	_
227-193	38708-38718	prevalence	_
227-194	38719-38722	and	_
227-195	38723-38733	correlates	_
227-196	38734-38736	of	_
227-197	38737-38747	depressive	_
227-198	38748-38762	symptomatology	_
227-199	38763-38768	among	_
227-200	38769-38770	a	_
227-201	38771-38780	community	_
227-202	38781-38787	sample	_
227-203	38788-38790	of	_
227-204	38791-38804	crack-cocaine	_
227-205	38805-38812	smokers	_
227-206	38813-38820	Spatial	_
227-207	38821-38829	patterns	_
227-208	38830-38832	of	_
227-209	38833-38838	brain	_
227-210	38839-38846	atrophy	_
227-211	38847-38849	in	_
227-212	38850-38853	MCI	_
227-213	38854-38862	patients	_
227-214	38862-38863	,	_
227-215	38864-38874	identified	_
227-216	38875-38878	via	_
227-217	38879-38895	high-dimensional	_
227-218	38896-38903	pattern	_
227-219	38904-38918	classification	_
227-220	38918-38919	,	_
227-221	38920-38927	predict	_
227-222	38928-38938	subsequent	_
227-223	38939-38948	cognitive	_
227-224	38949-38956	decline	_
227-225	38957-38966	Exploring	_
227-226	38967-38970	the	_
227-227	38971-38983	relationship	_
227-228	38984-38991	between	_
227-229	38992-39002	depressive	_
227-230	39003-39006	and	_
227-231	39007-39014	anxiety	_
227-232	39015-39023	symptoms	_
227-233	39024-39027	and	_
227-234	39028-39036	neuronal	_
227-235	39037-39045	response	_
227-236	39046-39048	to	_
227-237	39049-39056	alcohol	_
227-238	39057-39061	cues	_
227-239	39062-39071	Marijuana	_
227-240	39072-39079	craving	_
227-241	39080-39082	in	_
227-242	39083-39086	the	_
227-243	39087-39092	brain	_
227-244	39093-39103	Structured	_
227-245	39104-39112	Clinical	_
227-246	39113-39122	Interview	_
227-247	39123-39126	for	_
227-248	39127-39133	DSM-IV	_
227-249	39134-39135	(	_
227-250	39135-39139	SCID	_
227-251	39139-39140	)	_
227-252	39141-39157	Error-processing	_
227-253	39158-39166	deficits	_
227-254	39167-39169	in	_
227-255	39170-39178	patients	_
227-256	39179-39183	with	_
227-257	39184-39191	cocaine	_
227-258	39192-39202	dependence	_
227-259	39203-39206	DAT	_
227-260	39207-39215	genotype	_
227-261	39216-39225	modulates	_
227-262	39226-39231	brain	_
227-263	39232-39235	and	_
227-264	39236-39246	behavioral	_
227-265	39247-39256	responses	_
227-266	39257-39265	elicited	_
227-267	39266-39268	by	_
227-268	39269-39278	cigarette	_
227-269	39279-39283	cues	_
227-270	39284-39295	Orientation	_
227-271	39296-39304	decoding	_
227-272	39305-39312	depends	_
227-273	39313-39315	on	_
227-274	39316-39320	maps	_
227-275	39320-39321	,	_
227-276	39322-39325	not	_
227-277	39326-39333	columns	_
227-278	39334-39341	Spatial	_
227-279	39342-39354	registration	_
227-280	39355-39358	and	_
227-281	39359-39372	normalization	_
227-282	39373-39375	of	_
227-283	39376-39382	images	_
227-284	39383-39390	Pattern	_
227-285	39391-39405	classification	_
227-286	39406-39408	of	_
227-287	39409-39412	sad	_
227-288	39413-39419	facial	_
227-289	39420-39430	processing	_
227-290	39430-39431	:	_
227-291	39432-39438	toward	_
227-292	39439-39442	the	_
227-293	39443-39454	development	_
227-294	39455-39457	of	_
227-295	39458-39473	neurobiological	_
227-296	39474-39481	markers	_
227-297	39482-39484	in	_
227-298	39485-39495	depression	_
227-299	39496-39499	The	_
227-300	39500-39504	role	_
227-301	39505-39507	of	_
227-302	39508-39517	cognitive	_
227-303	39518-39525	control	_
227-304	39526-39528	in	_
227-305	39529-39536	cocaine	_
227-306	39537-39547	dependence	_
227-307	39548-39553	Acute	_
227-308	39554-39561	effects	_
227-309	39562-39564	of	_
227-310	39565-39572	cocaine	_
227-311	39573-39575	on	_
227-312	39576-39579	the	_
227-313	39580-39592	neurobiology	_
227-314	39593-39595	of	_
227-315	39596-39605	cognitive	_
227-316	39606-39613	control	_
227-317	39614-39617	The	_
227-318	39618-39624	effect	_
227-319	39625-39627	of	_
227-320	39628-39636	practice	_
227-321	39637-39639	on	_
227-322	39640-39641	a	_
227-323	39642-39651	sustained	_
227-324	39652-39661	attention	_
227-325	39662-39666	task	_
227-326	39667-39669	in	_
227-327	39670-39677	cocaine	_
227-328	39678-39685	abusers	_
227-329	39686-39694	Anterior	_
227-330	39695-39704	cingulate	_
227-331	39705-39711	cortex	_
227-332	39712-39727	hypoactivations	_
227-333	39728-39730	to	_
227-334	39731-39733	an	_
227-335	39734-39745	emotionally	_
227-336	39746-39753	salient	_
227-337	39754-39758	task	_
227-338	39759-39761	in	_
227-339	39762-39769	cocaine	_
227-340	39770-39779	addiction	_
227-341	39780-39791	Permutation	_
227-342	39792-39797	tests	_
227-343	39798-39801	for	_
227-344	39802-39816	classification	_
227-345	39816-39817	:	_
227-346	39818-39825	towards	_
227-347	39826-39837	statistical	_
227-348	39838-39850	significance	_
227-349	39851-39853	in	_
227-350	39854-39865	image-based	_
227-351	39866-39873	studies	_
227-352	39874-39886	Neuroimaging	_
227-353	39887-39895	evidence	_
227-354	39896-39898	of	_
227-355	39899-39906	altered	_
227-356	39907-39922	fronto-cortical	_
227-357	39923-39926	and	_
227-358	39927-39935	striatal	_
227-359	39936-39944	function	_
227-360	39945-39950	after	_
227-361	39951-39960	prolonged	_
227-362	39961-39968	cocaine	_
227-363	39969-39988	self-administration	_
227-364	39989-39991	in	_
227-365	39992-39995	the	_
227-366	39996-39999	rat	_
227-367	40000-40017	Mesocorticolimbic	_
227-368	40018-40026	circuits	_
227-369	40027-40030	are	_
227-370	40031-40039	impaired	_
227-371	40040-40042	in	_
227-372	40043-40050	chronic	_
227-373	40051-40058	cocaine	_
227-374	40059-40064	users	_
227-375	40065-40067	as	_
227-376	40068-40080	demonstrated	_
227-377	40081-40083	by	_
227-378	40084-40097	resting-state	_
227-379	40098-40108	functional	_
227-380	40109-40121	connectivity	_
227-381	40122-40126	Loss	_
227-382	40127-40129	of	_
227-383	40130-40140	functional	_
227-384	40141-40152	specificity	_
227-385	40153-40155	in	_
227-386	40156-40159	the	_
227-387	40160-40166	dorsal	_
227-388	40167-40175	striatum	_
227-389	40176-40178	of	_
227-390	40179-40186	chronic	_
227-391	40187-40194	cocaine	_
227-392	40195-40200	users	_
227-393	40201-40204	The	_
227-394	40205-40216	association	_
227-395	40217-40224	between	_
227-396	40225-40241	frontal-striatal	_
227-397	40242-40254	connectivity	_
227-398	40255-40258	and	_
227-399	40259-40271	sensorimotor	_
227-400	40272-40279	control	_
227-401	40280-40282	in	_
227-402	40283-40290	cocaine	_
227-403	40291-40296	users	_
227-404	40297-40305	Decoding	_
227-405	40306-40314	neuronal	_
227-406	40315-40324	ensembles	_
227-407	40325-40327	in	_
227-408	40328-40331	the	_
227-409	40332-40337	human	_
227-410	40338-40349	hippocampus	_
227-411	40350-40362	Multivariate	_
227-412	40363-40370	pattern	_
227-413	40371-40379	analysis	_
227-414	40380-40382	of	_
227-415	40383-40387	fMRI	_
227-416	40387-40388	:	_
227-417	40389-40392	the	_
227-418	40393-40398	early	_
227-419	40399-40409	beginnings	_
227-420	40410-40421	Distributed	_
227-421	40422-40425	and	_
227-422	40426-40437	overlapping	_
227-423	40438-40453	representations	_
227-424	40454-40456	of	_
227-425	40457-40462	faces	_
227-426	40463-40466	and	_
227-427	40467-40474	objects	_
227-428	40475-40477	in	_
227-429	40478-40485	ventral	_
227-430	40486-40494	temporal	_
227-431	40495-40501	cortex	_
227-432	40502-40512	Predicting	_
227-433	40513-40516	the	_
227-434	40517-40528	orientation	_
227-435	40529-40531	of	_
227-436	40532-40541	invisible	_
227-437	40542-40549	stimuli	_
227-438	40550-40554	from	_
227-439	40555-40563	activity	_
227-440	40564-40566	in	_
227-441	40567-40572	human	_
227-442	40573-40580	primary	_
227-443	40581-40587	visual	_
227-444	40588-40594	cortex	_
227-445	40595-40603	Decoding	_
227-446	40604-40610	mental	_
227-447	40611-40617	states	_
227-448	40618-40622	from	_
227-449	40623-40628	brain	_
227-450	40629-40637	activity	_
227-451	40638-40640	in	_
227-452	40641-40647	humans	_
227-453	40648-40659	Dissociable	_
227-454	40660-40669	processes	_
227-455	40670-40672	of	_
227-456	40673-40682	cognitive	_
227-457	40683-40690	control	_
227-458	40691-40697	during	_
227-459	40698-40703	error	_
227-460	40704-40707	and	_
227-461	40708-40717	non-error	_
227-462	40718-40727	conflicts	_
227-463	40727-40728	:	_
227-464	40729-40730	a	_
227-465	40731-40736	study	_
227-466	40737-40739	of	_
227-467	40740-40743	the	_
227-468	40744-40748	stop	_
227-469	40749-40755	signal	_
227-470	40756-40760	task	_
227-471	40761-40769	Blockade	_
227-472	40770-40772	of	_
227-473	40773-40784	cue-induced	_
227-474	40785-40790	brain	_
227-475	40791-40801	activation	_
227-476	40802-40804	of	_
227-477	40805-40814	abstinent	_
227-478	40815-40825	alcoholics	_
227-479	40826-40828	by	_
227-480	40829-40830	a	_
227-481	40831-40837	single	_
227-482	40838-40852	administration	_
227-483	40853-40855	of	_
227-484	40856-40867	amisulpride	_
227-485	40868-40870	as	_
227-486	40871-40879	measured	_
227-487	40880-40884	with	_
227-488	40885-40889	fMRI	_
227-489	40890-40899	Executive	_
227-490	40900-40911	dysfunction	_
227-491	40912-40914	in	_
227-492	40915-40922	cocaine	_
227-493	40923-40932	addiction	_
227-494	40932-40933	:	_
227-495	40934-40942	evidence	_
227-496	40943-40946	for	_
227-497	40947-40957	discordant	_
227-498	40958-40965	frontal	_
227-499	40965-40966	,	_
227-500	40967-40976	cingulate	_
227-501	40976-40977	,	_
227-502	40978-40981	and	_
227-503	40982-40992	cerebellar	_
227-504	40993-41001	activity	_
227-505	41002-41012	Post-error	_
227-506	41013-41021	behavior	_
227-507	41022-41024	in	_
227-508	41025-41031	active	_
227-509	41032-41039	cocaine	_
227-510	41040-41045	users	_
227-511	41045-41046	:	_
227-512	41047-41051	poor	_
227-513	41052-41061	awareness	_
227-514	41062-41064	of	_
227-515	41065-41071	errors	_
227-516	41072-41074	in	_
227-517	41075-41078	the	_
227-518	41079-41087	presence	_
227-519	41088-41090	of	_
227-520	41091-41097	intact	_
227-521	41098-41109	performance	_
227-522	41110-41121	adjustments	_
227-523	41122-41132	Validating	_
227-524	41133-41136	the	_
227-525	41137-41148	independent	_
227-526	41149-41159	components	_
227-527	41160-41162	of	_
227-528	41163-41175	neuroimaging	_
227-529	41176-41180	time	_
227-530	41181-41187	series	_
227-531	41188-41191	via	_
227-532	41192-41202	clustering	_
227-533	41203-41206	and	_
227-534	41207-41220	visualization	_
227-535	41221-41229	Conflict	_
227-536	41230-41242	anticipation	_
227-537	41243-41245	in	_
227-538	41246-41253	alcohol	_
227-539	41254-41264	dependence	_
227-540	41265-41266	-	_
227-541	41267-41268	A	_
227-542	41269-41280	model-based	_
227-543	41281-41285	fMRI	_
227-544	41286-41291	study	_
227-545	41292-41294	of	_
227-546	41295-41299	stop	_
227-547	41300-41306	signal	_
227-548	41307-41311	task	_
227-549	41312-41313	A	_
227-550	41314-41324	cerebellar	_
227-551	41325-41333	thalamic	_
227-552	41334-41342	cortical	_
227-553	41343-41350	circuit	_
227-554	41351-41354	for	_
227-555	41355-41368	error-related	_
227-556	41369-41378	cognitive	_
227-557	41379-41386	control	_
227-558	41387-41395	Impaired	_
227-559	41396-41404	Bayesian	_
227-560	41405-41413	learning	_
227-561	41414-41417	for	_
227-562	41418-41427	cognitive	_
227-563	41428-41435	control	_
227-564	41436-41438	in	_
227-565	41439-41446	cocaine	_
227-566	41447-41457	dependence	_
227-567	41458-41472	Frontoparietal	_
227-568	41473-41480	network	_
227-569	41481-41489	involved	_
227-570	41490-41492	in	_
227-571	41493-41503	successful	_
227-572	41504-41513	retrieval	_
227-573	41514-41518	from	_
227-574	41519-41527	episodic	_
227-575	41528-41534	memory	_
227-576	41534-41535	.	_

#Text=Spatial and temporal analyses using fMRI and ERP
#Text=
#Text=An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence
#Text=Decoding the visual and subjective contents of the human brain
#Text=Psychosocial stress and the duration of cocaine use in non-treatment seeking individuals with cocaine dependence
#Text=Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging
#Text=Reduced interhemispheric resting state functional connectivity in cocaine addiction
#Text=Automatic classification of MR scans in Alzheimer's disease
#Text=Responses of pulvinar neurons reflect a subject's confidence in visual categorization
#Text=Functional connectivity of the frontoparietal network predicts cognitive modulation of pain
#Text=Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction
#Text=Disentangling spatial perception and spatial memory in the hippocampus: a univariate and multivariate pattern analysis fMRI study
#Text=Transformed up-down methods in psychoacoustics
#Text=Inhibitory control and emotional stress regulation: neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction
#Text=Cocaine administration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI
#Text=Fore-period effect and stop-signal reaction time
#Text=Imaging response inhibition in a stop-signal task: neural correlates independent of signal monitoring and post-response processing
#Text=Estimating the number of independent components for functional magnetic resonance imaging data
#Text=Neural correlates of impulse control during stop signal inhibition in cocaine-dependent men
#Text=Increased error-related thalamic activity during early compared to late cocaine abstinence
#Text=Increased “default mode” activity in adolescents prenatally exposed to cocaine
#Text=Feature-specific attentional priority signals in human cortex
#Text=Identifying neural patterns of functional dyspepsia using multivariate pattern analysis: a resting-state FMRI study
#Text=
#Text=Depression and cocaine dependence
#Text=Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence
#Text=Abnormal brain default-mode network functional connectivity in drug addicts
#Text=Executive dysfunction in chronic cocaine users: an exploratory study
#Text=Mapping the functional connectivity of anterior cingulate cortex
#Text=Methylphenidate remediates error-preceding activation of the default mode brain regions in cocaine-addicted individuals
#Text=24-h smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum
#Text=Evidence for anomalous network connectivity during working memory encoding in schizophrenia: an ICA based analysis
#Text=High field FMRI reveals thalamocortical integration of segregated cognitive and emotional processing in mediodorsal and intralaminar thalamic nuclei
#Text=The human pulvinar and attentional processing of visual distractors
#Text=Reduced anterior corpus callosum white matter integrity is related to increased impulsivity and reduced discriminability in cocaine-dependent subjects: diffusion tensor imaging
#Text=Functional connectivity during language processing in acute cocaine withdrawal: a pilot study
#Text=Beyond mind-reading: multi-voxel pattern analysis of fMRI data
#Text=White Matter Connectivity of the Thalamus Delineates the Functional Architecture of Competing Thalamocortical Systems
#Text=Theoretical, statistical, and practical perspectives on pattern-based classification approaches to the analysis of functional neuroimaging data
#Text=Neural connections of the posteromedial cortex in the macaque
#Text=Review of treatment for cocaine dependence
#Text=Machine learning classifiers and fMRI: a tutorial overview
#Text=Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission
#Text=The effects of cocaine: a shifting target over the course of addiction
#Text=The frontoparietal attention network of the human brain: action, saliency, and a priority map of the environment
#Text=Errors and error correction in choice-response tasks
#Text=A default mode of brain function: a brief history of an evolving idea
#Text=Detecting individual memories through the neural decoding of memory states and past experience
#Text=Regional brain activity correlates of nicotine dependence
#Text=Early abstinence in cocaine dependence: influence of comorbid major depression
#Text=The pulvinar regulates information transmission between cortical areas based on attention demands
#Text=Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients
#Text=Anatomical investigation of projections from thalamus to posterior parietal cortex in the rhesus monkey: a WGA-HRP and fluorescent tracer study
#Text=Connectivity-based parcellation of the thalamus explains specific cognitive and behavioural symptoms in patients with bilateral thalamic infarct
#Text=Discriminative analysis of resting-state functional connectivity patterns of schizophrenia using low dimensional embedding of fMRI
#Text=Impaired attentional selection following lesions to human pulvinar: evidence for homology between human and monkey
#Text=Event-Related Potential Study of Executive Dysfunctions in a Speeded Reaction Task in Cocaine Addiction
#Text=
#Text=The phenomenology of error processing: the dorsal ACC response to stop-signal errors tracks reports of negative affect
#Text=The validity and reliability of a brief measure of cocaine craving
#Text=Resting state functional connectivity in addiction: Lessons learned and a road ahead
#Text=Medial frontal cortex activity and loss-related responses to errors
#Text=The development of a cocaine craving questionnaire
#Text=Thalamo-cortical dysfunction in cocaine abusers: implications in attention and perception
#Text=Widespread disruption in brain activation patterns to a working memory task during cocaine abstinence
#Text=Disrupted functional connectivity with dopaminergic midbrain in cocaine abusers
#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
#Text=Stimulus-response learning in long-term cocaine users: acquired equivalence and probabilistic category learning
#Text=The timing of action-monitoring processes in the anterior cingulate cortex
#Text=Fictitious inhibitory differences: how skewness and slowing distort the estimation of stopping latencies
#Text=Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects
#Text=Evidence for a frontoparietal control system revealed by intrinsic functional connectivity
#Text=Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
#Text=The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression
#Text=Neural substrates of abstinence-induced cigarette cravings in chronic smokers
#Text=Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion
#Text=Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences
#Text=Sequential estimation of quantal response curves: a new method of estimation
#Text=fMRI pattern recognition in obsessive-compulsive disorder
#Text=Diagnosing different binge-eating disorders based on reward-related brain activation patterns
#Text=Functional connectivity in a frontoparietal network involving the dorsal anterior cingulate cortex underlies decisions to accept a hypothesis
#Text=Enhanced cue reactivity and fronto-striatal functional connectivity in cocaine use disorders
#Text=Pulvinar inactivation disrupts selection of movement plans
#Text=The measurement of attention
#Text=Recent developments in multivariate pattern analysis for functional MRI
#Text=Parcellation of the Thalamus Using Diffusion Tensor Images and a Multi-object Geometric Deformable Model
#Text=Striatal connections of the parietal association cortices in rhesus monkeys
#Text=Biological clock: biological clocks may modulate drug addiction
#Text=Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis
#Text=A neural measure of behavioral engagement: task-residual low-frequency blood oxygenation level-dependent activity in the precuneus
#Text=Functional networks for cognitive control in a stop signal task: independent component analysis
#Text=Intrinsic functional relations between human cerebral cortex and thalamus
#Text=Noninvasive functional and structural connectivity mapping of the human thalamocortical system
#Text=Error-related functional connectivity of the thalamus in cocaine dependence
#Text=Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease
#Text=Fisher discriminative analysis of resting-state brain function for attention-deficit/hyperactivity disorder
#Text=A flow chart of the data analytic procedures.
228-1	41536-41543	Spatial	_
228-2	41544-41547	and	_
228-3	41548-41556	temporal	_
228-4	41557-41565	analyses	_
228-5	41566-41571	using	_
228-6	41572-41576	fMRI	_
228-7	41577-41580	and	_
228-8	41581-41584	ERP	_
228-9	41586-41588	An	_
228-10	41589-41596	initial	_
228-11	41597-41602	study	_
228-12	41603-41605	of	_
228-13	41606-41612	neural	_
228-14	41613-41622	responses	_
228-15	41623-41625	to	_
228-16	41626-41634	monetary	_
228-17	41635-41645	incentives	_
228-18	41646-41648	as	_
228-19	41649-41656	related	_
228-20	41657-41659	to	_
228-21	41660-41669	treatment	_
228-22	41670-41677	outcome	_
228-23	41678-41680	in	_
228-24	41681-41688	cocaine	_
228-25	41689-41699	dependence	_
228-26	41700-41708	Decoding	_
228-27	41709-41712	the	_
228-28	41713-41719	visual	_
228-29	41720-41723	and	_
228-30	41724-41734	subjective	_
228-31	41735-41743	contents	_
228-32	41744-41746	of	_
228-33	41747-41750	the	_
228-34	41751-41756	human	_
228-35	41757-41762	brain	_
228-36	41763-41775	Psychosocial	_
228-37	41776-41782	stress	_
228-38	41783-41786	and	_
228-39	41787-41790	the	_
228-40	41791-41799	duration	_
228-41	41800-41802	of	_
228-42	41803-41810	cocaine	_
228-43	41811-41814	use	_
228-44	41815-41817	in	_
228-45	41818-41831	non-treatment	_
228-46	41832-41839	seeking	_
228-47	41840-41851	individuals	_
228-48	41852-41856	with	_
228-49	41857-41864	cocaine	_
228-50	41865-41875	dependence	_
228-51	41876-41885	Cingulate	_
228-52	41886-41898	hypoactivity	_
228-53	41899-41901	in	_
228-54	41902-41909	cocaine	_
228-55	41910-41915	users	_
228-56	41916-41922	during	_
228-57	41923-41924	a	_
228-58	41925-41932	GO-NOGO	_
228-59	41933-41937	task	_
228-60	41938-41940	as	_
228-61	41941-41949	revealed	_
228-62	41950-41952	by	_
228-63	41953-41966	event-related	_
228-64	41967-41977	functional	_
228-65	41978-41986	magnetic	_
228-66	41987-41996	resonance	_
228-67	41997-42004	imaging	_
228-68	42005-42012	Reduced	_
228-69	42013-42029	interhemispheric	_
228-70	42030-42037	resting	_
228-71	42038-42043	state	_
228-72	42044-42054	functional	_
228-73	42055-42067	connectivity	_
228-74	42068-42070	in	_
228-75	42071-42078	cocaine	_
228-76	42079-42088	addiction	_
228-77	42089-42098	Automatic	_
228-78	42099-42113	classification	_
228-79	42114-42116	of	_
228-80	42117-42119	MR	_
228-81	42120-42125	scans	_
228-82	42126-42128	in	_
228-83	42129-42140	Alzheimer's	_
228-84	42141-42148	disease	_
228-85	42149-42158	Responses	_
228-86	42159-42161	of	_
228-87	42162-42170	pulvinar	_
228-88	42171-42178	neurons	_
228-89	42179-42186	reflect	_
228-90	42187-42188	a	_
228-91	42189-42198	subject's	_
228-92	42199-42209	confidence	_
228-93	42210-42212	in	_
228-94	42213-42219	visual	_
228-95	42220-42234	categorization	_
228-96	42235-42245	Functional	_
228-97	42246-42258	connectivity	_
228-98	42259-42261	of	_
228-99	42262-42265	the	_
228-100	42266-42280	frontoparietal	_
228-101	42281-42288	network	_
228-102	42289-42297	predicts	_
228-103	42298-42307	cognitive	_
228-104	42308-42318	modulation	_
228-105	42319-42321	of	_
228-106	42322-42326	pain	_
228-107	42327-42334	Effects	_
228-108	42335-42337	of	_
228-109	42338-42353	methylphenidate	_
228-110	42354-42356	on	_
228-111	42357-42370	resting-state	_
228-112	42371-42381	functional	_
228-113	42382-42394	connectivity	_
228-114	42395-42397	of	_
228-115	42398-42401	the	_
228-116	42402-42419	mesocorticolimbic	_
228-117	42420-42428	dopamine	_
228-118	42429-42437	pathways	_
228-119	42438-42440	in	_
228-120	42441-42448	cocaine	_
228-121	42449-42458	addiction	_
228-122	42459-42472	Disentangling	_
228-123	42473-42480	spatial	_
228-124	42481-42491	perception	_
228-125	42492-42495	and	_
228-126	42496-42503	spatial	_
228-127	42504-42510	memory	_
228-128	42511-42513	in	_
228-129	42514-42517	the	_
228-130	42518-42529	hippocampus	_
228-131	42529-42530	:	_
228-132	42531-42532	a	_
228-133	42533-42543	univariate	_
228-134	42544-42547	and	_
228-135	42548-42560	multivariate	_
228-136	42561-42568	pattern	_
228-137	42569-42577	analysis	_
228-138	42578-42582	fMRI	_
228-139	42583-42588	study	_
228-140	42589-42600	Transformed	_
228-141	42601-42608	up-down	_
228-142	42609-42616	methods	_
228-143	42617-42619	in	_
228-144	42620-42635	psychoacoustics	_
228-145	42636-42646	Inhibitory	_
228-146	42647-42654	control	_
228-147	42655-42658	and	_
228-148	42659-42668	emotional	_
228-149	42669-42675	stress	_
228-150	42676-42686	regulation	_
228-151	42686-42687	:	_
228-152	42688-42700	neuroimaging	_
228-153	42701-42709	evidence	_
228-154	42710-42713	for	_
228-155	42714-42728	frontal-limbic	_
228-156	42729-42740	dysfunction	_
228-157	42741-42743	in	_
228-158	42744-42760	psycho-stimulant	_
228-159	42761-42770	addiction	_
228-160	42771-42778	Cocaine	_
228-161	42779-42793	administration	_
228-162	42794-42803	decreases	_
228-163	42804-42814	functional	_
228-164	42815-42827	connectivity	_
228-165	42828-42830	in	_
228-166	42831-42836	human	_
228-167	42837-42844	primary	_
228-168	42845-42851	visual	_
228-169	42852-42855	and	_
228-170	42856-42861	motor	_
228-171	42862-42868	cortex	_
228-172	42869-42871	as	_
228-173	42872-42880	detected	_
228-174	42881-42883	by	_
228-175	42884-42894	functional	_
228-176	42895-42898	MRI	_
228-177	42899-42910	Fore-period	_
228-178	42911-42917	effect	_
228-179	42918-42921	and	_
228-180	42922-42933	stop-signal	_
228-181	42934-42942	reaction	_
228-182	42943-42947	time	_
228-183	42948-42955	Imaging	_
228-184	42956-42964	response	_
228-185	42965-42975	inhibition	_
228-186	42976-42978	in	_
228-187	42979-42980	a	_
228-188	42981-42992	stop-signal	_
228-189	42993-42997	task	_
228-190	42997-42998	:	_
228-191	42999-43005	neural	_
228-192	43006-43016	correlates	_
228-193	43017-43028	independent	_
228-194	43029-43031	of	_
228-195	43032-43038	signal	_
228-196	43039-43049	monitoring	_
228-197	43050-43053	and	_
228-198	43054-43067	post-response	_
228-199	43068-43078	processing	_
228-200	43079-43089	Estimating	_
228-201	43090-43093	the	_
228-202	43094-43100	number	_
228-203	43101-43103	of	_
228-204	43104-43115	independent	_
228-205	43116-43126	components	_
228-206	43127-43130	for	_
228-207	43131-43141	functional	_
228-208	43142-43150	magnetic	_
228-209	43151-43160	resonance	_
228-210	43161-43168	imaging	_
228-211	43169-43173	data	_
228-212	43174-43180	Neural	_
228-213	43181-43191	correlates	_
228-214	43192-43194	of	_
228-215	43195-43202	impulse	_
228-216	43203-43210	control	_
228-217	43211-43217	during	_
228-218	43218-43222	stop	_
228-219	43223-43229	signal	_
228-220	43230-43240	inhibition	_
228-221	43241-43243	in	_
228-222	43244-43261	cocaine-dependent	_
228-223	43262-43265	men	_
228-224	43266-43275	Increased	_
228-225	43276-43289	error-related	_
228-226	43290-43298	thalamic	_
228-227	43299-43307	activity	_
228-228	43308-43314	during	_
228-229	43315-43320	early	_
228-230	43321-43329	compared	_
228-231	43330-43332	to	_
228-232	43333-43337	late	_
228-233	43338-43345	cocaine	_
228-234	43346-43356	abstinence	_
228-235	43357-43366	Increased	_
228-236	43367-43368	“	_
228-237	43368-43375	default	_
228-238	43376-43380	mode	_
228-239	43380-43381	”	_
228-240	43382-43390	activity	_
228-241	43391-43393	in	_
228-242	43394-43405	adolescents	_
228-243	43406-43416	prenatally	_
228-244	43417-43424	exposed	_
228-245	43425-43427	to	_
228-246	43428-43435	cocaine	_
228-247	43436-43452	Feature-specific	_
228-248	43453-43464	attentional	_
228-249	43465-43473	priority	_
228-250	43474-43481	signals	_
228-251	43482-43484	in	_
228-252	43485-43490	human	_
228-253	43491-43497	cortex	_
228-254	43498-43509	Identifying	_
228-255	43510-43516	neural	_
228-256	43517-43525	patterns	_
228-257	43526-43528	of	_
228-258	43529-43539	functional	_
228-259	43540-43549	dyspepsia	_
228-260	43550-43555	using	_
228-261	43556-43568	multivariate	_
228-262	43569-43576	pattern	_
228-263	43577-43585	analysis	_
228-264	43585-43586	:	_
228-265	43587-43588	a	_
228-266	43589-43602	resting-state	_
228-267	43603-43607	FMRI	_
228-268	43608-43613	study	_
228-269	43615-43625	Depression	_
228-270	43626-43629	and	_
228-271	43630-43637	cocaine	_
228-272	43638-43648	dependence	_
228-273	43649-43654	Error	_
228-274	43655-43665	processing	_
228-275	43666-43669	and	_
228-276	43670-43683	gender-shared	_
228-277	43684-43687	and	_
228-278	43688-43689	-	_
228-279	43689-43697	specific	_
228-280	43698-43704	neural	_
228-281	43705-43715	predictors	_
228-282	43716-43718	of	_
228-283	43719-43726	relapse	_
228-284	43727-43729	in	_
228-285	43730-43737	cocaine	_
228-286	43738-43748	dependence	_
228-287	43749-43757	Abnormal	_
228-288	43758-43763	brain	_
228-289	43764-43776	default-mode	_
228-290	43777-43784	network	_
228-291	43785-43795	functional	_
228-292	43796-43808	connectivity	_
228-293	43809-43811	in	_
228-294	43812-43816	drug	_
228-295	43817-43824	addicts	_
228-296	43825-43834	Executive	_
228-297	43835-43846	dysfunction	_
228-298	43847-43849	in	_
228-299	43850-43857	chronic	_
228-300	43858-43865	cocaine	_
228-301	43866-43871	users	_
228-302	43871-43872	:	_
228-303	43873-43875	an	_
228-304	43876-43887	exploratory	_
228-305	43888-43893	study	_
228-306	43894-43901	Mapping	_
228-307	43902-43905	the	_
228-308	43906-43916	functional	_
228-309	43917-43929	connectivity	_
228-310	43930-43932	of	_
228-311	43933-43941	anterior	_
228-312	43942-43951	cingulate	_
228-313	43952-43958	cortex	_
228-314	43959-43974	Methylphenidate	_
228-315	43975-43985	remediates	_
228-316	43986-44001	error-preceding	_
228-317	44002-44012	activation	_
228-318	44013-44015	of	_
228-319	44016-44019	the	_
228-320	44020-44027	default	_
228-321	44028-44032	mode	_
228-322	44033-44038	brain	_
228-323	44039-44046	regions	_
228-324	44047-44049	in	_
228-325	44050-44066	cocaine-addicted	_
228-326	44067-44078	individuals	_
228-327	44079-44081	24	_
228-328	44081-44082	-	_
228-329	44082-44083	h	_
228-330	44084-44091	smoking	_
228-331	44092-44102	abstinence	_
228-332	44103-44114	potentiates	_
228-333	44115-44124	fMRI-BOLD	_
228-334	44125-44135	activation	_
228-335	44136-44138	to	_
228-336	44139-44146	smoking	_
228-337	44147-44151	cues	_
228-338	44152-44154	in	_
228-339	44155-44163	cerebral	_
228-340	44164-44170	cortex	_
228-341	44171-44174	and	_
228-342	44175-44181	dorsal	_
228-343	44182-44190	striatum	_
228-344	44191-44199	Evidence	_
228-345	44200-44203	for	_
228-346	44204-44213	anomalous	_
228-347	44214-44221	network	_
228-348	44222-44234	connectivity	_
228-349	44235-44241	during	_
228-350	44242-44249	working	_
228-351	44250-44256	memory	_
228-352	44257-44265	encoding	_
228-353	44266-44268	in	_
228-354	44269-44282	schizophrenia	_
228-355	44282-44283	:	_
228-356	44284-44286	an	_
228-357	44287-44290	ICA	_
228-358	44291-44296	based	_
228-359	44297-44305	analysis	_
228-360	44306-44310	High	_
228-361	44311-44316	field	_
228-362	44317-44321	FMRI	_
228-363	44322-44329	reveals	_
228-364	44330-44345	thalamocortical	_
228-365	44346-44357	integration	_
228-366	44358-44360	of	_
228-367	44361-44371	segregated	_
228-368	44372-44381	cognitive	_
228-369	44382-44385	and	_
228-370	44386-44395	emotional	_
228-371	44396-44406	processing	_
228-372	44407-44409	in	_
228-373	44410-44421	mediodorsal	_
228-374	44422-44425	and	_
228-375	44426-44438	intralaminar	_
228-376	44439-44447	thalamic	_
228-377	44448-44454	nuclei	_
228-378	44455-44458	The	_
228-379	44459-44464	human	_
228-380	44465-44473	pulvinar	_
228-381	44474-44477	and	_
228-382	44478-44489	attentional	_
228-383	44490-44500	processing	_
228-384	44501-44503	of	_
228-385	44504-44510	visual	_
228-386	44511-44522	distractors	_
228-387	44523-44530	Reduced	_
228-388	44531-44539	anterior	_
228-389	44540-44546	corpus	_
228-390	44547-44555	callosum	_
228-391	44556-44561	white	_
228-392	44562-44568	matter	_
228-393	44569-44578	integrity	_
228-394	44579-44581	is	_
228-395	44582-44589	related	_
228-396	44590-44592	to	_
228-397	44593-44602	increased	_
228-398	44603-44614	impulsivity	_
228-399	44615-44618	and	_
228-400	44619-44626	reduced	_
228-401	44627-44643	discriminability	_
228-402	44644-44646	in	_
228-403	44647-44664	cocaine-dependent	_
228-404	44665-44673	subjects	_
228-405	44673-44674	:	_
228-406	44675-44684	diffusion	_
228-407	44685-44691	tensor	_
228-408	44692-44699	imaging	_
228-409	44700-44710	Functional	_
228-410	44711-44723	connectivity	_
228-411	44724-44730	during	_
228-412	44731-44739	language	_
228-413	44740-44750	processing	_
228-414	44751-44753	in	_
228-415	44754-44759	acute	_
228-416	44760-44767	cocaine	_
228-417	44768-44778	withdrawal	_
228-418	44778-44779	:	_
228-419	44780-44781	a	_
228-420	44782-44787	pilot	_
228-421	44788-44793	study	_
228-422	44794-44800	Beyond	_
228-423	44801-44813	mind-reading	_
228-424	44813-44814	:	_
228-425	44815-44826	multi-voxel	_
228-426	44827-44834	pattern	_
228-427	44835-44843	analysis	_
228-428	44844-44846	of	_
228-429	44847-44851	fMRI	_
228-430	44852-44856	data	_
228-431	44857-44862	White	_
228-432	44863-44869	Matter	_
228-433	44870-44882	Connectivity	_
228-434	44883-44885	of	_
228-435	44886-44889	the	_
228-436	44890-44898	Thalamus	_
228-437	44899-44909	Delineates	_
228-438	44910-44913	the	_
228-439	44914-44924	Functional	_
228-440	44925-44937	Architecture	_
228-441	44938-44940	of	_
228-442	44941-44950	Competing	_
228-443	44951-44966	Thalamocortical	_
228-444	44967-44974	Systems	_
228-445	44975-44986	Theoretical	_
228-446	44986-44987	,	_
228-447	44988-44999	statistical	_
228-448	44999-45000	,	_
228-449	45001-45004	and	_
228-450	45005-45014	practical	_
228-451	45015-45027	perspectives	_
228-452	45028-45030	on	_
228-453	45031-45044	pattern-based	_
228-454	45045-45059	classification	_
228-455	45060-45070	approaches	_
228-456	45071-45073	to	_
228-457	45074-45077	the	_
228-458	45078-45086	analysis	_
228-459	45087-45089	of	_
228-460	45090-45100	functional	_
228-461	45101-45113	neuroimaging	_
228-462	45114-45118	data	_
228-463	45119-45125	Neural	_
228-464	45126-45137	connections	_
228-465	45138-45140	of	_
228-466	45141-45144	the	_
228-467	45145-45158	posteromedial	_
228-468	45159-45165	cortex	_
228-469	45166-45168	in	_
228-470	45169-45172	the	_
228-471	45173-45180	macaque	_
228-472	45181-45187	Review	_
228-473	45188-45190	of	_
228-474	45191-45200	treatment	_
228-475	45201-45204	for	_
228-476	45205-45212	cocaine	_
228-477	45213-45223	dependence	_
228-478	45224-45231	Machine	_
228-479	45232-45240	learning	_
228-480	45241-45252	classifiers	_
228-481	45253-45256	and	_
228-482	45257-45261	fMRI	_
228-483	45261-45262	:	_
228-484	45263-45264	a	_
228-485	45265-45273	tutorial	_
228-486	45274-45282	overview	_
228-487	45283-45290	Rostral	_
228-488	45291-45294	and	_
228-489	45295-45301	dorsal	_
228-490	45302-45310	anterior	_
228-491	45311-45320	cingulate	_
228-492	45321-45327	cortex	_
228-493	45328-45332	make	_
228-494	45333-45344	dissociable	_
228-495	45345-45358	contributions	_
228-496	45359-45365	during	_
228-497	45366-45377	antisaccade	_
228-498	45378-45383	error	_
228-499	45384-45394	commission	_
228-500	45395-45398	The	_
228-501	45399-45406	effects	_
228-502	45407-45409	of	_
228-503	45410-45417	cocaine	_
228-504	45417-45418	:	_
228-505	45419-45420	a	_
228-506	45421-45429	shifting	_
228-507	45430-45436	target	_
228-508	45437-45441	over	_
228-509	45442-45445	the	_
228-510	45446-45452	course	_
228-511	45453-45455	of	_
228-512	45456-45465	addiction	_
228-513	45466-45469	The	_
228-514	45470-45484	frontoparietal	_
228-515	45485-45494	attention	_
228-516	45495-45502	network	_
228-517	45503-45505	of	_
228-518	45506-45509	the	_
228-519	45510-45515	human	_
228-520	45516-45521	brain	_
228-521	45521-45522	:	_
228-522	45523-45529	action	_
228-523	45529-45530	,	_
228-524	45531-45539	saliency	_
228-525	45539-45540	,	_
228-526	45541-45544	and	_
228-527	45545-45546	a	_
228-528	45547-45555	priority	_
228-529	45556-45559	map	_
228-530	45560-45562	of	_
228-531	45563-45566	the	_
228-532	45567-45578	environment	_
228-533	45579-45585	Errors	_
228-534	45586-45589	and	_
228-535	45590-45595	error	_
228-536	45596-45606	correction	_
228-537	45607-45609	in	_
228-538	45610-45625	choice-response	_
228-539	45626-45631	tasks	_
228-540	45632-45633	A	_
228-541	45634-45641	default	_
228-542	45642-45646	mode	_
228-543	45647-45649	of	_
228-544	45650-45655	brain	_
228-545	45656-45664	function	_
228-546	45664-45665	:	_
228-547	45666-45667	a	_
228-548	45668-45673	brief	_
228-549	45674-45681	history	_
228-550	45682-45684	of	_
228-551	45685-45687	an	_
228-552	45688-45696	evolving	_
228-553	45697-45701	idea	_
228-554	45702-45711	Detecting	_
228-555	45712-45722	individual	_
228-556	45723-45731	memories	_
228-557	45732-45739	through	_
228-558	45740-45743	the	_
228-559	45744-45750	neural	_
228-560	45751-45759	decoding	_
228-561	45760-45762	of	_
228-562	45763-45769	memory	_
228-563	45770-45776	states	_
228-564	45777-45780	and	_
228-565	45781-45785	past	_
228-566	45786-45796	experience	_
228-567	45797-45805	Regional	_
228-568	45806-45811	brain	_
228-569	45812-45820	activity	_
228-570	45821-45831	correlates	_
228-571	45832-45834	of	_
228-572	45835-45843	nicotine	_
228-573	45844-45854	dependence	_
228-574	45855-45860	Early	_
228-575	45861-45871	abstinence	_
228-576	45872-45874	in	_
228-577	45875-45882	cocaine	_
228-578	45883-45893	dependence	_
228-579	45893-45894	:	_
228-580	45895-45904	influence	_
228-581	45905-45907	of	_
228-582	45908-45916	comorbid	_
228-583	45917-45922	major	_
228-584	45923-45933	depression	_
228-585	45934-45937	The	_
228-586	45938-45946	pulvinar	_
228-587	45947-45956	regulates	_
228-588	45957-45968	information	_
228-589	45969-45981	transmission	_
228-590	45982-45989	between	_
228-591	45990-45998	cortical	_
228-592	45999-46004	areas	_
228-593	46005-46010	based	_
228-594	46011-46013	on	_
228-595	46014-46023	attention	_
228-596	46024-46031	demands	_
228-597	46032-46039	Effects	_
228-598	46040-46042	of	_
228-599	46043-46052	modafinil	_
228-600	46053-46055	on	_
228-601	46056-46062	neural	_
228-602	46063-46073	correlates	_
228-603	46074-46076	of	_
228-604	46077-46085	response	_
228-605	46086-46096	inhibition	_
228-606	46097-46099	in	_
228-607	46100-46117	alcohol-dependent	_
228-608	46118-46126	patients	_
228-609	46127-46137	Anatomical	_
228-610	46138-46151	investigation	_
228-611	46152-46154	of	_
228-612	46155-46166	projections	_
228-613	46167-46171	from	_
228-614	46172-46180	thalamus	_
228-615	46181-46183	to	_
228-616	46184-46193	posterior	_
228-617	46194-46202	parietal	_
228-618	46203-46209	cortex	_
228-619	46210-46212	in	_
228-620	46213-46216	the	_
228-621	46217-46223	rhesus	_
228-622	46224-46230	monkey	_
228-623	46230-46231	:	_
228-624	46232-46233	a	_
228-625	46234-46241	WGA-HRP	_
228-626	46242-46245	and	_
228-627	46246-46257	fluorescent	_
228-628	46258-46264	tracer	_
228-629	46265-46270	study	_
228-630	46271-46289	Connectivity-based	_
228-631	46290-46302	parcellation	_
228-632	46303-46305	of	_
228-633	46306-46309	the	_
228-634	46310-46318	thalamus	_
228-635	46319-46327	explains	_
228-636	46328-46336	specific	_
228-637	46337-46346	cognitive	_
228-638	46347-46350	and	_
228-639	46351-46362	behavioural	_
228-640	46363-46371	symptoms	_
228-641	46372-46374	in	_
228-642	46375-46383	patients	_
228-643	46384-46388	with	_
228-644	46389-46398	bilateral	_
228-645	46399-46407	thalamic	_
228-646	46408-46415	infarct	_
228-647	46416-46430	Discriminative	_
228-648	46431-46439	analysis	_
228-649	46440-46442	of	_
228-650	46443-46456	resting-state	_
228-651	46457-46467	functional	_
228-652	46468-46480	connectivity	_
228-653	46481-46489	patterns	_
228-654	46490-46492	of	_
228-655	46493-46506	schizophrenia	_
228-656	46507-46512	using	_
228-657	46513-46516	low	_
228-658	46517-46528	dimensional	_
228-659	46529-46538	embedding	_
228-660	46539-46541	of	_
228-661	46542-46546	fMRI	_
228-662	46547-46555	Impaired	_
228-663	46556-46567	attentional	_
228-664	46568-46577	selection	_
228-665	46578-46587	following	_
228-666	46588-46595	lesions	_
228-667	46596-46598	to	_
228-668	46599-46604	human	_
228-669	46605-46613	pulvinar	_
228-670	46613-46614	:	_
228-671	46615-46623	evidence	_
228-672	46624-46627	for	_
228-673	46628-46636	homology	_
228-674	46637-46644	between	_
228-675	46645-46650	human	_
228-676	46651-46654	and	_
228-677	46655-46661	monkey	_
228-678	46662-46675	Event-Related	_
228-679	46676-46685	Potential	_
228-680	46686-46691	Study	_
228-681	46692-46694	of	_
228-682	46695-46704	Executive	_
228-683	46705-46717	Dysfunctions	_
228-684	46718-46720	in	_
228-685	46721-46722	a	_
228-686	46723-46730	Speeded	_
228-687	46731-46739	Reaction	_
228-688	46740-46744	Task	_
228-689	46745-46747	in	_
228-690	46748-46755	Cocaine	_
228-691	46756-46765	Addiction	_
228-692	46767-46770	The	_
228-693	46771-46784	phenomenology	_
228-694	46785-46787	of	_
228-695	46788-46793	error	_
228-696	46794-46804	processing	_
228-697	46804-46805	:	_
228-698	46806-46809	the	_
228-699	46810-46816	dorsal	_
228-700	46817-46820	ACC	_
228-701	46821-46829	response	_
228-702	46830-46832	to	_
228-703	46833-46844	stop-signal	_
228-704	46845-46851	errors	_
228-705	46852-46858	tracks	_
228-706	46859-46866	reports	_
228-707	46867-46869	of	_
228-708	46870-46878	negative	_
228-709	46879-46885	affect	_
228-710	46886-46889	The	_
228-711	46890-46898	validity	_
228-712	46899-46902	and	_
228-713	46903-46914	reliability	_
228-714	46915-46917	of	_
228-715	46918-46919	a	_
228-716	46920-46925	brief	_
228-717	46926-46933	measure	_
228-718	46934-46936	of	_
228-719	46937-46944	cocaine	_
228-720	46945-46952	craving	_
228-721	46953-46960	Resting	_
228-722	46961-46966	state	_
228-723	46967-46977	functional	_
228-724	46978-46990	connectivity	_
228-725	46991-46993	in	_
228-726	46994-47003	addiction	_
228-727	47003-47004	:	_
228-728	47005-47012	Lessons	_
228-729	47013-47020	learned	_
228-730	47021-47024	and	_
228-731	47025-47026	a	_
228-732	47027-47031	road	_
228-733	47032-47037	ahead	_
228-734	47038-47044	Medial	_
228-735	47045-47052	frontal	_
228-736	47053-47059	cortex	_
228-737	47060-47068	activity	_
228-738	47069-47072	and	_
228-739	47073-47085	loss-related	_
228-740	47086-47095	responses	_
228-741	47096-47098	to	_
228-742	47099-47105	errors	_
228-743	47106-47109	The	_
228-744	47110-47121	development	_
228-745	47122-47124	of	_
228-746	47125-47126	a	_
228-747	47127-47134	cocaine	_
228-748	47135-47142	craving	_
228-749	47143-47156	questionnaire	_
228-750	47157-47173	Thalamo-cortical	_
228-751	47174-47185	dysfunction	_
228-752	47186-47188	in	_
228-753	47189-47196	cocaine	_
228-754	47197-47204	abusers	_
228-755	47204-47205	:	_
228-756	47206-47218	implications	_
228-757	47219-47221	in	_
228-758	47222-47231	attention	_
228-759	47232-47235	and	_
228-760	47236-47246	perception	_
228-761	47247-47257	Widespread	_
228-762	47258-47268	disruption	_
228-763	47269-47271	in	_
228-764	47272-47277	brain	_
228-765	47278-47288	activation	_
228-766	47289-47297	patterns	_
228-767	47298-47300	to	_
228-768	47301-47302	a	_
228-769	47303-47310	working	_
228-770	47311-47317	memory	_
228-771	47318-47322	task	_
228-772	47323-47329	during	_
228-773	47330-47337	cocaine	_
228-774	47338-47348	abstinence	_
228-775	47349-47358	Disrupted	_
228-776	47359-47369	functional	_
228-777	47370-47382	connectivity	_
228-778	47383-47387	with	_
228-779	47388-47400	dopaminergic	_
228-780	47401-47409	midbrain	_
228-781	47410-47412	in	_
228-782	47413-47420	cocaine	_
228-783	47421-47428	abusers	_
228-784	47429-47438	Automated	_
228-785	47439-47449	anatomical	_
228-786	47450-47458	labeling	_
228-787	47459-47461	of	_
228-788	47462-47473	activations	_
228-789	47474-47476	in	_
228-790	47477-47480	SPM	_
228-791	47481-47486	using	_
228-792	47487-47488	a	_
228-793	47489-47500	macroscopic	_
228-794	47501-47511	anatomical	_
228-795	47512-47524	parcellation	_
228-796	47525-47527	of	_
228-797	47528-47531	the	_
228-798	47532-47535	MNI	_
228-799	47536-47539	MRI	_
228-800	47540-47554	single-subject	_
228-801	47555-47560	brain	_
228-802	47561-47578	Stimulus-response	_
228-803	47579-47587	learning	_
228-804	47588-47590	in	_
228-805	47591-47600	long-term	_
228-806	47601-47608	cocaine	_
228-807	47609-47614	users	_
228-808	47614-47615	:	_
228-809	47616-47624	acquired	_
228-810	47625-47636	equivalence	_
228-811	47637-47640	and	_
228-812	47641-47654	probabilistic	_
228-813	47655-47663	category	_
228-814	47664-47672	learning	_
228-815	47673-47676	The	_
228-816	47677-47683	timing	_
228-817	47684-47686	of	_
228-818	47687-47704	action-monitoring	_
228-819	47705-47714	processes	_
228-820	47715-47717	in	_
228-821	47718-47721	the	_
228-822	47722-47730	anterior	_
228-823	47731-47740	cingulate	_
228-824	47741-47747	cortex	_
228-825	47748-47758	Fictitious	_
228-826	47759-47769	inhibitory	_
228-827	47770-47781	differences	_
228-828	47781-47782	:	_
228-829	47783-47786	how	_
228-830	47787-47795	skewness	_
228-831	47796-47799	and	_
228-832	47800-47807	slowing	_
228-833	47808-47815	distort	_
228-834	47816-47819	the	_
228-835	47820-47830	estimation	_
228-836	47831-47833	of	_
228-837	47834-47842	stopping	_
228-838	47843-47852	latencies	_
228-839	47853-47863	Functional	_
228-840	47864-47874	alteration	_
228-841	47875-47877	in	_
228-842	47878-47890	frontolimbic	_
228-843	47891-47898	systems	_
228-844	47899-47907	relevant	_
228-845	47908-47910	to	_
228-846	47911-47916	moral	_
228-847	47917-47925	judgment	_
228-848	47926-47928	in	_
228-849	47929-47946	cocaine-dependent	_
228-850	47947-47955	subjects	_
228-851	47956-47964	Evidence	_
228-852	47965-47968	for	_
228-853	47969-47970	a	_
228-854	47971-47985	frontoparietal	_
228-855	47986-47993	control	_
228-856	47994-48000	system	_
228-857	48001-48009	revealed	_
228-858	48010-48012	by	_
228-859	48013-48022	intrinsic	_
228-860	48023-48033	functional	_
228-861	48034-48046	connectivity	_
228-862	48047-48058	Association	_
228-863	48059-48061	of	_
228-864	48062-48070	dopamine	_
228-865	48071-48082	transporter	_
228-866	48083-48092	reduction	_
228-867	48093-48097	with	_
228-868	48098-48109	psychomotor	_
228-869	48110-48120	impairment	_
228-870	48121-48123	in	_
228-871	48124-48139	methamphetamine	_
228-872	48140-48147	abusers	_
228-873	48148-48151	The	_
228-874	48152-48164	relationship	_
228-875	48165-48172	between	_
228-876	48173-48181	aberrant	_
228-877	48182-48190	neuronal	_
228-878	48191-48201	activation	_
228-879	48202-48204	in	_
228-880	48205-48208	the	_
228-881	48209-48218	pregenual	_
228-882	48219-48227	anterior	_
228-883	48228-48237	cingulate	_
228-884	48237-48238	,	_
228-885	48239-48246	altered	_
228-886	48247-48260	glutamatergic	_
228-887	48261-48271	metabolism	_
228-888	48271-48272	,	_
228-889	48273-48276	and	_
228-890	48277-48286	anhedonia	_
228-891	48287-48289	in	_
228-892	48290-48295	major	_
228-893	48296-48306	depression	_
228-894	48307-48313	Neural	_
228-895	48314-48324	substrates	_
228-896	48325-48327	of	_
228-897	48328-48346	abstinence-induced	_
228-898	48347-48356	cigarette	_
228-899	48357-48365	cravings	_
228-900	48366-48368	in	_
228-901	48369-48376	chronic	_
228-902	48377-48384	smokers	_
228-903	48385-48396	Attenuation	_
228-904	48397-48399	of	_
228-905	48400-48411	cue-induced	_
228-906	48412-48419	smoking	_
228-907	48420-48425	urges	_
228-908	48426-48429	and	_
228-909	48430-48435	brain	_
228-910	48436-48442	reward	_
228-911	48443-48451	activity	_
228-912	48452-48454	in	_
228-913	48455-48462	smokers	_
228-914	48463-48470	treated	_
228-915	48471-48483	successfully	_
228-916	48484-48488	with	_
228-917	48489-48498	bupropion	_
228-918	48499-48503	Poor	_
228-919	48504-48519	decision-making	_
228-920	48520-48522	by	_
228-921	48523-48530	chronic	_
228-922	48531-48540	marijuana	_
228-923	48541-48546	users	_
228-924	48547-48549	is	_
228-925	48550-48560	associated	_
228-926	48561-48565	with	_
228-927	48566-48575	decreased	_
228-928	48576-48586	functional	_
228-929	48587-48601	responsiveness	_
228-930	48602-48604	to	_
228-931	48605-48613	negative	_
228-932	48614-48626	consequences	_
228-933	48627-48637	Sequential	_
228-934	48638-48648	estimation	_
228-935	48649-48651	of	_
228-936	48652-48659	quantal	_
228-937	48660-48668	response	_
228-938	48669-48675	curves	_
228-939	48675-48676	:	_
228-940	48677-48678	a	_
228-941	48679-48682	new	_
228-942	48683-48689	method	_
228-943	48690-48692	of	_
228-944	48693-48703	estimation	_
228-945	48704-48708	fMRI	_
228-946	48709-48716	pattern	_
228-947	48717-48728	recognition	_
228-948	48729-48731	in	_
228-949	48732-48752	obsessive-compulsive	_
228-950	48753-48761	disorder	_
228-951	48762-48772	Diagnosing	_
228-952	48773-48782	different	_
228-953	48783-48795	binge-eating	_
228-954	48796-48805	disorders	_
228-955	48806-48811	based	_
228-956	48812-48814	on	_
228-957	48815-48829	reward-related	_
228-958	48830-48835	brain	_
228-959	48836-48846	activation	_
228-960	48847-48855	patterns	_
228-961	48856-48866	Functional	_
228-962	48867-48879	connectivity	_
228-963	48880-48882	in	_
228-964	48883-48884	a	_
228-965	48885-48899	frontoparietal	_
228-966	48900-48907	network	_
228-967	48908-48917	involving	_
228-968	48918-48921	the	_
228-969	48922-48928	dorsal	_
228-970	48929-48937	anterior	_
228-971	48938-48947	cingulate	_
228-972	48948-48954	cortex	_
228-973	48955-48964	underlies	_
228-974	48965-48974	decisions	_
228-975	48975-48977	to	_
228-976	48978-48984	accept	_
228-977	48985-48986	a	_
228-978	48987-48997	hypothesis	_
228-979	48998-49006	Enhanced	_
228-980	49007-49010	cue	_
228-981	49011-49021	reactivity	_
228-982	49022-49025	and	_
228-983	49026-49041	fronto-striatal	_
228-984	49042-49052	functional	_
228-985	49053-49065	connectivity	_
228-986	49066-49068	in	_
228-987	49069-49076	cocaine	_
228-988	49077-49080	use	_
228-989	49081-49090	disorders	_
228-990	49091-49099	Pulvinar	_
228-991	49100-49112	inactivation	_
228-992	49113-49121	disrupts	_
228-993	49122-49131	selection	_
228-994	49132-49134	of	_
228-995	49135-49143	movement	_
228-996	49144-49149	plans	_
228-997	49150-49153	The	_
228-998	49154-49165	measurement	_
228-999	49166-49168	of	_
228-1000	49169-49178	attention	_
228-1001	49179-49185	Recent	_
228-1002	49186-49198	developments	_
228-1003	49199-49201	in	_
228-1004	49202-49214	multivariate	_
228-1005	49215-49222	pattern	_
228-1006	49223-49231	analysis	_
228-1007	49232-49235	for	_
228-1008	49236-49246	functional	_
228-1009	49247-49250	MRI	_
228-1010	49251-49263	Parcellation	_
228-1011	49264-49266	of	_
228-1012	49267-49270	the	_
228-1013	49271-49279	Thalamus	_
228-1014	49280-49285	Using	_
228-1015	49286-49295	Diffusion	_
228-1016	49296-49302	Tensor	_
228-1017	49303-49309	Images	_
228-1018	49310-49313	and	_
228-1019	49314-49315	a	_
228-1020	49316-49328	Multi-object	_
228-1021	49329-49338	Geometric	_
228-1022	49339-49349	Deformable	_
228-1023	49350-49355	Model	_
228-1024	49356-49364	Striatal	_
228-1025	49365-49376	connections	_
228-1026	49377-49379	of	_
228-1027	49380-49383	the	_
228-1028	49384-49392	parietal	_
228-1029	49393-49404	association	_
228-1030	49405-49413	cortices	_
228-1031	49414-49416	in	_
228-1032	49417-49423	rhesus	_
228-1033	49424-49431	monkeys	_
228-1034	49432-49442	Biological	_
228-1035	49443-49448	clock	_
228-1036	49448-49449	:	_
228-1037	49450-49460	biological	_
228-1038	49461-49467	clocks	_
228-1039	49468-49471	may	_
228-1040	49472-49480	modulate	_
228-1041	49481-49485	drug	_
228-1042	49486-49495	addiction	_
228-1043	49496-49507	Identifying	_
228-1044	49508-49513	major	_
228-1045	49514-49524	depression	_
228-1046	49525-49530	using	_
228-1047	49531-49542	whole-brain	_
228-1048	49543-49553	functional	_
228-1049	49554-49566	connectivity	_
228-1050	49566-49567	:	_
228-1051	49568-49569	a	_
228-1052	49570-49582	multivariate	_
228-1053	49583-49590	pattern	_
228-1054	49591-49599	analysis	_
228-1055	49600-49601	A	_
228-1056	49602-49608	neural	_
228-1057	49609-49616	measure	_
228-1058	49617-49619	of	_
228-1059	49620-49630	behavioral	_
228-1060	49631-49641	engagement	_
228-1061	49641-49642	:	_
228-1062	49643-49656	task-residual	_
228-1063	49657-49670	low-frequency	_
228-1064	49671-49676	blood	_
228-1065	49677-49688	oxygenation	_
228-1066	49689-49704	level-dependent	_
228-1067	49705-49713	activity	_
228-1068	49714-49716	in	_
228-1069	49717-49720	the	_
228-1070	49721-49730	precuneus	_
228-1071	49731-49741	Functional	_
228-1072	49742-49750	networks	_
228-1073	49751-49754	for	_
228-1074	49755-49764	cognitive	_
228-1075	49765-49772	control	_
228-1076	49773-49775	in	_
228-1077	49776-49777	a	_
228-1078	49778-49782	stop	_
228-1079	49783-49789	signal	_
228-1080	49790-49794	task	_
228-1081	49794-49795	:	_
228-1082	49796-49807	independent	_
228-1083	49808-49817	component	_
228-1084	49818-49826	analysis	_
228-1085	49827-49836	Intrinsic	_
228-1086	49837-49847	functional	_
228-1087	49848-49857	relations	_
228-1088	49858-49865	between	_
228-1089	49866-49871	human	_
228-1090	49872-49880	cerebral	_
228-1091	49881-49887	cortex	_
228-1092	49888-49891	and	_
228-1093	49892-49900	thalamus	_
228-1094	49901-49912	Noninvasive	_
228-1095	49913-49923	functional	_
228-1096	49924-49927	and	_
228-1097	49928-49938	structural	_
228-1098	49939-49951	connectivity	_
228-1099	49952-49959	mapping	_
228-1100	49960-49962	of	_
228-1101	49963-49966	the	_
228-1102	49967-49972	human	_
228-1103	49973-49988	thalamocortical	_
228-1104	49989-49995	system	_
228-1105	49996-50009	Error-related	_
228-1106	50010-50020	functional	_
228-1107	50021-50033	connectivity	_
228-1108	50034-50036	of	_
228-1109	50037-50040	the	_
228-1110	50041-50049	thalamus	_
228-1111	50050-50052	in	_
228-1112	50053-50060	cocaine	_
228-1113	50061-50071	dependence	_
228-1114	50072-50081	Divergent	_
228-1115	50082-50089	network	_
228-1116	50090-50102	connectivity	_
228-1117	50103-50110	changes	_
228-1118	50111-50113	in	_
228-1119	50114-50125	behavioural	_
228-1120	50126-50133	variant	_
228-1121	50134-50148	frontotemporal	_
228-1122	50149-50157	dementia	_
228-1123	50158-50161	and	_
228-1124	50162-50173	Alzheimer's	_
228-1125	50174-50181	disease	_
228-1126	50182-50188	Fisher	_
228-1127	50189-50203	discriminative	_
228-1128	50204-50212	analysis	_
228-1129	50213-50215	of	_
228-1130	50216-50229	resting-state	_
228-1131	50230-50235	brain	_
228-1132	50236-50244	function	_
228-1133	50245-50248	for	_
228-1134	50249-50266	attention-deficit	_
228-1135	50266-50267	/	_
228-1136	50267-50280	hyperactivity	_
228-1137	50281-50289	disorder	_
228-1138	50290-50291	A	_
228-1139	50292-50296	flow	_
228-1140	50297-50302	chart	_
228-1141	50303-50305	of	_
228-1142	50306-50309	the	_
228-1143	50310-50314	data	_
228-1144	50315-50323	analytic	_
228-1145	50324-50334	procedures	_
228-1146	50334-50335	.	_

#Text=In step 0, the fMRI data of 100 CD and 100 HC were analyzed by independent component analysis (ICA) to generate 30 networks.
229-1	50336-50338	In	_
229-2	50339-50343	step	_
229-3	50344-50345	0	_
229-4	50345-50346	,	_
229-5	50347-50350	the	_
229-6	50351-50355	fMRI	_
229-7	50356-50360	data	_
229-8	50361-50363	of	_
229-9	50364-50367	100	_
229-10	50368-50370	CD	_
229-11	50371-50374	and	_
229-12	50375-50378	100	_
229-13	50379-50381	HC	_
229-14	50382-50386	were	_
229-15	50387-50395	analyzed	_
229-16	50396-50398	by	_
229-17	50399-50410	independent	_
229-18	50411-50420	component	_
229-19	50421-50429	analysis	_
229-20	50430-50431	(	_
229-21	50431-50434	ICA	_
229-22	50434-50435	)	_
229-23	50436-50438	to	_
229-24	50439-50447	generate	_
229-25	50448-50450	30	_
229-26	50451-50459	networks	_
229-27	50459-50460	.	_

#Text=In step 1, six task-related networks were selected for further analysis.
230-1	50461-50463	In	_
230-2	50464-50468	step	_
230-3	50469-50470	1	_
230-4	50470-50471	,	_
230-5	50472-50475	six	_
230-6	50476-50488	task-related	_
230-7	50489-50497	networks	_
230-8	50498-50502	were	_
230-9	50503-50511	selected	_
230-10	50512-50515	for	_
230-11	50516-50523	further	_
230-12	50524-50532	analysis	_
230-13	50532-50533	.	_

#Text=A thalamus mask was applied to generate feature set including only voxels within the thalamus for multivariate pattern analysis (MVPA).
231-1	50534-50535	A	_
231-2	50536-50544	thalamus	_
231-3	50545-50549	mask	_
231-4	50550-50553	was	_
231-5	50554-50561	applied	_
231-6	50562-50564	to	_
231-7	50565-50573	generate	_
231-8	50574-50581	feature	_
231-9	50582-50585	set	_
231-10	50586-50595	including	_
231-11	50596-50600	only	_
231-12	50601-50607	voxels	_
231-13	50608-50614	within	_
231-14	50615-50618	the	_
231-15	50619-50627	thalamus	_
231-16	50628-50631	for	_
231-17	50632-50644	multivariate	_
231-18	50645-50652	pattern	_
231-19	50653-50661	analysis	_
231-20	50662-50663	(	_
231-21	50663-50667	MVPA	_
231-22	50667-50668	)	_
231-23	50668-50669	.	_

#Text=In step 2, MVPA was applied using leave-one-out cross-validation to obtain true accuracy rates in group classification.
232-1	50670-50672	In	_
232-2	50673-50677	step	_
232-3	50678-50679	2	_
232-4	50679-50680	,	_
232-5	50681-50685	MVPA	_
232-6	50686-50689	was	_
232-7	50690-50697	applied	_
232-8	50698-50703	using	_
232-9	50704-50717	leave-one-out	_
232-10	50718-50734	cross-validation	_
232-11	50735-50737	to	_
232-12	50738-50744	obtain	_
232-13	50745-50749	true	_
232-14	50750-50758	accuracy	_
232-15	50759-50764	rates	_
232-16	50765-50767	in	_
232-17	50768-50773	group	_
232-18	50774-50788	classification	_
232-19	50788-50789	.	_

#Text=Classification features were selected and support vector machine (SVM) classifier was trained based on the training data set.
233-1	50790-50804	Classification	_
233-2	50805-50813	features	_
233-3	50814-50818	were	_
233-4	50819-50827	selected	_
233-5	50828-50831	and	_
233-6	50832-50839	support	_
233-7	50840-50846	vector	_
233-8	50847-50854	machine	_
233-9	50855-50856	(	_
233-10	50856-50859	SVM	_
233-11	50859-50860	)	_
233-12	50861-50871	classifier	_
233-13	50872-50875	was	_
233-14	50876-50883	trained	_
233-15	50884-50889	based	_
233-16	50890-50892	on	_
233-17	50893-50896	the	_
233-18	50897-50905	training	_
233-19	50906-50910	data	_
233-20	50911-50914	set	_
233-21	50914-50915	.	_

#Text=During testing, the same features from the testing data set were applied to the trained SVM classifier to obtain classification results (CD or HC).
234-1	50916-50922	During	_
234-2	50923-50930	testing	_
234-3	50930-50931	,	_
234-4	50932-50935	the	_
234-5	50936-50940	same	_
234-6	50941-50949	features	_
234-7	50950-50954	from	_
234-8	50955-50958	the	_
234-9	50959-50966	testing	_
234-10	50967-50971	data	_
234-11	50972-50975	set	_
234-12	50976-50980	were	_
234-13	50981-50988	applied	_
234-14	50989-50991	to	_
234-15	50992-50995	the	_
234-16	50996-51003	trained	_
234-17	51004-51007	SVM	_
234-18	51008-51018	classifier	_
234-19	51019-51021	to	_
234-20	51022-51028	obtain	_
234-21	51029-51043	classification	_
234-22	51044-51051	results	_
234-23	51052-51053	(	_
234-24	51053-51055	CD	_
234-25	51056-51058	or	_
234-26	51059-51061	HC	_
234-27	51061-51062	)	_
234-28	51062-51063	.	_

#Text=This procedure was repeated until each of the 100 CD and 100 HC was selected once as the validation data.
235-1	51064-51068	This	_
235-2	51069-51078	procedure	_
235-3	51079-51082	was	_
235-4	51083-51091	repeated	_
235-5	51092-51097	until	_
235-6	51098-51102	each	_
235-7	51103-51105	of	_
235-8	51106-51109	the	_
235-9	51110-51113	100	_
235-10	51114-51116	CD	_
235-11	51117-51120	and	_
235-12	51121-51124	100	_
235-13	51125-51127	HC	_
235-14	51128-51131	was	_
235-15	51132-51140	selected	_
235-16	51141-51145	once	_
235-17	51146-51148	as	_
235-18	51149-51152	the	_
235-19	51153-51163	validation	_
235-20	51164-51168	data	_
235-21	51168-51169	.	_

#Text=The mean accuracy rate was computed to index overall accuracy.
236-1	51170-51173	The	_
236-2	51174-51178	mean	_
236-3	51179-51187	accuracy	_
236-4	51188-51192	rate	_
236-5	51193-51196	was	_
236-6	51197-51205	computed	_
236-7	51206-51208	to	_
236-8	51209-51214	index	_
236-9	51215-51222	overall	_
236-10	51223-51231	accuracy	_
236-11	51231-51232	.	_

#Text=Finally, in step 3, the selected thalamic voxels from each ICA network were analyzed across 200 leave-one-out cross validation runs.
237-1	51233-51240	Finally	_
237-2	51240-51241	,	_
237-3	51242-51244	in	_
237-4	51245-51249	step	_
237-5	51250-51251	3	_
237-6	51251-51252	,	_
237-7	51253-51256	the	_
237-8	51257-51265	selected	_
237-9	51266-51274	thalamic	_
237-10	51275-51281	voxels	_
237-11	51282-51286	from	_
237-12	51287-51291	each	_
237-13	51292-51295	ICA	_
237-14	51296-51303	network	_
237-15	51304-51308	were	_
237-16	51309-51317	analyzed	_
237-17	51318-51324	across	_
237-18	51325-51328	200	_
237-19	51329-51342	leave-one-out	_
237-20	51343-51348	cross	_
237-21	51349-51359	validation	_
237-22	51360-51364	runs	_
237-23	51364-51365	.	_

#Text=Fig. 1
#Text=Six task-related independent component networks identified from ICA (p < 0.000001, FWE corrected), shown in sagittal, coronal and axial views.
238-1	51366-51369	Fig	_
238-2	51369-51370	.	_
238-3	51371-51372	1	_
238-4	51373-51376	Six	_
238-5	51377-51389	task-related	_
238-6	51390-51401	independent	_
238-7	51402-51411	component	_
238-8	51412-51420	networks	_
238-9	51421-51431	identified	_
238-10	51432-51436	from	_
238-11	51437-51440	ICA	_
238-12	51441-51442	(	_
238-13	51442-51443	p	_
238-14	51443-51444	 	_
238-15	51444-51445	<	_
238-16	51445-51446	 	_
238-17	51446-51454	0.000001	_
238-18	51454-51455	,	_
238-19	51456-51459	FWE	_
238-20	51460-51469	corrected	_
238-21	51469-51470	)	_
238-22	51470-51471	,	_
238-23	51472-51477	shown	_
238-24	51478-51480	in	_
238-25	51481-51489	sagittal	_
238-26	51489-51490	,	_
238-27	51491-51498	coronal	_
238-28	51499-51502	and	_
238-29	51503-51508	axial	_
238-30	51509-51514	views	_
238-31	51514-51515	.	_

#Text=Fig. 2
#Text=(A) Identified thalamic clusters, of which the connectivities to each of the six ICA networks were used in the classifier to distinguish CD from HC.
239-1	51516-51519	Fig	_
239-2	51519-51520	.	_
239-3	51521-51522	2	_
239-4	51523-51524	(	_
239-5	51524-51525	A	_
239-6	51525-51526	)	_
239-7	51527-51537	Identified	_
239-8	51538-51546	thalamic	_
239-9	51547-51555	clusters	_
239-10	51555-51556	,	_
239-11	51557-51559	of	_
239-12	51560-51565	which	_
239-13	51566-51569	the	_
239-14	51570-51584	connectivities	_
239-15	51585-51587	to	_
239-16	51588-51592	each	_
239-17	51593-51595	of	_
239-18	51596-51599	the	_
239-19	51600-51603	six	_
239-20	51604-51607	ICA	_
239-21	51608-51616	networks	_
239-22	51617-51621	were	_
239-23	51622-51626	used	_
239-24	51627-51629	in	_
239-25	51630-51633	the	_
239-26	51634-51644	classifier	_
239-27	51645-51647	to	_
239-28	51648-51659	distinguish	_
239-29	51660-51662	CD	_
239-30	51663-51667	from	_
239-31	51668-51670	HC	_
239-32	51670-51671	.	_

#Text=Only clusters with at least 10 voxels were shown.
240-1	51672-51676	Only	_
240-2	51677-51685	clusters	_
240-3	51686-51690	with	_
240-4	51691-51693	at	_
240-5	51694-51699	least	_
240-6	51700-51702	10	_
240-7	51703-51709	voxels	_
240-8	51710-51714	were	_
240-9	51715-51720	shown	_
240-10	51720-51721	.	_

#Text=(B) Z scores of each cluster for CD and HC with mean ± standard error. p-Value reflects two sample t test result of the Z scores of each cluster.
241-1	51722-51723	(	_
241-2	51723-51724	B	_
241-3	51724-51725	)	_
241-4	51726-51727	Z	_
241-5	51728-51734	scores	_
241-6	51735-51737	of	_
241-7	51738-51742	each	_
241-8	51743-51750	cluster	_
241-9	51751-51754	for	_
241-10	51755-51757	CD	_
241-11	51758-51761	and	_
241-12	51762-51764	HC	_
241-13	51765-51769	with	_
241-14	51770-51774	mean	_
241-15	51774-51775	 	_
241-16	51775-51776	±	_
241-17	51776-51777	 	_
241-18	51777-51785	standard	_
241-19	51786-51791	error	_
241-20	51791-51792	.	_
241-21	51793-51800	p-Value	_
241-22	51801-51809	reflects	_
241-23	51810-51813	two	_
241-24	51814-51820	sample	_
241-25	51821-51822	t	_
241-26	51823-51827	test	_
241-27	51828-51834	result	_
241-28	51835-51837	of	_
241-29	51838-51841	the	_
241-30	51842-51843	Z	_
241-31	51844-51850	scores	_
241-32	51851-51853	of	_
241-33	51854-51858	each	_
241-34	51859-51866	cluster	_
241-35	51866-51867	.	_

#Text=With the exception for the connectivity of the red cluster to DMN (IC022), all clusters showed significant differences between the CD and HC with correction for multiple comparisons.
242-1	51868-51872	With	_
242-2	51873-51876	the	_
242-3	51877-51886	exception	_
242-4	51887-51890	for	_
242-5	51891-51894	the	_
242-6	51895-51907	connectivity	_
242-7	51908-51910	of	_
242-8	51911-51914	the	_
242-9	51915-51918	red	_
242-10	51919-51926	cluster	_
242-11	51927-51929	to	_
242-12	51930-51933	DMN	_
242-13	51934-51935	(	_
242-14	51935-51940	IC022	_
242-15	51940-51941	)	_
242-16	51941-51942	,	_
242-17	51943-51946	all	_
242-18	51947-51955	clusters	_
242-19	51956-51962	showed	_
242-20	51963-51974	significant	_
242-21	51975-51986	differences	_
242-22	51987-51994	between	_
242-23	51995-51998	the	_
242-24	51999-52001	CD	_
242-25	52002-52005	and	_
242-26	52006-52008	HC	_
242-27	52009-52013	with	_
242-28	52014-52024	correction	_
242-29	52025-52028	for	_
242-30	52029-52037	multiple	_
242-31	52038-52049	comparisons	_
242-32	52049-52050	.	_

#Text=We further tested whether the Z scores of CD or HC were significantly different from zero, with * indicating a p < 0.05, corrected for multiple comparisons, and with ** indicating a p < 0.0001, uncorrected.
243-1	52051-52053	We	_
243-2	52054-52061	further	_
243-3	52062-52068	tested	_
243-4	52069-52076	whether	_
243-5	52077-52080	the	_
243-6	52081-52082	Z	_
243-7	52083-52089	scores	_
243-8	52090-52092	of	_
243-9	52093-52095	CD	_
243-10	52096-52098	or	_
243-11	52099-52101	HC	_
243-12	52102-52106	were	_
243-13	52107-52120	significantly	_
243-14	52121-52130	different	_
243-15	52131-52135	from	_
243-16	52136-52140	zero	_
243-17	52140-52141	,	_
243-18	52142-52146	with	_
243-19	52147-52148	*	_
243-20	52149-52159	indicating	_
243-21	52160-52161	a	_
243-22	52162-52163	p	_
243-23	52163-52164	 	_
243-24	52164-52165	<	_
243-25	52165-52166	 	_
243-26	52166-52170	0.05	_
243-27	52170-52171	,	_
243-28	52172-52181	corrected	_
243-29	52182-52185	for	_
243-30	52186-52194	multiple	_
243-31	52195-52206	comparisons	_
243-32	52206-52207	,	_
243-33	52208-52211	and	_
243-34	52212-52216	with	_
243-35	52217-52218	*	_
243-36	52218-52219	*	_
243-37	52220-52230	indicating	_
243-38	52231-52232	a	_
243-39	52233-52234	p	_
243-40	52234-52235	 	_
243-41	52235-52236	<	_
243-42	52236-52237	 	_
243-43	52237-52243	0.0001	_
243-44	52243-52244	,	_
243-45	52245-52256	uncorrected	_
243-46	52256-52257	.	_

#Text=Fig. 3
#Text=The permutation distribution of the estimated generalization rate using the linear support vector machine classifier (repetition times = 1000).
244-1	52258-52261	Fig	_
244-2	52261-52262	.	_
244-3	52263-52264	3	_
244-4	52265-52268	The	_
244-5	52269-52280	permutation	_
244-6	52281-52293	distribution	_
244-7	52294-52296	of	_
244-8	52297-52300	the	_
244-9	52301-52310	estimated	_
244-10	52311-52325	generalization	_
244-11	52326-52330	rate	_
244-12	52331-52336	using	_
244-13	52337-52340	the	_
244-14	52341-52347	linear	_
244-15	52348-52355	support	_
244-16	52356-52362	vector	_
244-17	52363-52370	machine	_
244-18	52371-52381	classifier	_
244-19	52382-52383	(	_
244-20	52383-52393	repetition	_
244-21	52394-52399	times	_
244-22	52399-52400	 	_
244-23	52400-52401	=	_
244-24	52401-52402	 	_
244-25	52402-52406	1000	_
244-26	52406-52407	)	_
244-27	52407-52408	.	_

#Text=GR0 represented the real generalization rate as obtained from the current data set.
245-1	52409-52412	GR0	_
245-2	52413-52424	represented	_
245-3	52425-52428	the	_
245-4	52429-52433	real	_
245-5	52434-52448	generalization	_
245-6	52449-52453	rate	_
245-7	52454-52456	as	_
245-8	52457-52465	obtained	_
245-9	52466-52470	from	_
245-10	52471-52474	the	_
245-11	52475-52482	current	_
245-12	52483-52487	data	_
245-13	52488-52491	set	_
245-14	52491-52492	.	_

#Text=Only 1 sample showed a higher generalization rate than the real data in 1000 runs (p = 0.001).
246-1	52493-52497	Only	_
246-2	52498-52499	1	_
246-3	52500-52506	sample	_
246-4	52507-52513	showed	_
246-5	52514-52515	a	_
246-6	52516-52522	higher	_
246-7	52523-52537	generalization	_
246-8	52538-52542	rate	_
246-9	52543-52547	than	_
246-10	52548-52551	the	_
246-11	52552-52556	real	_
246-12	52557-52561	data	_
246-13	52562-52564	in	_
246-14	52565-52569	1000	_
246-15	52570-52574	runs	_
246-16	52575-52576	(	_
246-17	52576-52577	p	_
246-18	52577-52578	 	_
246-19	52578-52579	=	_
246-20	52579-52580	 	_
246-21	52580-52585	0.001	_
246-22	52585-52586	)	_
246-23	52586-52587	.	_

#Text=Fig. 4
#Text=Demographics of the subjects.
247-1	52588-52591	Fig	_
247-2	52591-52592	.	_
247-3	52593-52594	4	_
247-4	52595-52607	Demographics	_
247-5	52608-52610	of	_
247-6	52611-52614	the	_
247-7	52615-52623	subjects	_
247-8	52623-52624	.	_

#Text=Table 1\t \t
#Text=Subject characteristic\tCD (n = 100)\tHC (n = 100)\tp-Value\t \tAge (years)\t40.3 ± 7.4\t38.0 ± 10.6\t0.08a\t \tGender (M/F)\t62/38\t55/45\t0.39b\t \tYears of alcohol use\t17 ± 9.0\t20 ± 10.2\t0.02a\t \tYears of Marijuana use\t10 ± 4.2\t1.0 ± 1.3\t0.001a\t \tAmount of average monthly cocaine use (gm) in the prior year\t16.9 ± 25.8\tN/A\tN/A\t \tAmount per use in grams\t1.0 ± 1.2\tN/A\tN/A\t \tDays of cocaine use in the prior month\t15.1 ± 8.8\tN/A\tN/A\t \tYears of cocaine use\t17.5 ± 8.3\tN/A\tN/A\t \tDays abstinent prior to scan\t18.2 ± 6.1\tN/A\tN/A\t \t
#Text=Note: values are mean ± S.D.
248-1	52625-52630	Table	_
248-2	52631-52632	1	_
248-3	52636-52643	Subject	_
248-4	52644-52658	characteristic	_
248-5	52659-52661	CD	_
248-6	52662-52663	(	_
248-7	52663-52664	n	_
248-8	52664-52665	 	_
248-9	52665-52666	=	_
248-10	52666-52667	 	_
248-11	52667-52670	100	_
248-12	52670-52671	)	_
248-13	52672-52674	HC	_
248-14	52675-52676	(	_
248-15	52676-52677	n	_
248-16	52677-52678	 	_
248-17	52678-52679	=	_
248-18	52679-52680	 	_
248-19	52680-52683	100	_
248-20	52683-52684	)	_
248-21	52685-52692	p-Value	_
248-22	52695-52698	Age	_
248-23	52699-52700	(	_
248-24	52700-52705	years	_
248-25	52705-52706	)	_
248-26	52707-52711	40.3	_
248-27	52711-52712	 	_
248-28	52712-52713	±	_
248-29	52713-52714	 	_
248-30	52714-52717	7.4	_
248-31	52718-52722	38.0	_
248-32	52722-52723	 	_
248-33	52723-52724	±	_
248-34	52724-52725	 	_
248-35	52725-52729	10.6	_
248-36	52730-52735	0.08a	_
248-37	52738-52744	Gender	_
248-38	52745-52746	(	_
248-39	52746-52747	M	_
248-40	52747-52748	/	_
248-41	52748-52749	F	_
248-42	52749-52750	)	_
248-43	52751-52753	62	_
248-44	52753-52754	/	_
248-45	52754-52756	38	_
248-46	52757-52759	55	_
248-47	52759-52760	/	_
248-48	52760-52762	45	_
248-49	52763-52768	0.39b	_
248-50	52771-52776	Years	_
248-51	52777-52779	of	_
248-52	52780-52787	alcohol	_
248-53	52788-52791	use	_
248-54	52792-52794	17	_
248-55	52794-52795	 	_
248-56	52795-52796	±	_
248-57	52796-52797	 	_
248-58	52797-52800	9.0	_
248-59	52801-52803	20	_
248-60	52803-52804	 	_
248-61	52804-52805	±	_
248-62	52805-52806	 	_
248-63	52806-52810	10.2	_
248-64	52811-52816	0.02a	_
248-65	52819-52824	Years	_
248-66	52825-52827	of	_
248-67	52828-52837	Marijuana	_
248-68	52838-52841	use	_
248-69	52842-52844	10	_
248-70	52844-52845	 	_
248-71	52845-52846	±	_
248-72	52846-52847	 	_
248-73	52847-52850	4.2	_
248-74	52851-52854	1.0	_
248-75	52854-52855	 	_
248-76	52855-52856	±	_
248-77	52856-52857	 	_
248-78	52857-52860	1.3	_
248-79	52861-52867	0.001a	_
248-80	52870-52876	Amount	_
248-81	52877-52879	of	_
248-82	52880-52887	average	_
248-83	52888-52895	monthly	_
248-84	52896-52903	cocaine	_
248-85	52904-52907	use	_
248-86	52908-52909	(	_
248-87	52909-52911	gm	_
248-88	52911-52912	)	_
248-89	52913-52915	in	_
248-90	52916-52919	the	_
248-91	52920-52925	prior	_
248-92	52926-52930	year	_
248-93	52931-52935	16.9	_
248-94	52935-52936	 	_
248-95	52936-52937	±	_
248-96	52937-52938	 	_
248-97	52938-52942	25.8	_
248-98	52943-52944	N	_
248-99	52944-52945	/	_
248-100	52945-52946	A	_
248-101	52947-52948	N	_
248-102	52948-52949	/	_
248-103	52949-52950	A	_
248-104	52953-52959	Amount	_
248-105	52960-52963	per	_
248-106	52964-52967	use	_
248-107	52968-52970	in	_
248-108	52971-52976	grams	_
248-109	52977-52980	1.0	_
248-110	52980-52981	 	_
248-111	52981-52982	±	_
248-112	52982-52983	 	_
248-113	52983-52986	1.2	_
248-114	52987-52988	N	_
248-115	52988-52989	/	_
248-116	52989-52990	A	_
248-117	52991-52992	N	_
248-118	52992-52993	/	_
248-119	52993-52994	A	_
248-120	52997-53001	Days	_
248-121	53002-53004	of	_
248-122	53005-53012	cocaine	_
248-123	53013-53016	use	_
248-124	53017-53019	in	_
248-125	53020-53023	the	_
248-126	53024-53029	prior	_
248-127	53030-53035	month	_
248-128	53036-53040	15.1	_
248-129	53040-53041	 	_
248-130	53041-53042	±	_
248-131	53042-53043	 	_
248-132	53043-53046	8.8	_
248-133	53047-53048	N	_
248-134	53048-53049	/	_
248-135	53049-53050	A	_
248-136	53051-53052	N	_
248-137	53052-53053	/	_
248-138	53053-53054	A	_
248-139	53057-53062	Years	_
248-140	53063-53065	of	_
248-141	53066-53073	cocaine	_
248-142	53074-53077	use	_
248-143	53078-53082	17.5	_
248-144	53082-53083	 	_
248-145	53083-53084	±	_
248-146	53084-53085	 	_
248-147	53085-53088	8.3	_
248-148	53089-53090	N	_
248-149	53090-53091	/	_
248-150	53091-53092	A	_
248-151	53093-53094	N	_
248-152	53094-53095	/	_
248-153	53095-53096	A	_
248-154	53099-53103	Days	_
248-155	53104-53113	abstinent	_
248-156	53114-53119	prior	_
248-157	53120-53122	to	_
248-158	53123-53127	scan	_
248-159	53128-53132	18.2	_
248-160	53132-53133	 	_
248-161	53133-53134	±	_
248-162	53134-53135	 	_
248-163	53135-53138	6.1	_
248-164	53139-53140	N	_
248-165	53140-53141	/	_
248-166	53141-53142	A	_
248-167	53143-53144	N	_
248-168	53144-53145	/	_
248-169	53145-53146	A	_
248-170	53150-53154	Note	_
248-171	53154-53155	:	_
248-172	53156-53162	values	_
248-173	53163-53166	are	_
248-174	53167-53171	mean	_
248-175	53171-53172	 	_
248-176	53172-53173	±	_
248-177	53173-53174	 	_
248-178	53174-53177	S.D	_
248-179	53177-53178	.	_

#Text=Two-tailed two-sample t test.
#Text=χ2 test.
249-1	53179-53189	Two-tailed	_
249-2	53190-53200	two-sample	_
249-3	53201-53202	t	_
249-4	53203-53207	test	_
249-5	53207-53208	.	_
249-6	53209-53211	χ2	_
249-7	53212-53216	test	_
249-8	53216-53217	.	_

#Text=SST performance.
250-1	53218-53221	SST	_
250-2	53222-53233	performance	_
250-3	53233-53234	.	_

#Text=Table 2\t \t
#Text=\tSSRT (ms)\tFP effect (effect size)\tMedian go RT (ms)\t%go\t%stop\tPES (effect size)\t \tCD (n = 100)\t231 ± 51\t1.92 ± 1.45\t589 ± 113\t97.1 ± 6.2\t52.6 ± 3.9\t1.20 ± 1.87\t \tHC (n = 100)\t220 ± 44\t2.05 ± 1.55\t618 ± 110\t99.0 ± 1.8\t52.7 ± 3.2\t1.79 ± 1.79\t \tp-Value⁎\t0.11\t0.56\t0.07\t0.004\t0.88\t0.02\t \t
#Text=Note: All values are mean ± standard deviation; CD: individuals with cocaine dependence; HC: healthy controls; SSRT: stop signal reaction time; FP: fore-period; RT: reaction time; %go: percentage of go response trials; %stop: percentage of stop success trials; PES: post-error slowing.
#Text=p-Value based on 2-tailed 2-sample t test.
251-1	53235-53240	Table	_
251-2	53241-53242	2	_
251-3	53247-53251	SSRT	_
251-4	53252-53253	(	_
251-5	53253-53255	ms	_
251-6	53255-53256	)	_
251-7	53257-53259	FP	_
251-8	53260-53266	effect	_
251-9	53267-53268	(	_
251-10	53268-53274	effect	_
251-11	53275-53279	size	_
251-12	53279-53280	)	_
251-13	53281-53287	Median	_
251-14	53288-53290	go	_
251-15	53291-53293	RT	_
251-16	53294-53295	(	_
251-17	53295-53297	ms	_
251-18	53297-53298	)	_
251-19	53299-53300	%	_
251-20	53300-53302	go	_
251-21	53303-53304	%	_
251-22	53304-53308	stop	_
251-23	53309-53312	PES	_
251-24	53313-53314	(	_
251-25	53314-53320	effect	_
251-26	53321-53325	size	_
251-27	53325-53326	)	_
251-28	53329-53331	CD	_
251-29	53332-53333	(	_
251-30	53333-53334	n	_
251-31	53334-53335	 	_
251-32	53335-53336	=	_
251-33	53336-53337	 	_
251-34	53337-53340	100	_
251-35	53340-53341	)	_
251-36	53342-53345	231	_
251-37	53345-53346	 	_
251-38	53346-53347	±	_
251-39	53347-53348	 	_
251-40	53348-53350	51	_
251-41	53351-53355	1.92	_
251-42	53355-53356	 	_
251-43	53356-53357	±	_
251-44	53357-53358	 	_
251-45	53358-53362	1.45	_
251-46	53363-53366	589	_
251-47	53366-53367	 	_
251-48	53367-53368	±	_
251-49	53368-53369	 	_
251-50	53369-53372	113	_
251-51	53373-53377	97.1	_
251-52	53377-53378	 	_
251-53	53378-53379	±	_
251-54	53379-53380	 	_
251-55	53380-53383	6.2	_
251-56	53384-53388	52.6	_
251-57	53388-53389	 	_
251-58	53389-53390	±	_
251-59	53390-53391	 	_
251-60	53391-53394	3.9	_
251-61	53395-53399	1.20	_
251-62	53399-53400	 	_
251-63	53400-53401	±	_
251-64	53401-53402	 	_
251-65	53402-53406	1.87	_
251-66	53409-53411	HC	_
251-67	53412-53413	(	_
251-68	53413-53414	n	_
251-69	53414-53415	 	_
251-70	53415-53416	=	_
251-71	53416-53417	 	_
251-72	53417-53420	100	_
251-73	53420-53421	)	_
251-74	53422-53425	220	_
251-75	53425-53426	 	_
251-76	53426-53427	±	_
251-77	53427-53428	 	_
251-78	53428-53430	44	_
251-79	53431-53435	2.05	_
251-80	53435-53436	 	_
251-81	53436-53437	±	_
251-82	53437-53438	 	_
251-83	53438-53442	1.55	_
251-84	53443-53446	618	_
251-85	53446-53447	 	_
251-86	53447-53448	±	_
251-87	53448-53449	 	_
251-88	53449-53452	110	_
251-89	53453-53457	99.0	_
251-90	53457-53458	 	_
251-91	53458-53459	±	_
251-92	53459-53460	 	_
251-93	53460-53463	1.8	_
251-94	53464-53468	52.7	_
251-95	53468-53469	 	_
251-96	53469-53470	±	_
251-97	53470-53471	 	_
251-98	53471-53474	3.2	_
251-99	53475-53479	1.79	_
251-100	53479-53480	 	_
251-101	53480-53481	±	_
251-102	53481-53482	 	_
251-103	53482-53486	1.79	_
251-104	53489-53496	p-Value	_
251-105	53496-53497	⁎	_
251-106	53498-53502	0.11	_
251-107	53503-53507	0.56	_
251-108	53508-53512	0.07	_
251-109	53513-53518	0.004	_
251-110	53519-53523	0.88	_
251-111	53524-53528	0.02	_
251-112	53532-53536	Note	_
251-113	53536-53537	:	_
251-114	53538-53541	All	_
251-115	53542-53548	values	_
251-116	53549-53552	are	_
251-117	53553-53557	mean	_
251-118	53557-53558	 	_
251-119	53558-53559	±	_
251-120	53559-53560	 	_
251-121	53560-53568	standard	_
251-122	53569-53578	deviation	_
251-123	53578-53579	;	_
251-124	53580-53582	CD	_
251-125	53582-53583	:	_
251-126	53584-53595	individuals	_
251-127	53596-53600	with	_
251-128	53601-53608	cocaine	_
251-129	53609-53619	dependence	_
251-130	53619-53620	;	_
251-131	53621-53623	HC	_
251-132	53623-53624	:	_
251-133	53625-53632	healthy	_
251-134	53633-53641	controls	_
251-135	53641-53642	;	_
251-136	53643-53647	SSRT	_
251-137	53647-53648	:	_
251-138	53649-53653	stop	_
251-139	53654-53660	signal	_
251-140	53661-53669	reaction	_
251-141	53670-53674	time	_
251-142	53674-53675	;	_
251-143	53676-53678	FP	_
251-144	53678-53679	:	_
251-145	53680-53691	fore-period	_
251-146	53691-53692	;	_
251-147	53693-53695	RT	_
251-148	53695-53696	:	_
251-149	53697-53705	reaction	_
251-150	53706-53710	time	_
251-151	53710-53711	;	_
251-152	53712-53713	%	_
251-153	53713-53715	go	_
251-154	53715-53716	:	_
251-155	53717-53727	percentage	_
251-156	53728-53730	of	_
251-157	53731-53733	go	_
251-158	53734-53742	response	_
251-159	53743-53749	trials	_
251-160	53749-53750	;	_
251-161	53751-53752	%	_
251-162	53752-53756	stop	_
251-163	53756-53757	:	_
251-164	53758-53768	percentage	_
251-165	53769-53771	of	_
251-166	53772-53776	stop	_
251-167	53777-53784	success	_
251-168	53785-53791	trials	_
251-169	53791-53792	;	_
251-170	53793-53796	PES	_
251-171	53796-53797	:	_
251-172	53798-53808	post-error	_
251-173	53809-53816	slowing	_
251-174	53816-53817	.	_
251-175	53818-53825	p-Value	_
251-176	53826-53831	based	_
251-177	53832-53834	on	_
251-178	53835-53836	2	_
251-179	53836-53837	-	_
251-180	53837-53843	tailed	_
251-181	53844-53845	2	_
251-182	53845-53846	-	_
251-183	53846-53852	sample	_
251-184	53853-53854	t	_
251-185	53855-53859	test	_
251-186	53859-53860	.	_

#Text=Aggregation index (AI) of the thalamus and comparison regions.
252-1	53861-53872	Aggregation	_
252-2	53873-53878	index	_
252-3	53879-53880	(	_
252-4	53880-53882	AI	_
252-5	53882-53883	)	_
252-6	53884-53886	of	_
252-7	53887-53890	the	_
252-8	53891-53899	thalamus	_
252-9	53900-53903	and	_
252-10	53904-53914	comparison	_
252-11	53915-53922	regions	_
252-12	53922-53923	.	_

#Text=Table 3\t \t
#Text=\tIC003\tIC009\tIC022\tIC024\tIC027\tIC029\tMean\tp-Value\t \tThalamus\t0.81\t0.41\t0.67\t0.64\t0.80\t0.61\t0.66\tN/A\t \t  \t \tComparison regions\t \tCaudate\t0.40\t0.46\t0.45\t0.00\t0.00\t0.67\t0.33\t0.03\t \tParacentral\t0.00\t0.00\t0.00\t0.95\t0.69\t0.55\t0.37\t0.14\t \tOccipital_Inf\t0.87\t0.55\t0.00\t0.00\t0.00\t0.00\t0.24\t0.03\t \tFrontal_Orb_Mid\t0.16\t0.40\t0.26\t0.00\t0.60\t0.61\t0.34\t0.02\t \tParahippocampal G\t0.54\t0.23\t0.15\t0.20\t0.00\t0.60\t0.29\t0.008\t \t
#Text=Note: p-value: paired t test of the AI of the thalamus, as compared to each of the other regions, across all six components.
253-1	53924-53929	Table	_
253-2	53930-53931	3	_
253-3	53936-53941	IC003	_
253-4	53942-53947	IC009	_
253-5	53948-53953	IC022	_
253-6	53954-53959	IC024	_
253-7	53960-53965	IC027	_
253-8	53966-53971	IC029	_
253-9	53972-53976	Mean	_
253-10	53977-53984	p-Value	_
253-11	53987-53995	Thalamus	_
253-12	53996-54000	0.81	_
253-13	54001-54005	0.41	_
253-14	54006-54010	0.67	_
253-15	54011-54015	0.64	_
253-16	54016-54020	0.80	_
253-17	54021-54025	0.61	_
253-18	54026-54030	0.66	_
253-19	54031-54032	N	_
253-20	54032-54033	/	_
253-21	54033-54034	A	_
253-22	54042-54052	Comparison	_
253-23	54053-54060	regions	_
253-24	54063-54070	Caudate	_
253-25	54071-54075	0.40	_
253-26	54076-54080	0.46	_
253-27	54081-54085	0.45	_
253-28	54086-54090	0.00	_
253-29	54091-54095	0.00	_
253-30	54096-54100	0.67	_
253-31	54101-54105	0.33	_
253-32	54106-54110	0.03	_
253-33	54113-54124	Paracentral	_
253-34	54125-54129	0.00	_
253-35	54130-54134	0.00	_
253-36	54135-54139	0.00	_
253-37	54140-54144	0.95	_
253-38	54145-54149	0.69	_
253-39	54150-54154	0.55	_
253-40	54155-54159	0.37	_
253-41	54160-54164	0.14	_
253-42	54167-54180	Occipital_Inf	_
253-43	54181-54185	0.87	_
253-44	54186-54190	0.55	_
253-45	54191-54195	0.00	_
253-46	54196-54200	0.00	_
253-47	54201-54205	0.00	_
253-48	54206-54210	0.00	_
253-49	54211-54215	0.24	_
253-50	54216-54220	0.03	_
253-51	54223-54238	Frontal_Orb_Mid	_
253-52	54239-54243	0.16	_
253-53	54244-54248	0.40	_
253-54	54249-54253	0.26	_
253-55	54254-54258	0.00	_
253-56	54259-54263	0.60	_
253-57	54264-54268	0.61	_
253-58	54269-54273	0.34	_
253-59	54274-54278	0.02	_
253-60	54281-54296	Parahippocampal	_
253-61	54297-54298	G	_
253-62	54299-54303	0.54	_
253-63	54304-54308	0.23	_
253-64	54309-54313	0.15	_
253-65	54314-54318	0.20	_
253-66	54319-54323	0.00	_
253-67	54324-54328	0.60	_
253-68	54329-54333	0.29	_
253-69	54334-54339	0.008	_
253-70	54343-54347	Note	_
253-71	54347-54348	:	_
253-72	54349-54356	p-value	_
253-73	54356-54357	:	_
253-74	54358-54364	paired	_
253-75	54365-54366	t	_
253-76	54367-54371	test	_
253-77	54372-54374	of	_
253-78	54375-54378	the	_
253-79	54379-54381	AI	_
253-80	54382-54384	of	_
253-81	54385-54388	the	_
253-82	54389-54397	thalamus	_
253-83	54397-54398	,	_
253-84	54399-54401	as	_
253-85	54402-54410	compared	_
253-86	54411-54413	to	_
253-87	54414-54418	each	_
253-88	54419-54421	of	_
253-89	54422-54425	the	_
253-90	54426-54431	other	_
253-91	54432-54439	regions	_
253-92	54439-54440	,	_
253-93	54441-54447	across	_
253-94	54448-54451	all	_
253-95	54452-54455	six	_
253-96	54456-54466	components	_
253-97	54466-54467	.	_

#Text=MVPA accuracy rates of the thalamus and comparison regions.
254-1	54468-54472	MVPA	_
254-2	54473-54481	accuracy	_
254-3	54482-54487	rates	_
254-4	54488-54490	of	_
254-5	54491-54494	the	_
254-6	54495-54503	thalamus	_
254-7	54504-54507	and	_
254-8	54508-54518	comparison	_
254-9	54519-54526	regions	_
254-10	54526-54527	.	_

#Text=Table 4\t \t
#Text=\tTotal features\tUsed features (at p < 0.05)\tMVPA performance of CD\tPermutation test\t \tTPR\tTNR\tACC\tF1\tAUC ROC\t \tThalamus\t4188\t513 ± 10\t76%\t68%\t72%\t73%\t73%\tp < 0.001\t \t  \t \tComparison regions\t \tCaudate\t3948\t338 ± 7\t60%\t53%\t56.5%\t58%\t57%\tp ≤ 0.16\t \tParacentral\t4170\t334 ± 8\t58%\t59%\t58.5%\t58%\t58%\tp ≤ 0.08\t \tOccipital_Inf\t3828\t308 ± 6\t53%\t53%\t53%\t53%\t53%\tp ≤ 0.36\t \tFrontal_Orb_Mid\t4164\t226 ± 7\t52%\t54%\t53%\t53%\t53%\tp ≤ 0.43\t \tParahippocampal G\t4368\t298 ± 6\t53%\t52%\t52.5%\t53%\t53%\tp ≤ 0.32\t \t
#Text=Note: Values under “used features at p < 0.05” are mean ± standard deviation; CD: individuals with cocaine dependence; HC: healthy controls; Paracentral: paracentral gyrus; Occipital_Inf: inferior occipital gyurs; Frontal_Orb_Mid: middle part of orbital frontal gyrus; Parahippocampal G: parahippocampal gyrus.
255-1	54528-54533	Table	_
255-2	54534-54535	4	_
255-3	54540-54545	Total	_
255-4	54546-54554	features	_
255-5	54555-54559	Used	_
255-6	54560-54568	features	_
255-7	54569-54570	(	_
255-8	54570-54572	at	_
255-9	54573-54574	p	_
255-10	54574-54575	 	_
255-11	54575-54576	<	_
255-12	54576-54577	 	_
255-13	54577-54581	0.05	_
255-14	54581-54582	)	_
255-15	54583-54587	MVPA	_
255-16	54588-54599	performance	_
255-17	54600-54602	of	_
255-18	54603-54605	CD	_
255-19	54606-54617	Permutation	_
255-20	54618-54622	test	_
255-21	54625-54628	TPR	_
255-22	54629-54632	TNR	_
255-23	54633-54636	ACC	_
255-24	54637-54639	F1	_
255-25	54640-54643	AUC	_
255-26	54644-54647	ROC	_
255-27	54650-54658	Thalamus	_
255-28	54659-54663	4188	_
255-29	54664-54667	513	_
255-30	54667-54668	 	_
255-31	54668-54669	±	_
255-32	54669-54670	 	_
255-33	54670-54672	10	_
255-34	54673-54676	76%	_
255-35	54677-54680	68%	_
255-36	54681-54684	72%	_
255-37	54685-54688	73%	_
255-38	54689-54692	73%	_
255-39	54693-54694	p	_
255-40	54694-54695	 	_
255-41	54695-54696	<	_
255-42	54696-54697	 	_
255-43	54697-54702	0.001	_
255-44	54710-54720	Comparison	_
255-45	54721-54728	regions	_
255-46	54731-54738	Caudate	_
255-47	54739-54743	3948	_
255-48	54744-54747	338	_
255-49	54747-54748	 	_
255-50	54748-54749	±	_
255-51	54749-54750	 	_
255-52	54750-54751	7	_
255-53	54752-54755	60%	_
255-54	54756-54759	53%	_
255-55	54760-54765	56.5%	_
255-56	54766-54769	58%	_
255-57	54770-54773	57%	_
255-58	54774-54775	p	_
255-59	54775-54776	 	_
255-60	54776-54777	≤	_
255-61	54777-54778	 	_
255-62	54778-54782	0.16	_
255-63	54785-54796	Paracentral	_
255-64	54797-54801	4170	_
255-65	54802-54805	334	_
255-66	54805-54806	 	_
255-67	54806-54807	±	_
255-68	54807-54808	 	_
255-69	54808-54809	8	_
255-70	54810-54813	58%	_
255-71	54814-54817	59%	_
255-72	54818-54823	58.5%	_
255-73	54824-54827	58%	_
255-74	54828-54831	58%	_
255-75	54832-54833	p	_
255-76	54833-54834	 	_
255-77	54834-54835	≤	_
255-78	54835-54836	 	_
255-79	54836-54840	0.08	_
255-80	54843-54856	Occipital_Inf	_
255-81	54857-54861	3828	_
255-82	54862-54865	308	_
255-83	54865-54866	 	_
255-84	54866-54867	±	_
255-85	54867-54868	 	_
255-86	54868-54869	6	_
255-87	54870-54873	53%	_
255-88	54874-54877	53%	_
255-89	54878-54881	53%	_
255-90	54882-54885	53%	_
255-91	54886-54889	53%	_
255-92	54890-54891	p	_
255-93	54891-54892	 	_
255-94	54892-54893	≤	_
255-95	54893-54894	 	_
255-96	54894-54898	0.36	_
255-97	54901-54916	Frontal_Orb_Mid	_
255-98	54917-54921	4164	_
255-99	54922-54925	226	_
255-100	54925-54926	 	_
255-101	54926-54927	±	_
255-102	54927-54928	 	_
255-103	54928-54929	7	_
255-104	54930-54933	52%	_
255-105	54934-54937	54%	_
255-106	54938-54941	53%	_
255-107	54942-54945	53%	_
255-108	54946-54949	53%	_
255-109	54950-54951	p	_
255-110	54951-54952	 	_
255-111	54952-54953	≤	_
255-112	54953-54954	 	_
255-113	54954-54958	0.43	_
255-114	54961-54976	Parahippocampal	_
255-115	54977-54978	G	_
255-116	54979-54983	4368	_
255-117	54984-54987	298	_
255-118	54987-54988	 	_
255-119	54988-54989	±	_
255-120	54989-54990	 	_
255-121	54990-54991	6	_
255-122	54992-54995	53%	_
255-123	54996-54999	52%	_
255-124	55000-55005	52.5%	_
255-125	55006-55009	53%	_
255-126	55010-55013	53%	_
255-127	55014-55015	p	_
255-128	55015-55016	 	_
255-129	55016-55017	≤	_
255-130	55017-55018	 	_
255-131	55018-55022	0.32	_
255-132	55026-55030	Note	_
255-133	55030-55031	:	_
255-134	55032-55038	Values	_
255-135	55039-55044	under	_
255-136	55045-55046	“	_
255-137	55046-55050	used	_
255-138	55051-55059	features	_
255-139	55060-55062	at	_
255-140	55063-55064	p	_
255-141	55064-55065	 	_
255-142	55065-55066	<	_
255-143	55066-55067	 	_
255-144	55067-55071	0.05	_
255-145	55071-55072	”	_
255-146	55073-55076	are	_
255-147	55077-55081	mean	_
255-148	55081-55082	 	_
255-149	55082-55083	±	_
255-150	55083-55084	 	_
255-151	55084-55092	standard	_
255-152	55093-55102	deviation	_
255-153	55102-55103	;	_
255-154	55104-55106	CD	_
255-155	55106-55107	:	_
255-156	55108-55119	individuals	_
255-157	55120-55124	with	_
255-158	55125-55132	cocaine	_
255-159	55133-55143	dependence	_
255-160	55143-55144	;	_
255-161	55145-55147	HC	_
255-162	55147-55148	:	_
255-163	55149-55156	healthy	_
255-164	55157-55165	controls	_
255-165	55165-55166	;	_
255-166	55167-55178	Paracentral	_
255-167	55178-55179	:	_
255-168	55180-55191	paracentral	_
255-169	55192-55197	gyrus	_
255-170	55197-55198	;	_
255-171	55199-55212	Occipital_Inf	_
255-172	55212-55213	:	_
255-173	55214-55222	inferior	_
255-174	55223-55232	occipital	_
255-175	55233-55238	gyurs	_
255-176	55238-55239	;	_
255-177	55240-55255	Frontal_Orb_Mid	_
255-178	55255-55256	:	_
255-179	55257-55263	middle	_
255-180	55264-55268	part	_
255-181	55269-55271	of	_
255-182	55272-55279	orbital	_
255-183	55280-55287	frontal	_
255-184	55288-55293	gyrus	_
255-185	55293-55294	;	_
255-186	55295-55310	Parahippocampal	_
255-187	55311-55312	G	_
255-188	55312-55313	:	_
255-189	55314-55329	parahippocampal	_
255-190	55330-55335	gyrus	_
255-191	55335-55336	.	_

#Text=TPR: true positive rate; TNR: true negative rate; ACC: accuracy; F1: F1 score; AUC ROC: Area under the Curve of receiver operating characteristic curve.
256-1	55337-55340	TPR	_
256-2	55340-55341	:	_
256-3	55342-55346	true	_
256-4	55347-55355	positive	_
256-5	55356-55360	rate	_
256-6	55360-55361	;	_
256-7	55362-55365	TNR	_
256-8	55365-55366	:	_
256-9	55367-55371	true	_
256-10	55372-55380	negative	_
256-11	55381-55385	rate	_
256-12	55385-55386	;	_
256-13	55387-55390	ACC	_
256-14	55390-55391	:	_
256-15	55392-55400	accuracy	_
256-16	55400-55401	;	_
256-17	55402-55404	F1	_
256-18	55404-55405	:	_
256-19	55406-55408	F1	_
256-20	55409-55414	score	_
256-21	55414-55415	;	_
256-22	55416-55419	AUC	_
256-23	55420-55423	ROC	_
256-24	55423-55424	:	_
256-25	55425-55429	Area	_
256-26	55430-55435	under	_
256-27	55436-55439	the	_
256-28	55440-55445	Curve	_
256-29	55446-55448	of	_
256-30	55449-55457	receiver	_
256-31	55458-55467	operating	_
256-32	55468-55482	characteristic	_
256-33	55483-55488	curve	_
256-34	55488-55489	.	_
